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Iodine is a microelement that is naturally present in some foods, added to others, and available
as a dietary supplement. Iodine from the diet is converted into the iodide ion before it is absorbed
throughout the gastrointestinal tract [1,2]. When iodide enters the circulation, the thyroid gland
selectively concentrates it in the appropriate amounts required for thyroid hormone synthesis, and
most of the remaining amount is excreted in the urine [3]. The iodine-replete healthy adult has
about 15–20 mg of iodine, 70–80% of which is contained in the thyroid [4]. The estimated average
requirement of iodine can be extrapolated from a median urinary iodine concentration of 100 μg/L,
which corresponds roughly to 150 μg daily iodine intake [5]. Median urinary iodine concentrations
of 100–199 μg/L in children and adults, 150–249 μg/L in pregnant women and >100 μg/L in lactating
women indicate iodine intakes are adequate [6,7]. Values lower than 100 μg/L in children and
non-pregnant adults indicate insufficient iodine intake, although iodine deficiency is not classified as
severe until urinary iodine levels are lower than 20 μg/L. Seaweed (kelp, nori, kombu, and wakame) is
one of the best food sources of iodine, although it is highly variable in its content [8]. Other dietary
sources of iodine are seafood, dairy products (partly due to the use of iodine feed supplements and
iodophor sanitizing agents in the dairy industry), milk, green beans and eggs [9]. Iodine is also
present in human breast milk, in infant formulas and in many multivitamin/mineral supplements,
which contain iodine in the forms of potassium iodide or sodium iodide [7,10,11]. Over the last years,
there has been a growing interest in some nutraceuticals, including selenium, carnitine, myo-inositol,
flavonoids, omega-3 polyunsaturated fatty acids, resveratrol and vitamins, for their potential role
in thyroid function [12–14]. Nutraceuticals could represent an opportunity in the prevention and
treatment of some thyroid diseases, even though their effective action and high safety level should need
to be supported by large clinical outcome trials. However, iodine remains the essential element for the
thyroid gland being the key component of the thyroid hormones thyroxine (T4) and triiodothyronine
(T3), which regulate a wide variety of physiological processes, such as protein synthesis and enzymatic
activity, and are critical determinants of metabolic activity. They are also required for proper skeletal
and central nervous system development in fetuses and infants [15].
Thyroid function is primarily regulated by the thyroid-stimulating hormone (TSH), secreted by
the pituitary gland, which increases thyroidal uptake of iodine and stimulates the synthesis and release
of T3 and T4. In the presence of inadequate iodine intake, TSH levels remain elevated, leading to
goiter, an enlargement of the thyroid gland that reflects the body’s attempt to trap more iodine from
the circulation and produce thyroid hormones.
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Iodine deficiency impairs thyroid hormone production and has many adverse effects during the
course of the life, collectively termed the iodine deficiency disorders (IDDs), which depend on its
severity and the age of the affected subjects. Although goiter is the classic sign of iodine deficiency,
and can take place at any age, the most serious adverse effect of iodine deficiency is damage to the
fetus during pregnancy, since the absence or inadequate level of thyroid hormones cause significant
clinical manifestations such as increased risk of stillbirths, abortions, perinatal mortality, congenital
abnormalities, cretinism, impaired growth [9,16]. Nowadays, IDDs are still a public health problem in
most countries, including industrialized and developing regions of the world, in which all groups of
people are affected, even though pregnant women are the most susceptible group to insufficient iodine
intake [17–20].
Over the last few decades, intensive efforts have been made by the governments of IDD-affected
countries to implement and control salt iodization program, since the most cost-effective strategy
for IDD is universal salt iodization with the recommended iodine concentration of 20–40 mg iodine
per kg salt [5]. Despite a significant improvement in iodine nutrition being observed over the years,
some countries still remain at risk of deficiency, implying that further strategies should be designed to
achieve iodine sufficiency worldwide.
In this issue, we provide an update on the iodine status of the general population in different
countries of the world, including Moldovia [21], Korea [22], the United States [23,24], Sri Lanka [25],
Finland [26] and Italy [27,28], with a special focus on newborns [24] and pregnant women [24,26],
which are the most vulnerable categories. Importantly, we have invited an international panel of
endocrinologists to review the literature and to comment upon the effects of the most common
nutraceuticals on thyroid function, based on the most recent in vitro and in vivo [29,30], as well as
human, studies [31]. We believe that this collection represents a useful summary of iodine intake on
human health, and provides a critical opinion on the benefits of some popular nutraceuticals that may
play a role in clinical thyroidology.
Author Contributions: The Authors contributed equally to the development and finalization of this Editorial.
All authors have read and agreed to the published version of the manuscript.
Funding: This research received no external funding.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Haldimann, M.; Alt, A.; Blanc, A.; Blondeau, K. Iodine content of food groups. J. Food Comp. Anal. 2005, 18,
461–471. [CrossRef]
2. Alexander, W.D.; Harden, R.M.; Harrison, M.T.; Shimmins, J. Some aspects of the absorption and concentration
of iodide by the alimentary tract in man. Proc. Nutr. Soc. 1967, 26, 62–66. [CrossRef] [PubMed]
3. Vought, R.L.; London, W.T. Iodine intake, excretion and thyroidal accumulation in healthy subjects. J. Clin.
Endocrinol. Metab. 1967, 27, 913–919. [CrossRef] [PubMed]
4. Fisher, D.A.; Oddie, T.H. Thyroid iodine content and turnover in euthyroid subjects: Validity of estimation of
thyroid iodine accumulation from short-term clearance studies. J. Clin. Endocrinol. Metab. 1969, 29, 721–727.
[CrossRef] [PubMed]
5. Institute of Medicine. Academy of Sciences 2001 Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic,
Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc; National
Academy Press: Washington, DC, USA, 2001.
6. World Health Organization; United Nations Children’s Fund; International Council for the Control of Iodine
Deficiency Disorders. Assessment of Iodine Deficiency Disorders and Monitoring Their Elimination, 3rd ed.; World
Health Organization: Geneva, Switzerland, 2007.
7. Semba, R.D.; Delange, F. Iodine in human milk: Perspectives for human health. Nutr. Rev. 2001, 59, 269–278.
[CrossRef]
8. Nagataki, S. The average of dietary iodine intake due to the ingestion of seaweeds is 1.2 mg/day in Japan.
Thyroid 2008, 18, 667–668. [CrossRef] [PubMed]
2
Nutrients 2020, 12, 1491
9. Hernando, V.U.; Anilza, B.P.; Hernan, S.T.C. Iodine deficiency disorders. Thyroid Disord. Ther. 2015, 4, 172.
10. Azizi, F.; Smyth, P. Breastfeeding and maternal and infant iodine nutrition. Clin. Endocrinol. 2009, 70, 803–809.
[CrossRef]
11. Pearce, E.N.; Pino, S.; He, X.; Bazrafshan, H.R.; Lee, S.L.; Braverman, L.E. Sources of dietary iodine: Bread,
cows’ milk, and infant formula in the Boston area. J. Clin. Endocrinol. Metab. 2004, 89, 3421–3424. [CrossRef]
12. Montanelli, L.; Benvenga, S.; Vitti, P.; Latrofa, F.; Duntas, L.H. Drugs and other substances interfering
with thyroid function. In Thyroid Diseases; Vitti, P., Hegedus, L., Eds.; Springer: Cham, Switzerland, 2018;
pp. 733–761.
13. Sharma, R.; Bharti, S.; Kumar, K.V.S.H. Diet and thyroid: Myths and facts. J. Med. Nutr. Nutraceuticals 2014,
3, 60–65.
14. Das, L.; Bhaumik, E.; Raychaudhuri, U.; Chakraborty, R. Role of nutraceuticals in human health. J. Food Sci.
Technol. 2012, 49, 173–183. [CrossRef] [PubMed]
15. Zimmermann, M.B. The role of iodine in human growth and development. Semin. Cell Dev. Biol. 2011, 22,
645–652. [CrossRef]
16. Eastman, C.J.; Zimmermann, M.B. The Iodine Deficiency Disorders. In Endotext; Feingold, K.R., Anawalt, B.,
Boyce, A., Chrousos, G., Dungan, K., Grossman, A., Hershman, J.M., Kaltsas, G., Koch, C., Kopp, P., et al.,
Eds.; MDText.com, Inc.: South Dartmouth, MA, USA, 2000.
17. Li, M.; Eastman, C.J. The changing epidemiology of iodine deficiency. Nat. Rev. Endocrinol. 2012, 8, 434–440.
[CrossRef]
18. Mohammadi, M.; Azizi, F.; Hedayati, M. Iodine deficiency status in the WHO Eastern Mediterranean Region:
A systematic review. Environ. Geochem. Health 2018, 40, 87–97. [CrossRef]
19. The Iodine Global Network: 2018 Annual Report. Available online: https://www.ign.org/cm_data/IGN_
2018_Annual_Report_5_web.pdf (accessed on 19 March 2020).
20. Candido, A.C.; Morais, N.S.; Dutra, L.V.; Pinto, C.A.; Franceschini, S.D.C.C.; Alfenas, R.C.G. Insufficient
iodine intake in pregnant women in different regions of the world: A systematic review. Arch. Endocrinol.
Metab. 2019, 63, 306–311. [CrossRef] [PubMed]
21. D’Elia, L.; Obreja, G.; Ciobanu, A.; Breda, J.; Jewell, J.; Cappuccio, F.P. The Salt Consumption Survey in the
Republic of Moldova Study Group; Sodium, Potassium and Iodine Intake, in a National Adult Population
Sample of the Republic of Moldova. Nutrients 2019, 11, 2896. [CrossRef]
22. Kim, S.; Kwon, Y.S.; Kim, J.Y.; Hong, K.H.; Park, Y.K. Association between Iodine Nutrition Status and
Thyroid Disease-Related Hormone in Korean Adults: Korean National Health and Nutrition Examination
Survey VI (2013–2015). Nutrients 2019, 11, 2757. [CrossRef] [PubMed]
23. Gostas, D.E.; Larson-Meyer, D.E.; Yoder, H.A.; Huffman, A.E.; Johnson, E.C. Dietary Relationship with 24 h
Urinary Iodine Concentrations of Young Adults in the Mountain West Region of the United States. Nutrients
2020, 12, 121. [CrossRef]
24. Ellsworth, L.; McCaffery, H.; Harman, E.; Abbott, J.; Gregg, B. Breast Milk Iodine Concentration Is Associated
with Infant Growth, Independent of Maternal Weight. Nutrients 2020, 12, 358. [CrossRef]
25. Jayatissa, R.; Gorstein, J.; Okosieme, O.E.; Lazarus, J.H.; Premawardhana, L.D. Stable Iodine Nutrition During
Two Decades of Continuous Universal Salt Iodisation in Sri Lanka. Nutrients 2020, 12, 1109. [CrossRef]
26. Purdue-Smithe, A.C.; Männistö, T.; Bell, G.A.; Mumford, S.L.; Liu, A.; Kannan, K.; Kim, U.-J.; Suvanto, E.;
Surcel, H.-M.; Gissler, M.; et al. The Joint Role of Thyroid Function and Iodine Status on Risk of Preterm
Birth and Small for Gestational Age: A Population-Based Nested Case-Control Study of Finnish Women.
Nutrients 2019, 11, 2573. [CrossRef] [PubMed]
27. Giordano, C.; Barone, I.; Marsico, S.; Bruno, R.; Bonofiglio, D.; Catalano, S.; Andò, S. Endemic Goiter and
Iodine Prophylaxis in Calabria, a Region of Southern Italy: Past and Present. Nutrients 2019, 11, 2428.
[CrossRef] [PubMed]
28. Baldini, E.; Virili, C.; D’Armiento, E.; Centanni, M.; Ulisse, S. Iodine Status in Schoolchildren and Pregnant
Women of Lazio, a Central Region of Italy. Nutrients 2019, 11, 1647. [CrossRef] [PubMed]
29. Benvenga, S.; Marini, H.R.; Micali, A.; Freni, J.; Pallio, G.; Irrera, N.; Squadrito, F.; Altavilla, D.; Antonelli, A.;
Ferrari, S.M.; et al. Protective Effects of Myo-Inositol and Selenium on Cadmium-Induced Thyroid Toxicity
in Mice. Nutrients 2020, 12, 1222. [CrossRef] [PubMed]
3
Nutrients 2020, 12, 1491
30. Benvenga, S.; Ferrari, S.M.; Elia, G.; Ragusa, F.; Patrizio, A.; Paparo, S.R.; Camastra, S.; Bonofiglio, D.;
Antonelli, A.; Fallahi, P. Nutraceuticals in Thyroidology: A Review of in Vitro, and in Vivo Animal Studies.
Nutrients 2020, 12, 1337. [CrossRef]
31. Benvenga, S.; Feldt-Rasmussen, U.; Bonofiglio, D.; Asamoah, E. Nutraceutical Supplements in the Thyroid
Setting: Health Benefits beyond Basic Nutrition. Nutrients 2019, 11, 2214. [CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution




Stable Iodine Nutrition During Two Decades of
Continuous Universal Salt Iodisation in Sri Lanka
Renuka Jayatissa 1,*, Jonathan Gorstein 2, Onyebuchi E. Okosieme 3, John H. Lazarus 3 and
Lakdasa D. Premawardhana 3
1 Department of Nutrition, Medical Research Institute, Danister De Silva Mawatha, Colombo 8, Sri Lanka
2 University of Washington, Department of Global Health, Seattle, WA 98195, USA; jgorstein@ign.org
3 Centre for Endocrine and Diabetes Sciences and Thyroid Research Group, C2 Link Corridor,
University Hospital of Wales, Heath Park, Cardiff CF14 4XN, UK; Okosiemeoe@cardiff.ac.uk (O.E.O.);
Lazarus@cardiff.ac.uk (J.H.L.); PremawadhanaLD@cardiff.ac.uk (L.D.P.)
* Correspondence: renukajayatissa@ymail.com; Tel.: +94-777-788-444
Received: 23 March 2020; Accepted: 9 April 2020; Published: 16 April 2020
Abstract: Universal salt iodisation (USI) was introduced in Sri Lanka in 1995. Since then, four
national iodine surveys have assessed the iodine nutrition status of the population. We retrospectively
reviewed median urine iodine concentration (mUIC) and goitre prevalence in 16,910 schoolchildren
(6–12 years) in all nine provinces of Sri Lanka, the mUIC of pregnant women, drinking-water iodine
level, and the percentage of households consuming adequately (15 mg/kg) iodised salt (household
salt iodine, HHIS). The mUIC of schoolchildren increased from 145.3 μg/L (interquartile range (IQR)
= 84.6–240.4) in 2000 to 232.5 μg/L (IQR = 159.3–315.8) in 2016, but stayed within recommended levels.
Some regional variability in mUIC was observed (178.8 and 297.3 μg/L in 2016). There was positive
association between mUIC in schoolchildren and water iodine concentration. Goitre prevalence to
palpation was a significantly reduced from 18.6% to 2.1% (p < 0.05). In pregnant women, median UIC
increased in each trimester (102.3 (61.7–147.1); 217.5 (115.6–313.0); 273.1 (228.9–337.6) μg/L (p = 0.000)).
We conclude that the introduction and maintenance of a continuous and consistent USI programme
has been a success in Sri Lanka. In order to sustain the programme, it is important to retain monitoring
of iodine status while tracking salt-consumption patterns to adjust the recommended iodine content
of edible salt.
Keywords: iodine schoolchildren; urine iodine; goitre; iodised salt; water iodine; iodine
pregnant women
1. Introduction
Iodine is a micronutrient that primarily acts through the thyroid gland and its two hormones
(thyroxine and triiodothyronine), and it is vital to the integrity of many physiological functions in the
human body [1,2]. Iodine deficiency may affect multiple aspects of human development (including
intrauterine physical and neurological development), linear growth, and physiological organ function.
Organs such as the brain and nervous system are particularly vulnerable in their formative stages
during intrauterine life [1,2]. Fortunately, iodine deficiency is relatively easy and inexpensive to
prevent through universal iodisation of all edible salt. This is a pure food-chain effect, beginning
with soil erosion and leading to environmental iodine deficiency, and a lack of iodine sources in our
typical diet. Iodised salt was first introduced in Switzerland in 1922 [2,3] and has been used in many
previously iodine-deficient countries with good results [4]. The restoration of iodine sufficiency in
many of these countries has been a major public-health triumph facilitated by the United Nations
Children’s Fund (UNICEF), World Health Organisation (WHO), and International Council of Control
Iodine Deficiency Disorders (ICCIDD, now named Iodine Global Network (IGN)). Statutory regulations
Nutrients 2020, 12, 1109; doi:10.3390/nu12041109 www.mdpi.com/journal/nutrients5
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enforcing universal salt iodisation (USI) were implemented by regulatory authorities in each country [5].
Sri Lanka is one such country that has successfully adopted a USI programme since 1995.
History of Iodine Deficiency and Its Management in Sri Lanka
Bennet and Pridham first referred to the existence of endemic goitre along the coast of Galle in
the southern province of Sri Lanka in 1849 [6]. However, the link between poor iodine consumption
and endemic goitre was first recognised only in the 20th century in a WHO study that confirmed
high goitre rates, an iodine-poor diet, and low iodine concentrations in drinking water in 1950 [7].
Mahadeva and his group in 1960 identified a “goitre belt” extending across the western, central,
southern, sabaragamuwa, and uva provinces in Sri Lanka [8]. The high annual rainfall in these regions
led experts to believe that iodine was “leeched” from the soil, leading to iodine deficiency. At that
stage, almost no goitre had been identified in the northern, eastern, and north-western provinces [9].
However, in 1986, Fernando et al. described a high goitre rate of 18.8% in schoolchildren in 17 of 24
districts in Sri Lanka—a variable prevalence of 6.5% in the Matale district and 30.2% in the Kalutara
district [10]. This study used palpation as the method of goitre assessment, and was the first to
recognise iodine deficiency as a major public-health problem.
USI was introduced nationwide by the government in 1995 by statutory regulation [11].
This legislation banned the sale of non-iodised salt for human consumption, thus ensuring access
to iodised salt to all consumers in the country. Potassium iodate was used as the vehicle of iodine
supplementation, and added to salt at an optimal concentration of 50 ppm at producer level and 25
ppm at consumer level. The national reference laboratory for monitoring USI was established at the
Medical Research Institute (MRI) in 2000 with the aid of UNICEF. This laboratory has the dual role of
monitoring USI and of assessing its clinical impact by performing periodic national iodine surveys
(NISs). External quality control is linked to the EQUIP programme of the Centers for Disease Control
(CDC), Atlanta, Georgia, USA [12].
We review and describe the iodine-nutrition status in Sri Lanka by utilising serial datasets from
the four national iodine surveys carried out by the MRI between 2000 and 2016. We assessed the
success of USI in Sri Lanka in relation to global indicators of population iodine status, i.e., median
urine iodine concentration (mUIC), total goitre prevalence rates (TGRs), and household salt iodine
(HHIS) consumption.
2. Methods
2.1. Available Data Sources for Analysis
mUIC, TGRs, and HHIS were available for analysis from 4 national iodine surveys (NISs) between
2000 and 2016—NIS2000, NIS2005, NIS2010, and NIS2016 [13–16]. These NIS used a two-stage stratified
cluster-sampling technique as specified by the WHO, UNICEF, and IGN [17,18]. During each NIS,
the same team of field investigators visited all nine administrative provinces of the country to detect
goitres by palpation, and collected urine from 6–12-year–old schoolchildren, and salt from their
households and drinking-water samples from the household or school locality. Figure 1 illustrates
the map of Sri Lanka demarcating 9 provinces. All four national studies were carried out to ascertain
provincial variation. A total of 16,910 schoolchildren of 6–12 years of age were studied in the four
surveys and included in the final analysis (Table 1). Furthermore, we had available data for analysis
from the national micronutrient study in pregnant women in 2015 (MNSPM2015) (Table 2) [19].
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Figure 1. Map of Sri Lanka demarcating nine provinces.
Table 1. Median urine iodine concentration (mUIC), goitre prevalence, and household salt iodine
consumption in schoolchildren aged 6–12 years in 2000–2016. TGR, total goitre prevalence rate; HHIS,
household salt iodine; IQR, interquartile range.
Surveys UIC (μg/L) TGR 3 HHIS (%) 4
% < 50 1 Median (IQR) 2 % <5 5–14.9 15–30 >30
NIS–2016
(n = 5000) 1.6
232.5
(159.3–315.8) 1.9 3.1 18.4 63.5 15.0
NIS–2010
(n = 7401) 6.7
163.4
(99.1–245.1) 4.4 4.6 27.1 52.5 16.1
NIS–2005
(n = 1879) 7.4
154.4
(90.3–252.6) 3.8 0.0 8.7 47.7 43.5
NIS–2000
(n = 2628) 2.7
145.3
(84.6–315.8) 18.0 – – – –
Note: 1–4 p = 0.000. (- No data)
Table 2. Median UIC in pregnant women in three trimesters (national micronutrient study in pregnant
women in 2015, NNMSPM2015).
Trimesters UIC (μg/L) No
Period of Amenorrhea (POA) % <50 1 Median (IQR) 2
First trimester
(≤12 weeks of POA) 17.0 102.3 (61.7–147.1) 447
Second trimester




(>28 weeks of POA) 0.0
273.1
(228.9–337.6) 176
Overall 10.1 157.7 (91.2–256.4) 962
1,2 p = 0.000.
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2.2. Indicators of Population Iodine Status
Three primary indicators of population iodine status were considered, and we used the
methodology described below to assess the outcomes of the USI programme: (i) mUIC was measured
by ammonium persulfate digestion with spectrophotometric detection of the Sandell–Kolthoff reaction
in a laboratory certified by the EQUIP programme [20–22]; (ii) TGR—the grading of goitres was done
by palpation by the same team utilising the classification recommended by the WHO, UNICEF, and
IGN [3,18]: (a) “no goitre”—thyroid not palpable or visible; (b) “goitre present”—thyroid palpable not
visible or palpable and visible; and (iii) iodine content in salt: titration method to measure the iodine
content of salt certified by a regional iodine laboratory [3,18]. Geographical location (province), iodine
in drinking water, and household salt were measured to estimate their influence on optimal iodine
consumption. Iodine levels in drinking water at the household level and school localities were tested
using ammonium persulfate oxidation [20].
3. Data Analysis
The following definitions were used for classifying population iodine nutrition status [22].
(i) Median UIC: (a) adequate mUIC—150–299μg/L (pregnant women) and 100–299μg/L (schoolchildren);
(b) excessive mUIC—≥300 μg/L; and (c) iodine sufficiency—<20% samples should have mUIC of
<50 μg/L. (ii) Household salt iodine (HHIS) content: we classified salt iodine content as follows.
(a) <5 mg/kg—non-iodised; (b) 5–14.9 mg/kg—inadequately iodised; (c) 15–30 mg/kg—adequately
iodised; and (d) >30 mg/kg—over-iodised. (iii) Iodine content in drinking water: iodine in
drinking water was classified as follows. (a) <5 mg/kg—no iodine; (b) 5–14.9 mg/kg—low iodine;
(c) 15–30 mg/kg—moderate iodine; and (d) >30 mg/kg—high iodine [23,24].
Statistical analysis was performed using SPSS (IBM version 24). Data that were not normally
distributed were expressed as median and interquartile range (IQR) unless otherwise stated.
The Mann–Whitney U–test was used to compare data between the two groups. The Kruskal–Wallis
test (nonparametric analysis of variance (ANOVA)) was used to assess the significance of differences
between more than two groups. Categorical variables were analysed using the chi-squared test for
trend; a p–value of <0.05 was considered statistically significant.
4. Results
(i) mUIC was consistently in the adequate or iodine-sufficient range in all four national iodine
surveys of 2000–2016. There has been a significant increase in mUIC, but still within the adequate
range in surveys between 2000 (145.3 (84.6–240.4)) and 2016 (232.5 (159.3–315.8)); p = 0.000). There has
also been a significant reduction in the percentage of schoolchildren with mUIC < 50 μg/L (2.7% in
2000 vs 1.6% in 2016; p = 0.000). As shown in Table 2, the mUIC of pregnant women was also in the
adequate or iodine-sufficient range (157.7 (228.9–337.6) μg/L) at the national level, and in the second
and third trimesters 217.5 (115.6–313.0), and 273.1 (228.9–337.6) μg/L; p < 0.000). Table 3 shows there
is regional variability in mUIC levels in children of 6–12 years of age (297.3 vs. 178.8 μg/L in 2016;
p = 0.000). It was significantly higher in the northern and north–central provinces when compared to
the rest of the country since 2005.
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Table 3. Regional variations of key indicators of population iodine nutrition in 2000–2016.
Province









































































































































Note: 1–10 p = 0.000.
(ii) There was significant reduction in TGR by palpation between surveys done in 2000 (18.0%)
and 2016 (1.9%; p = 0.000; Table 1).
(iii) The iodine content of HHIS was only measured since 2005, and since that time, over 95% of
all HHIS has contained at least some iodine (>5 mg/kg). The percentage of HHIS with adequate iodine
concentrations (defined as 15–30 mg/kg) showed a significant increase—47.7% in NIS2005 vs. 63.5% in
NIS2016 (p = 0.000). Furthermore, only 3.1% had a salt content of <5 mg/kg (non-iodised) in the last
survey in 2016. The prevalence of over-iodised salt (>30mg/kg) significantly fell from 43.5% in 2005 to
15.0% in 2016 (p = 0.000; Table 1). HHIS was less than 90% at the national level, and in all provinces in
2010 and 2016 except for the central and eastern provinces. In 2016, the interprovincial difference of
median iodine content in HHIS was between 18.0 and 27.5 mg/kg (Table 3).
(iv) Median iodine content of drinking water was 33.4 (12.3–66.8) μg/L. Wide variation was
observed between provinces (8.3 (4.6–29.0) vs 75.5 (48.4–102.5) μg/L; p = 0.000) in the uva and
north–central provinces, respectively (Table 4).
Table 4. Regional variations of median iodine content of drinking water in 2016.
Province No Median (IQR) μg/L
Western 67 15.6 (4.1–29.1)
Southern 70 19.1 (15.3–29.9)
Central 68 18.0 (5.7–44.6)
Northern 78 53.4 (28.9–79.4)
Eastern 189 33.3 (17.0–69.6)
North Western 122 39.9 (9.4–61.4)
North Central 170 75.5 (48.4–102.5)
Uva 62 8.3 (4.6–50.4)
Sabaragamuwa 108 31.3 (15.1–50.4)
Sri Lanka 934 33.4 (12.3–66.8)
Note: p = 0.000.
Figure 2 provides a graphical representation of the data on median UIC of children aged 6–12 years
in 2016, stratified by the iodine content in HHIS and in drinking water. These data are noteworthy
since the mUIC was within the optimal range in all subgroups, including those households of which
the iodine content in HHIS was <5 ppm or in the range of 5–14.9 ppm, suggesting that the consumed
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iodine in HHIS is not the exclusive diet source of iodine. There was a significant increase in median
UIC with increasing iodine concentrations in drinking water (p = 0.000).
Figure 2. Median urine iodine concentration (IQR) and its relationship with iodine concentrations in
household salt and drinking water in school children aged 6–12 years in 2016.
5. Discussion
USI was first implemented in Sri Lanka in 1995. We demonstrated in this retrospective review of
data from four national iodine surveys of over more than two decades of continuous salt iodisation
that (i) mUIC has consistently been in the adequate range with a sequential increase within safe
and recommended limits; (ii) the goitre-prevalence rate to palpation in children between 6–12 years
significantly decreased between 2000 and 2016 (18.0% to 1.9%; p = 0.000); and (iii) the percentage of
adequately iodised household salt samples significantly increased during this period (47.7% in 2005 vs.
63.3% in 2016; p = 0.000), and its household consumption remains satisfactory (Tables 1 and 3).
These indices of population iodine nutrition favourably reflect the success of the USI programme
enforced by successive governments of Sri Lanka, having adequate iodine status at the national level
and in most provinces (Tables 1 and 3). Furthermore, there has been a recurrence of iodine deficiency
in several countries where iodine-deficiency disorders (IDDs) were eliminated with USI because of
inadequate monitoring of their USI programmes [25–29]. Strict monitoring is essential in sustaining
proper iodine nutrition in countries that adopt USI [28].
However, there is a need for caution. (a) The median UIC of pregnant women is only marginally
above the recommended cut off of 150 μg/L, and iodine-insufficient in the first trimester (102.3
(61.7–147.1) μg/L (Table 2)). There was a remarkable improvement in the iodine status of pregnant
women compared to 2011 (113.7 μg/L) [30]. There was also a significant minority of pregnant women
(nearly 10%) who had a median UIC of <50 μg/L. This is an important population group, and
inadequate iodine delivery to this group may have important long-term consequences, particularly
regarding the intrauterine development of the brain, central nervous system, and physical growth [29].
(b) The median UIC of schoolchildren in the northern and north–central provinces in 2016 approached
300 μg/L. In these two areas at risk of iodine excess, iodine content in drinking water was the highest
among those provinces (Table 4). Other countries’ experience with high iodine content in drinking
water should be reviewed [31,32]. (c) Some regional variability in mUIC was observed over the course
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of the programme, but in the most recent survey, the range was between 178.8 and 297.3 μg/L, all within
the optimal range. The reasons for regional variability of median UIC have not been investigated in
detail, but need to be noted (Table 2). There is a clear need, therefore, to closely monitor these groups
in the future, with periodic well-designed and more elaborate studies. However, we acknowledge that
these UIC assessments were done on single “spot” samples of urine and may not be truly representative
of the iodine-nutrition status of each individual in these communities [28].
We also showed that the supervision and monitoring of salt iodisation has improved over two
decades of USI. The percentage of samples delivering adequate levels of salt at the consumer level
(i.e., 15–30 mg/kg) increased from 47.5% in NIS2005 to 63.3% in NIS2016 (p = 0.000), while at the
same time, the percentage of over-iodised salt samples has significantly decreased (p = 0.000; Table 1).
The percentage of households using adequately iodised salt was less than 90% (the WHO goal for USI)
at the national level and in seven out of nine provinces (Table 3). However, it showed that the median
HHIS content in provinces was between 18.0 and 27.5 mg/kg, confirming that household iodised salt
was providing a significant amount of iodine to the diet [33].
Despite a <90% of households consuming adequately iodised salt, there has been an increase
in mUIC, and some provinces in the country consistently showed a high level of mUIC. Daily mean
per capita salt intake of Sri Lankans was reported as 8.3 g (CI: 7.9, 8.8) in 2012 [34]. We also need to
be aware of the contribution of other sources of iodine contributing to population iodine nutrition,
e.g., drinking water, processed foods, or condiments, which are being manufactured with iodised salt,
as well as some iodine in foods. Our results indicated a positive association between iodine status
in schoolchildren and water iodine concentration, although the major contributor to iodine intake
is iodised salt in the diet (Figure 2). In fact, over 95% of households have consistently had access to
iodised salt since 2005. A similar contribution was observed in other countries [24,32]. There is a need
to adjust the recommended level of HHIS, and to explore the iodine supply through different dietary
sources and the geological assessment of soil iodine content for future monitoring.
IGN/UNICEF recommends that the optimal iodine intake, as measured by the median UIC
for school-age children, should be <300 μg/L, while the mUIC among pregnant women should be
<500 μg/L [22]. Thus, the current salt-iodisation programme is having its desired impact and not
placing the Sri Lankan population at risk for iodine excess, as described in the previous study [33].
The salt-iodisation programme needs to be consistently monitored so that the level of iodine in all
edible salt, including that used at the household level as well as in processed foods and condiments,
leads to an optimal intake. As salt-reduction efforts are implemented, there may be a decline in overall
salt consumption, in which case the government may need to accordingly adjust the recommended
salt iodine level to ensure that public-health strategies of iodine-deficiency prevention, salt reduction,
and reduction in NCDs are realised.
Despite adequate iodine nutrition among schoolchildren, iodine nutrition among pregnant women
remains just above the cut-off levels in the country. There is a need to focus on pregnant women for
continuous monitoring while sustaining the iodised-salt programme.
This study has several strengths. (a) Data availability from a large number of 6–12-year-old
schoolchildren (16,910 in total); (b) uniform methodology for UIC assessments over the period of
review in a single laboratory with stringent external quality control; (c) permanent health staff used
as a single team in all four studies and goitre palpation; (d) minimising variability in urine- and
salt-assay methodology using the same protocols developed by the UNICEF, WHO, and IGN. However,
the unavailability of pre-USI data for comparison was an inherent shortcoming of this study.
6. Conclusions
The iodine nutrition of the population has remained optimal and stable in Sri Lanka during more
than two decades of continuous salt iodisation after its introduction in 1995. However, we recommend
the close and careful monitoring of pregnant women and schoolchildren in view of the data we presented.
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The delivery of salt to consumers has improved and is adequate in the majority. The contribution of
dietary sources other than salt needs to be assessed in well-planned studies.
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Abstract: Background: Iodine deficiency is not seen as a public health concern in the US. However
certain subpopulations may be vulnerable due to inadequate dietary sources. The purpose of the
present study was to determine the dietary habits that influence iodine status in young adult men
and women, and to evaluate the relationship between iodine status and thyroid function. Methods:
111 participants (31.6 ± 0.8 years, 173.2 ± 1.0 cm, 74.9 ± 1.7 kg) provided 24 h urine samples and
completed an iodine-specific Food Frequency Questionnaire (FFQ) for assessment of urinary iodine
content (UIC) as a marker of iodine status and habitual iodine intake, respectively. Serum Thyroid
Stimulating Hormone (TSH) concentration was evaluated as a marker of thyroid function. Spearman
correlational and regression analysis were performed to analyze the associations between iodine
intake and iodine status, and iodine status and thyroid function. Results: 50.4% of participants had
a 24 h UIC < 100 μg/L). Dairy (r = 0.391, p < 0.000) and egg intake (r = 0.192, p = 0.044) were the
best predictors of UIC, accounting for 19.7% of the variance (p ≤ 0.0001). There was a significant
correlation between UIC and serum TSH (r = 0.194, p < 0.05) but TSH did not vary by iodine status
category (F = 1.087, p = 0.372). Discussion: Total dairy and egg intake were the primary predictors
of estimated iodine intake, as well as UIC. Iodized salt use was not a significant predictor, raising
questions about the reliability of iodized salt recall. These data will be useful in directing public
health and clinical assessment efforts in the US and other countries.
Keywords: Iodine Status; Food Frequency Questionnaire; iodized salt; iodine intake; dairy
intake; adults
1. Introduction
Iodine is an essential trace mineral that forms the building blocks of the thyroid hormones
thyroxine and triiodothyronine, which are critical regulators of metabolic activity [1]. Iodine’s major
environmental source is the ocean [2], with seafood and seaweed providing significant dietary sources.
The iodine content of most other foods, however, is low and dependent on soil content and agriculture
practices [3]. Exceptions include dairy products, which may be richer sources due to livestock iodine
supplementation and use of iodophors for cleaning milk udders [4–6]. Insufficient iodine intake
leads to iodine deficiency, which can manifest as hypothyroidism and endemic goiter in adults [3,7].
Iodine deficiency is of particular concern in women of reproductive age, as many pregnancies are
unplanned [8], and deficiency can impair fetal cognitive and physical development [3,7].
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Although iodine deficiency is a worldwide concern, with nearly one-third of the global population
thought to be deficient [9], the iodine status of the US population has been viewed as adequate since
the widespread iodization of salt in the late 1920s [10]. Urinary iodine concentration (UIC) measured
over 24 h is a commonly used biomarker to assess iodine status in populations [3,11]. The most
recent data from the National Health and Nutrition Examination Survey (NHANES 2005–2006 and
2007–2008) [12] show median UIC as adequate at 164 μg/L, with just under 10% of the population
categorized as severely deficient [12]. Still, some subpopulations of the US may be vulnerable to
deficiency due to food selection patterns or avoidance of iodized salt. These at-risk subpopulations
include vegans/vegetarians [13], those who avoid seafood and/or dairy [14], and those follow a sodium
restricted diet [15–17] or eat local foods in regions with iodine-depleted soils [2,3]. The Institute of
Medicine [18] and the American Heart Association [19] have advocated for decreasing sodium intake
to less than 2300 mg per day [18] and, more prudently, to less than 1500 mg per day [19], which
could be reducing Americans’ intake of iodized salt. Additionally, apparent trends toward local and
plant-based diets may negatively influence iodine status depending on food selection patterns and
habits (e.g., avoidance of seafood and dairy) and the content of local soils. Therefore, despite the
labeling of the US populations’ iodine intake as adequate, certain dietary choices, including strict
adherence to dietary recommendations to restrict salt intake [20], may directly influence iodine status
and indirectly influence thyroid function.
The present study was a pilot study that aimed to assess iodine intake and status in a sample
of young adult men and women and determine the dietary patterns and habits that influence the
observed iodine status. Twenty-four hour UIC was used as a reference standard for estimation of
iodine status [7,21] although there is no consensus on the biomarker to use for the assessment of
individual iodine status [22,23]. We hypothesized, based on the above, that we would observe at least
some individuals with a low 24 h UIC (<100 μg/L), and that UIC would be associated with dietary
factors such as the frequency of milk, fish and seafood intake, multivitamin and iodized salt use, and
vegetarian status. A secondary purpose was to explore the relationship between iodine status and
hypothyroidism using the thyroid stimulating hormone (TSH) as a general marker of thyroid function.
2. Materials and Methods
This study was conducted concurrently as part of a larger study evaluating urine color as a
marker of change in daily water intake [24] conducted over a 13 month period beginning in the spring
of 2016. Male and female participants between the age of 18 and 45 years were recruited from the
Laramie, Wyoming community. To be eligible, participants had to be in good overall health and not
have a health condition that could influence study results (e.g., anemia, diabetes, cystic fibrosis, cancer
autoimmune disorders). Exclusionary criteria are previously published [24] and include: inability
to understand and write English (for ability to complete written survey instruments); evidence of
clinically relevant metabolic, cardiovascular, hematologic, hepatic, gastrointestinal, renal, pulmonary,
endocrine or psychiatric history of disease (based on the medical history questionnaire); pregnancy or
breast-feeding; regular prescription drug treatment within 15 days prior to start of the study; inability
to discontinue use of specific dietary/herbal supplements (calcium, chromium, vitamin C, cat’s claw,
chaparral, cranberry, creatine, ephedra, germanium, hydrazine, licorice, l-lysine, pennyroyal, thunder
god vine, willow bark, wormwood oil, yellow oleander, yohimbe); currently exercising >4 h per week;
changes in diet or in body mass of >2.5 kg (~5 lbs) in the past month; or recent relocation from low
altitude to Laramie within the past three months. The study was approved by the Institutional Review
Board of the University of Wyoming. Volunteers were informed that the urine samples collected to
assess hydration status would also be used to establish the iodine status of a healthy population of
individuals through measurement of iodine levels in urine and if these levels are related to specific
dietary or lifestyle factors. They were also informed of any possible risks prior to giving written formal
consent to participate in the study.
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2.1. Overview of Testing
This analysis was performed on 111 of the 125 total participants enrolled in the study, who
had complete data on 24 h urinary iodine concentrations (UIC) and valid responses from a food
frequency questionnaire (FFQ). Reasons for exclusion of 14 of the 125 participants included: voluntary
withdrawal prior to completion, not following study protocol instructions, not providing adequate
urine for analysis or not turning in complete dietary data. At study initiation (baseline), participants
completed a dietary habits survey and an iodine-specific food-frequency questionnaire (FFQ). Height
and weight were measured on a stadiometer (Health o meter ®, Model 201 HR) and digital weight scale
(Seca, Model 780 2321138), respectively, with body mass index (BMI) calculated as kg/m2. Physical
activity was estimated using the International physical Activity Questionnaire (IPAQ) [25].
2.2. Measurement of Urinary Iodine Concentration and Iodine Status
As part of an 11 day collection protocol, participants collected a 24 h urine sample for the purpose
of UIC measurement on the morning of day two. Participants were asked to void and discard the first
morning urine sample and then collect all subsequent samples for 24 h, ending with the first sample
upon waking on day three. Food and fluid intake were ad libitum during this 24 h urine collection.
Iodine in urine was measured by a commercial laboratory (Mayo Clinic, Rochester, MN) using an
inductively coupled plasma-mass spectrometry using tellurium as an internal standard and an aqueous
acid calibration. The repeated tolerance acceptability was 10 ng/mL or 10%. Twenty-four hour UIC
was defined using the following criteria: <20 μg/L (severe iodine deficiency), 20–49 μg/L (moderate
iodine deficiency), 50–99 μg/L (mild iodine deficiency), 100–199 μg/L (adequate iodine nutrition),
200–299 μg/L (more than adequate iodine intake), ≥300 μg/L (excessive iodine intake) [15]. UIC was
also entered into the equation of Zitterman, which incorporates body mass to estimate intake [26,27].
Urinary iodine (μg/L) × 0.0235 × body weight (kg) = Daily Iodine Intake.
2.3. Iodine Intake, Frequency of Iodine Containing Foods and Dietary Habits
The iodine-specific FFQ (Appendix A) evaluated the frequency of consumption of 43 food items
known to have significant iodine content (e.g., seafood, seaweed, dairy—see Table 1). Frequency was
evaluated according to the following responses: (a) never or less than one time per month; (b) one to
three times per month; (c) one time per week; (d) two to four times per week; (e) five to six times per
week; (f) one time per day; (g) two to three times per day; (h) four to five times per day; (i) or six or
more times per day). Daily intake of iodine was estimated by multiplying the frequency midpoint by
the average content of each vitamin D-containing food and expressed as IU/day (assuming 30 days
per month), as previously outlined by Halliday et al. [28]. As iodine content is not available in food
composition tables or databases, iodine content of the food items in the FFQ was derived from several
sources (Table 1), with a majority of the data coming from the ongoing Total Diet Study (TDS) [29].
Iodine content in the TDS is listed per 100 g of the selected food item. Iodine content was recalculated
from the TDS to iodine per serving size, to match the household measured listed in the FFQ. The iodine
content in other sources was also converted to adjust given units to iodine per serving size. For ease of
analysis, iodine intake from specific categories of foods were combined, which included estimates of
iodine intake from total dairy (fluid milk plus yogurt), total fish (all types of fish) and total seafood
(total fish plus all types of shellfish).
The Dietary Habits Survey (Appendix B) addressed questions regarding the frequency of table salt
use in salting and cooking foods, and the type of table salt typically consumed (iodized, non-iodized).
It also addressed whether participants followed a vegetarian diet, frequented a farmer’s market for
local food purchases, were a member of a Community Supported Agriculture program (CSA), or
maintained a home garden for growing food, based on Yes, Sometimes, or NO responses (Appendix B).
Both instruments were developed for the current study and have not yet been validated.
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Table 1. Iodine content of foods deduced from current available resources.
Food Item Estimated Iodine Level (μg per Serving) Serving Size
Milk (fluid) 90.86 a 1 cup
Soy Milk 2.2 b 1 cup
Soy Protein Bar 20 c 1 bar
Soy Protein Powder 0 d 1 scoop
Soy Sauce 0 d 1 Tbsp
Non-dairy Milk 2.2 b 1 cup
Orange Juice 0 a 1 cup
Cereal 1.62 a 34 cup
Bread 1.18 a 1 slice (26 g)
Subway Sandwich 4.14 a 6-inch sandwich
Bagel 4.312 a 1 bagel (95 g)
Yogurt 87 a 1 cup
Cheese 13.33 a 2 oz
Egg 21.42 a 1 egg (50 g)
Margarine 0 a 1 tsp
Liver 11 a 100 g (3.5 oz)
Cod 93 e 3.5 oz
Grouper 84 f 3.5 oz
Haddock 224 e 3.5 oz
Halibut 9.9 e 3.5 oz
Herring 84 f 3.5 oz
Mackerel 84 f 3.5 oz
Perch 10.89 e 3.5 oz
Salmon 10.43 e 3.5 oz
Sardines 6.69 g 3.5 oz
Seabass 84 f 3.5 oz
Swordfish 19.8 e 3.5 oz
Tukaoua 84 f 3.5 oz
Tuna Albacore 6.69 a 3.5 oz
Tuna Light 6.69 a 3.5 oz
Walleye 84 f 3.5 oz
Other Fish 22 h 3.5 oz
Clams 74.8 e 4 oz
Crabmeat 42.56 e 4 oz
Lobster 209.67 e 4 oz
Mussels 9.14 i 4 oz
Oysters 135 e 4 oz
Scallops 9.14 e 4 oz
Shimp 8.184 a 4 oz
Seaweed 34.56 j 2.6 g (1 sheet)
Iodized Table Salt 68 k 1.5 g (1/4 tsp)
Other Salt 0 l 1.5 g
Multivitamin-(Iodine-Containing) 150 m 1 tablet
Kelp Supplement 225 c 1 capsule
Sources: a Total Diet Study 2006–2013 [29], b Bath et al. [30], c Popular product nutrient labels, d American
Thyroid Association [31], e United States Department of Agriculture (USDA) National Food and Nutrient Analysis
Program [32], f Inferred from other fish values from USDA’s National Food and Nutrient Analysis Program,
g Inferred from Canned Tuna TDS 2006–2013, h Inferred from the average of multiple fish types from USDA’s
National Food and Nutrient Analysis Program, I Inferred from the scallop value from USDA’s National Food and
Nutrient Analysis Program, j Teas et al. 2004 [33], k Total Diet Study 1982–1991 [34], l Dasgupta et al. 2008 [35],
m Summation of observation of popular multivitamins available at local grocery stories and pharmacies.
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2.4. Assessment of Thyroid Function
A blood sample was obtained on the morning of day three for measurement of TSH via
immunometric assay, (Regional West, Scotts Bluff, NE). Daily quality control at different representative
levels was evaluated across the measurement range, as precision changed with concentration for
112 replicates. The CV was 3.4% when the mean was 50 μg I per 24 h, and 1.3% when the mean was
191 μg I per 24 h. The presence of hypothyroidism (TSH > 4.68 mIU/L) and hyperthyroidism (TSH <
0.47 mIU/L) was evaluated based on standard laboratory ranges (normal TSH = 0.47 to 4.68 mIU/L) as
well as using recent, more conservative criteria for subclinical hypothyroidism (TSH > 2.5) [36].
2.5. Statistical Analysis
Data were analyzed using IBM SPSS statistics software (SPSS Inc., Chicago, IL; version 24.0).
Analysis of Variance (ANOVA) was used to compare differences in iodine intake, iodine status, thyroid
function and other key variables by sex (male vs. female). Correlation coefficients (Pearson or
Spearman Rank) were used to evaluate the associations between iodine status (i.e., UIC) and gross
iodine intake, or iodine intake from specific foods or supplements (dairy, seafood, seaweed, iodized
salt, multivitamin intake, etc.). Pearson correlations were also used for the evaluation of UIC and
serum TSH relationships. In most cases, Spearman Rank Coefficients were used instead of Pearson
Correlation Coefficients, due to the general non-normal distribution of intake data. Multiple linear
Regression Models (Backwards Regression) were created to determine which dietary source(s) were the
largest contributors to iodine intake and iodine status. ANOVA was also used to determine whether
there were differences in iodine intake and status by the items indicated on the dietary habits survey,
which included following a vegetarian diet, frequenting farmer’s markets for local food purchases,
being CSA members or maintaining a home garden for growing food. Data are expressed as means ±
SEM unless otherwise specified. Significance was set as an alpha < 0.05.
3. Results
3.1. Subject Characteristics
The characteristics of the 111 participants are shown in Table 2. BMI and reported physical activity
varied widely among participants. Men were taller, heavier, and had a higher BMI than women
(p < 0.05). The sample size is provided in parenthesis in the case of occasional missing datapoints,
attributed to inadequate samples for analysis or missing responses on questionnaires.
Table 2. Descriptive characteristics of Participants and Frequency of Overweight, Smoking and Physical
Activity by Sex.
Mean ± SEM n
Age 31.6 ± 0.8 111
Height (cm) 173.2 ± 1.0 111
Body Mass (kg) 74.9 ± 1.7 111
BMI (kg/M2) 24.8 ± 0.4 111
Hematocrit (%) 45.1 ± 0.28 110
TSH (mIU/L) 2.1 ± 0.11 107
Male (n) Female (n)
Sex 59 52 111
BMI Underweight 1 0 1
BMI Normal 25 36 61
BMI Overweight 26 13 39
BMI Obese 7 3 10
Smokers 4 0 4
IPAQ Low 10 7 17
IPAQ Moderate 21 30 51
IPAQ High 22 14 36
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3.2. 24 h UIC and Iodine Status
Twenty-four hour UIC ranged between 15 and 714 μg/L. The median value was 98.0 μg/L
(interquartile range = 60.0–180.0), with no difference by sex (p = 0.36). The frequency of the various








Figure 1. Iodine status based on the World Health Organization (WHO) criteria for urinary iodine
concentration (UIC) [15]: <20 μg/L (Severe Deficiency); 20–49 μg/L (Moderate Deficiency); 50–99 μg/L
(Mild Deficiency); 100–199 μg/L (Adequate); 200–299 μg/L (More than Adequate); ≥300 μg/L (Excessive).
Body Mass Index (BMI) and International Physical Activity Questionnaire (IPAQ) [37] scales
were used in classifications. BMI classifications are as follows: Underweight (<18.5), Normal weight
(18.5–24.9), Overweight (25.0–29.9), Obese (>30.0). IPAQ classifications are as follows: Low (not
meeting criteria for Moderate or High), Moderate (likely doing 30 min moderate intensity physical
activity on most days), High (likely doing at least 1 h of moderate intensity physical activity per
day) [25].
3.3. Estimated Daily Iodine Intake and Frequency of Intake of Iodine-Containing Foods
Frequency of consumption of selected iodine-containing foods along with supplements is shown
in Table 3. Overall, estimated daily iodine intake ranged from 36.4 to 1113.3 μg/day. Daily intake
averaged 327.7 μg (SD: 21.0; median 291.4) and was not different by sex (p = 0.49). While the mean
and median iodine intake was higher than the U.S. Recommended Dietary Allowance (RDA) for
adults of 150 μg/day, 21.6% (n = 24) had estimated intakes less than the RDA, and 1.8% (n = 2) had
intakes greater than the Upper Limit of 1100 μg/day. The estimated average daily iodine intakes
from contributing foods are as follows) total dairy (100.0 μg ± 8.6), eggs (18.7 μg ± 2.3), total fish
(4.4 μg ± 1.3), total seafood (includes fish plus shellfish; 8.4 μg ± 1.7), iodized table salt (33.7 μg ±
5.1), multivitamin (47.61 μg ± 9.0), and seaweed (0.81 μg ± 0.25). Using Spearman rank correlation
coefficients, the total estimated iodine intake from the FFQ was correlated with reported total milk
intake (r = 0.769, p < 0.001), dairy intake (milk plus yogurt) (r = 0.716, p < 0.01), egg consumption (r =
0.295, p = 0.002), total fish intake (r = 0.191, p = 0.044) and multivitamin use (r = 0.460, p < 0.01) but
not with total seafood consumption (r =0.169, p = 0.08), seaweed consumption (r = −0.050, p = 0.6),
or iodized salt intake (r = 0.141, p = 0.14).
A linear regression model was created to determine which food source was the biggest determinant
of estimated iodine intake. Dietary sources that were significantly correlated with total intake by simple
correlation analysis (total dairy, egg consumption, total fish and multivitamin use) were entered, along
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with iodized table salt and seaweed. As shown in Table 4, all sources remained significant contributors
to estimated iodine intake.
Table 3. Frequency of major sources of reported dietary iodine by serving.
Food Serving Size Iodine (μg per Serving) Frequency
Milk (1 cup fluid) (n = 110 *) 90.86 0 or <1 times·month−1 = 17
1–3 times·month−1 = 12
1 time·week−1 = 10
2–4 times·week−1 = 26
5–6 times·week−1 = 15
1 time·day−1 = 17
2–3 times·day−1 = 11
4–5 times·day−1 = 2
Yogurt (1 cup) (n = 111 *) 87 0 or <1 month−1 = 26
1–3 times·month−1 = 17
1 time·week−1 = 15
2–4 times·week−1 = 24
5–6 times·week−1 = 18
1 time·day−1 = 9
2–3 times·day−1 = 2
4–5 times·day−1 = 0
Eggs (1 whole) (n = 109 *) 21.42 0 or <1 month−1 = 16
1–3 times·month−1 = 8
1 time·week−1 = 15
2–4 times·week−1 = 29
5–6 times·week−1 = 18
1 time·day−1 = 6
2–3 times·day−1 = 11
4–5 times·day−1 = 6
Total Seafood (3.75 oz) (n = 110 *) 61 0 or <1 month−1 = 28
1–3 times·month−1 = 48
1 time·week−1 = 22
2–4 times·week−1 = 9
5–6 times·week−1 = 1
1 time·day−1 = 2
2–3 times·day−1 = 0
4–5 times·day−1 = 0
Iodized Table Salt (1.5 g) (n = 108 *) 68 0 or <1 month−1 = 28
1–3 times·month−1 = 18
1 time·week−1 = 12
2–4 times·week−1 = 12
5–6 times·week−1 = 12
1 time·day−1 = 14
2–3 times·day−1 = 10
4–5 times·day−1 = 2
Multivitamin (1 tablet) (n = 106 *) 150 0 or <1 month−1 = 67
1–3 times·month−1 = 8
1 time·week−1 = 3
2–4 times·week−1 = 4
5–6 times·week−1 = 4
1 time·day−1 = 17
2–3 times·day−1 = 2
4–5 times·day−1 = 1
* Number of participants who reported consuming each food source.
Table 4. Backwards Regression Model with Estimated iodine intake from food frequency questionnaire
(FFQ) as the dependent variable and estimated iodine intake from various food categories as
independent variables.
R2 SEE Beta Sig.
Model 0.991 21.81 0.005
Total Dairy - - 0.066 >0.001
Total Fish - - 0.108 >0.001
Multivitamin - - 0.034 >0.001
Iodized Table Salt - - 0.033 >0.001
Seaweed - - 0.122 >0.001
Egg - - 0.032 >0.001
SEE, standard error of the estimate.
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3.4. Relationship between Iodine Intake and Iodine Status
Using Spearman Rank Correlations, the estimated total iodine intake from the FFQ was correlated
with UIC (r = 0.310, p = 0.001) (Figure 2a). FFQ-estimated iodine intake was also correlated with
predicted iodine intake using the equation of Zimmerman UIC (r = 0.327, p = 0.001) which incorporates





Figure 2. Estimated iodine intake by Food Frequency Questionnaire versus Urinary Iodine
Concentration (a) and Iodine Intake Prediction (using the equation of Zimmerman) [26,27] where Daily
Iodine Intake = Urinary iodine (μg/L) × 0.0235 × body weight (kg) (b).
By Spearman Rank Correlation Coefficients, UIC was correlated with reported total dairy intake
(r = 0.391, p < 0.01), egg consumption (r = 0.192, p = 0.044) and seaweed consumption (r = −0.239,
p = 0.011), but not with total fish intake (r = −0.003, p = 0.973), total seafood consumption (r = −0.055,
p = 0.569), iodized table salt use (r = 0.044, p = 0.646) or multivitamin use (r = 0.031, p = 0.749).
A linear regression model was created to determine which food source(s) were the biggest
determinant of 24 h UIC. Intake of iodine from dairy products, eggs, seaweed, fish, iodized salt and
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eggs were entered into the model. As shown in Table 5, only dairy and eggs remained significant
contributors to UIC, explaining 19.7% of the variance (p ≤ 0.0001). Total fish, iodized table salt,
multivitamin use and seaweed consumption accounted for an additional 3.2% of the variance, but
were not significant contributors (p > 0.10).
Table 5. Backwards regression models with urinary iodine concentration (UIC) as the dependent
variable and estimated iodine intake from total dairy, total fish, multivitamin, iodized salt, seaweed
and egg consumption entered as independent variables.
R2 SEE Beta Sig.
Model 1 0.229 118.1 0.001
Total Dairy - - 0.017 0.001
Total Fish - - −0.033 0.249
Multivitamin - - −0.006 0.128
Iodized Table Salt - - 0.003 0.704
Seaweed - - 0.111 0.455
Egg - - 0.037 0.032
Model 2 0.228 117.6 0.001
Total Dairy - - 0.017 0.001
Total Fish - - −0.033 0.234
Multivitamin - - −0.006 0.118
Seaweed - - 0.105 0.474
Egg - - 0.038 0.024
Model 3 0.224 117.3 0.001
Total Dairy - - 0.016 0.001
Total Fish - - −0.033 0.234
Multivitamin - - −0.006 0.125
Egg - - 0.040 0.016
Model 4 0.213 117.5 0.001
Total Dairy - - 0.016 0.001
Multivitamin - - −0.006 0.136
Egg - - 0.041 0.013
Model 5 0.197 118.2 0.000
Total Dairy - - 0.016 0.000
Egg - - 0.039 0.018
3.5. Dietary Habits, Iodine Intakes and Intake Status
Twenty-one participants neglected to complete all questions on the Dietary Habits Survey.
Complete data for those responding to questions addressing vegetarian status (n = 94), frequently
visiting a farmer’s market or food co-op for local food purchases (n = 95), having membership in a
CSA (n = 94), and growing food in a home garden (n = 95) are shown in parentheses. Of those who
completed the questions, five reported following a vegetarian or vegan diet, 49 reported regularly or
sometimes frequenting a farmer’s market for local food purchases, with 37 being members of a CSA or
maintaining a home garden for growing food. Differences between estimated iodine intake or UIC
were not observed according to whether participants reported following a vegetarian diet (p = 0.52 and
0.91), regularly or sometimes frequenting a farmer’s market (p = 0.60 and 0.49), being a CAS member
(p = 0.44 and 0.38) or maintaining a home garden (0.58 and 0.49) (p > 0.05).
3.6. Relationship between Iodine Status and Thyroid Function
The mean TSH (n = 107) was 2.07 ± 0.11 mIU/L. Based on standard laboratory criteria, four
participants were classified with hypothyroidism (TSH > 4.68 mIU/L) and one was classified with
hyperthyroidism (TSH < 0.47 mIU/L). Using more conservative criteria (TSH > 2.5), 24 were considered
to have an underactive thyroid [36]. By Spearman rank correlation coefficients there was a correlation
(p < 0.05) between serum TSH concentration and UIC (r = 0.194, p = 0.045). TSH concentration,
however, did not differ by WHO iodine deficiency categories (p = 0.372). Notably, no differences in
iodine intake or status were observed in those with TSH indicative of hypo- or hyperthyroid.
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4. Discussion
The overall purpose of this pilot study was to evaluate iodine intake and status in a sample of
young adult men and women and determine if intake and UIC, as a biomarker of status, are influenced
by dietary patterns. Overall, we found that our sample, with a median UIC of 98.0 μg/L and with 16.2%
with a UIC below <50 μg/L, may be borderline deficient. However, there was high intersubjective
variability, providing an opportunity to explore dietary relationships with UICs. In contrast, 23.4% of
participants had a 24 h UIC of >200 μg/L. These data suggest that some members of our population
may be at risk of compromised or excessive iodine status if such patterns are consistently observed (e.g.,
are not based on a single 24 h UIC). Both inadequate and excess iodine intake can be linked to adverse
health consequences [15,38]. These findings, however, are relevant only to the sample examined and
cannot be extrapolated to, and are not necessarily representative of, the young adults in our town, the
mountain west region or elsewhere in the US. However, the high intersubjective variability provided
the opportunity to explore dietary relationships with UIC to estimate the dietary factors that may place
individuals at risk of a single suboptimal 24 h UIC.
Total dairy and egg intake were the primary predictors of estimated iodine intake as well as
UIC. Importantly, these two foods together predicted approximately 20% of the variance in UIC
(Table 5). These results are in agreement with previous research showing a link between dairy and
egg consumption and iodine status [39,40]. Dairy has been determined to be a reliable source due
to iodine-fortified cattle feed [14] (which influences circulating iodine and the uptake of iodine by
mammary epithelial cells and secretion into milk) [41] and the use of iodophor disinfecting agents on
udders, although this can vary across the seasons and with industry practices [5,14,42]. In agreement
with our study, a published review has suggested that milk and dairy contribute ~13% to 64% of the
recommended daily iodine intake based on country-specific food intake data [6]. Eggs draw their
iodine content from the laying hen’s feed [43–46], which is increased with iodine supplementation.
Dairy and eggs might be easier to recall compared to other sources such as iodized table salt, seafood
or fish. Also, dairy is often a habitual food item, with yogurts and milk often complimenting popular
breakfast and snacks such as ready-to-eat cereal with milk, yogurt with fruit, coffee with milk or a
protein shake mixed with milk. Additionally, since eggs must be cracked or consumed individually,
the physical nature of preparation could make serving frequency and size easier to recall.
In contrast, iodine intake from iodized table salt consumption was not found to be a primary
predictor of iodine status within the present study. This finding is contrary to our hypothesis, as
iodized salt is among the densest iodine sources, with more than threefold the amount of iodine per
serving compared to an egg. This may be due to several factors. People may not know what iodized
salt is or be aware of which sources of salt are iodized. This includes salt found in the kitchen, used in
restaurants or used in processed foods. Iodization of salt, which was initiated in the United States in
the late 1920s [10], is not currently mandated by the Food and Drug Administration. It is estimated that
only 20% of the salt consumed in the United States is iodized [35]. Error may have been introduced if
participants assumed that salt in processed foods or all salt in the saltshakers at restaurants is iodized.
Additionally, it may be objectively difficult for participants to recall iodized salt use over a three month
period. Salt is a seasoning that may be used sporadically in cooking and when salting foods to taste and,
under these conditions, may contribute little to overall dietary intake. Finally, the amount of iodine
found in iodized salt may vary considerably and depend on how long the salt has been on the grocery
store shelf and in individual cupboards. One study found that iodine content varied among different
brands of salt, and even within a single container [35]. Several others found that the iodine content of
foods cooked with iodized salt depends on the food type and cooking method [47,48]. The increased
popularity of blended salts (i.e., garlic salt) and artesian salts (i.e., Pink Himalayan, sea salt and Kosher
rock salt) add another element of uncertainty as these products are typically not iodized [35], yet often
share the same shelf space as iodized salt. As it is likely that habitual use of iodized salt does contribute
to iodine status [49], future versions of our FFQ will consider the recall time of our FFQ as well as use
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of a photographic album during FFQ administration, along with more detailed and explicit questions
related to salt intake, to help improve the accuracy of subjects’ salt use recall.
Similar to table salt, seaweed consumption was also not found to be a positive contributor of
iodine status, despite its known influence on status in countries including Korea, Japan and parts of
coastal Alaska [50,51]. Our negative correlation between seaweed consumption and iodine status
may be due to the low number of participants (n = 26) who reported eating seaweed and our use
of a single value for seaweed by “serving” (Table 1). As different types of seaweed have different
amounts of iodine [33], future versions of the FFQ should consider including better descriptions of the
type of seaweed consumed to improve estimated iodine consumption. For example, one analysis of
12 common types of seaweed estimated that nori contained ~16 μg while processed kelp contained over
8000 μg per serving. Additionally, iodine status was not found to differ according to dietary patterns
identified on the Dietary Habits Survey (vegetarian status, CSA membership, regular gardener, etc.).
This is likely due to a low sample size of participants who identified with these specific dietary habits.
Only about half of the subjects identified with at least one dietary preference (n = 61). Further studies
could target these groups, as well as those adhering to AHA guidelines regarding reduced salt intake,
to better analyze the influence of dietary habits on iodine status.
As both insufficient and excess iodine intake can affect thyroid function, a secondary purpose of
this study was to explore the relationship between iodine status and serum TSH concentration as a
marker of hypothyroidism and general thyroid function [7]. While we were expecting that participants
with 24 h UICs in the WHO severe-to-moderate deficiency category would have high, normal or slightly
elevated TSH concentrations, we instead found no relationship between thyroid function and WHO
iodine deficiency category. In the typical hormone feedback scenario, serum TSH concentration should
increase as iodine status drops [52], although the thyroid is very efficient at compensating for instances
of low and excess iodine intake [53] and 24 h UIC may be more reflective of acute intake than long-term
status (as discussed below). For example, a healthy adult stores ~15–20 mg of iodine, with 70–80% of
these stores in the thyroid. These stores are in excess of the daily recommendation of 150 μg and can
help prevent a drop in the synthesis of thyroid hormone (and subsequent increase in TSH) during
periods of low iodine intake. The thyroid can also alter the efficiency of iodine organification or the
incorporation of iodine into the thyroglobulin in times of excess iodine intake via ‘the Wolff-Chaikoff
effect’ [54,55]. The weak but significant association between TSH and 24 h UIC (r = 0.194, p = 0.045)
could be explained by a few participants that shifted the simple correlation in the positive direction
in our sample, which had only a few subjects with TSH concentration falling in the hypo- (TSH >
4.68 mIU/L) or hyperthyroid (TSH <0.47 mIU/L) ranges, at 3.7% and 1%, respectively. The data may
have also been influenced by the inclusion of participants with autoimmune disorders (as we did not
measure thyroid autoantibodies) or the inclusion of four smokers.
The lack of a national database for iodine content in food was a major limitation of this study.
The USDA is currently developing an iodine database for commonly consumed food products [56]
which should greatly improve the assessment of iodine intake in relation to iodine status. However, the
potential variability of the iodine content of foods due to iodine content of the soil in different regions [3]
is likely to consistently complicate assessment of iodine intake and status. Further modification of
our FFQ may also enhance its future use as a tool to estimate iodine intake and help determine the
dietary habits that place an individual at risk of compromised iodine status. These include better
clarification of iodized salt and specific fish and seaweed sources. Portion sizes may also be better
quantified by allowing participants the opportunity to enter typical portion sizes or by including
images and metaphors to visually clarify standard serving sizes (i.e., “3 oz”). A major strength of our
study, however, was the creation of our own aggregated dietary iodine database for items in our FFQ.
We combined multiple sources of the recent literature investigating iodine content in various foods
(Table 1) and converted the listed units to iodine content per serving for better applicability to our FFQ
and, ultimately, increased ease of analysis. The significant association between estimated dietary iodine
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intake from the FFQ and UIC further increased our confidence in our novel database. This database
can be built upon for additional research until the USDA completes their official iodine database.
An additional limitation of our study and many others is the use of UIC as the biomarker of
iodine status. Twenty-four hour UIC is a widely used biomarker for the assessment of iodine status,
as approximately 90% of dietary iodine is excreted in the urine [57]. However, 24 h UIC is prone to
collection and methodological errors and is thought to be more representative of acute (i.e., days)
versus chronic iodine status [15], due to variations in 24 h UIC samples [58]. Some of this variability
may be due to day-to-day differences in dietary iodine intake, but confounders such as circadian [59]
and seasonal differences [60,61] also account for individual variability. Currently, there is no consensus
on the biomarker to use for assessment of individual iodine status [22,23]. Additionally, in the current
study, differences in the period of collection in our comparison of 24 h UIC and our FFQ, which
addressed intake over three months, may have been a further limitation. While other biomarkers for
assessment of this status have been suggested, including multiple 24 h UIC samples [22], age-adjusted
iodine–creatine ratio [62], and serum thyroglobulin concentration [63], use of these markers are
not without error and come with practical and logistics concerns when testing a large number of
participants [64]. Thus, as mentioned previously, the results of the current study, particularly those
related to UIC, are relevant only to the sample examined and cannot be extrapolated to, and are not
necessarily representative of young adults, in our town, the mountain west region or elsewhere in the
US. They do, however, support the need for continuous national iodine monitoring with emphasis on
subgroups that may be susceptible to iodine deficiency [21] based on dietary choices.
5. Conclusions
The current study found an indication that our sample of healthy young individuals living in the
mountain west region of the U.S. may be borderline deficient (based on a median 24 h UIC of 98 μg/L),
although a high degree of variability in 24 h UIC was observed. These results, however, are indicative
of the status of this sample only, and not of other, similar subsamples. Dairy and egg consumption
were found to be significant predicators of 24 h UIC, whereas reported intake of iodized salt was
not. Iodized salt consumption may either be difficult to assess reliably, or not as big a predictor of
iodine status in iodine-replete areas. Development of a national dietary iodine database and better
biomarkers for the assessment of iodine status in individuals will greatly improve understanding of
the relationships between iodine intake, iodine status and thyroid function.
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Appendix A
Food Frequency Questionnaire (FFQ)  
Instructions: For each food listed, check the box indicating how often on average you have used the amount 
specified during the last three months 
Foods Consumed  
Never 
or 


























1.Milk, 1 cup                    
2.Soy Milk, 1 cup                   
3.Soy Protein bars, 1 bar                   
4.Soy Protein powders, serving                   
5.Soy Sauce, 1 Tablespoon                    
6.Other non-dairy milks,   
Vit D fortified, 1 cup,  
                  
7.Orange Juice, Vitamin D fortified  
(Tropicana), 1cup 
                  
8.Cereal, Vitamin D fortified (Total         
Corn Flakes, Kelloggs Raisin Bran, Oat 
Bran, Cheerios), 3/4 cup 
                  
9.Bread, commercial, not homemade                     
10.Subway Sandwich, 6 inch                     
11.Bagels, 1 each                      
12.Yogurt, 1 cup                   
13.Cheese, 2 ounce                   
14.Egg, 1 whole                   
15.Margarine, Vitamin D fortified           
(Promise, etc.), 1 teaspoon 
                  
16.Liver, cooked, 3 ½ oz.                   
17.Cod, cooked, 3 ½ oz                   
18.Grouper cooked, 3 ½ oz                   
19.Haddock cooked, 3 ½ oz                   
20.Halibut, cooked, 3 ½ oz                    
21.Herring, 3 1/2 oz.                    
22.Mackerel, cooked, 3 ½ oz                   
23. Perch, cooked, 3 ½ oz                   
24.Salmon, cooked, 3 ½ oz                   
25.Sardines, canned in oil, 3 ½ oz                   
26.Sea Bass, cooked, 3 ½ oz                   
27.Swordfish, cooked, 3 ½ oz                   
28.Tukaoua, cooked, 3 ½ oz                   
29.Tuna, Albacore, canned3 ½ oz                    
30.Tuna, light, canned, 3 ½ oz                    
31.Walleye, cooked, 3 ½ oz                   
32.Other fish, 3 ½ oz                   
33.Clams, 4 oz                   
34.Crabmeat, 4 oz                   
35.Lobster, 4 oz                   
36.Mussels, 4 oz                   
37.Oysters, 4 oz                   
38.Scallops, 4 oz                   
39.Shrimp, 4 oz                   
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40.Sea weed (Nori, Komgu, Dulse, 
Wakame, Kelp) 
                  
41.Iodized Table Salt                   































1.Multiple Vitamin, 1 Tablet                   
2.Calcium Vitamin, 1 Tablet                   
3.Vitamin D , 1 Tablet               
(list amount __________) 
                
 
4.Calcium + Vitamin D (Viactiv), 1 Tablet                   
5.Kelp (or other iodine supplement),    
1 Tablet 
                
 
If you take any of the above , please list which you use, brand name, etc.  
Appendix B
Dietary Habits Survey 
How frequently do you use the salt shaker to salt your foods? Never Sometimes Usually 
What type of salt do you use?         
How frequently do you use salt in your cooking?  Never Sometimes Usually 
What type of salt do you use?         
Applicable Questions on the Dietary Preferences Survey 
Do you follow a vegetarian Diet?      Yes  No                   
Do you shop at the Farmers Market or Food Coop)?  Yes  No     Sometimes 
Do you belong to a CSA (Community Supported Agriculture)?  Yes  No                   
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Abstract: This study aimed to observe the relationship between iodine nutrition status (dietary
iodine intake and estimated iodine intake based on urinary iodine concentration (UIC)) and thyroid
disease-related hormones. This study involved 6090 subjects >19 years old with valid UIC, assessed
between 2013 and 2015 by the Korean National Health and Nutrition Examination Survey, using
a stratified, multistage, clustered probability-sampling design. The estimated iodine intake in
participants was measured using UIC and urine creatinine. To examine the effect of iodine intake
on thyroid disease, the iodine intake was divided into Korean Dietary Reference Intakes groups,
and logistic regression analysis was performed via the surveylogistic procedure to obtain odds
ratios (ORs) and 95% confidence intervals (CIs). The estimated iodine intake showed a significant
positive correlation with dietary iodine intake (r = 0.021, p < 0.001), UIC (r = 0.918, p < 0.001), and
thyroid-stimulating hormone (TSH) (r = 0.043, p < 0.001), but a significant negative correlation with
free thyroxine (FT4) (r = −0.037, p < 0.001). Additionally, as the estimated iodine intake increased,
age, TSH, and UIC increased, but FT4 decreased (p for trend < 0.0001). The risk of thyroid disease
was higher in the “≥tolerable upper intake level (UL ≥ 2400 μg/day)” group than in the “<estimated
average requirement (EAR < 150 μg/day)” group in females (OR: 2.418; 95% CI: 1.010–5.787). Also, as
iodine intake increased, the risk of thyroid disease increased (p for trend < 0.038).
Keywords: iodine nutrition status; thyroid disease; thyrotropin; urine iodine; epidemiologic
studies; Korean
1. Introduction
Korea is geographically rich in iodine and one of the iodine-rich countries with a high intake of
seaweeds [1]. According to a recent study, the mean dietary iodine intake was 763.5 μg for Korean
female subjects and 953.1 μg for males [2]. In a study involving the trend analysis of iodine intake,
the iodine intake for males was 326.2–817.0 μg and for females 257.0–802.4 μg [3]. It seems that a
majority of the studies indicate that most of the Koreans’ iodine intake is within the upper limit (UL)
(2400 μg) intake, but over two times higher than the recommended nutrient intake (RNI) (150 μg) [4–8].
Iodine controls the speed of, and is therefore an essential element in, thyroid hormone synthesis. When
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the iodine intake is insufficient, the hypothalamus hormones, thyrotropin-releasing hormone (TRH)
is secreted, and thyroid-stimulating hormone (TSH) further increases the secretion of the thyroid to
increase the synthesis and secretion of the thyroid hormone. When blood levels of triiodothyronine (T3)
and thyroxine (T4) decrease, and in response the thyroid activity is increased to compensate for iodine
deficiency, a sudden excessive intake can increase the risk of hyperthyroidism. Additionally, excessive
iodine intake can change the thyroid function, and according to several studies, the prevalence of
hypothyroidism, hyperthyroidism, and autoimmune thyroiditis has increased [9–13]. Many studies
have reported that deficiency and excess of iodine are associated with thyroid dysfunction [7,10,14,15].
Therefore, it is important to find out effects on thyroid hormones made by level of iodine nutrition
status. The iodine nutrition status of the population is measured based on dietary iodine intake or
urinary iodine concentration (UIC), which is a well-accepted, cost-effective, and readily available
indicator. Furthermore, according to the iodine nutritional epidemiology standard of the World Health
Organization (WHO), UIC is a recommended barometer for iodine intake that assesses the iodine
status of the population and is a sensitive indicator [16,17].
TSH, T4, T3, and thyroid autoantibodies (TPOAb) measurements are biochemical tests in the
diagnosis and control of thyroid disease [18]. Serum TSH is the most sensitive marker for assessing the
status of thyroid function and measurement of serum TSH level is used as a screening test for patients
with thyroid dysfunction [19]. TSH is known to be affected by factors such as age, sex, race, iodine
intake, smoking, presence of antibodies, and body mass index (BMI) [15,20].
The purpose of this study is to investigate the relationship between iodine nutrition status (dietary
iodine intake and estimated iodine intake based on UIC) and thyroid disease-related hormones, such
as serum TSH and free thyroxine (FT4). Also, we investigated the association of the iodine nutrition
status and the thyroid disease incidence among Korean adults.
This is the nationwide study to observe the relationship between thyroid disease-related functions,
such as serum TSH and FT4 level, and UIC, which was first introduced by the Korean National Health
and Nutrition Examination Survey (KNHANES) VI (2013–2015), and also examined the relationship
between iodine nutrition status including iodine intake in people’s diet and estimated iodine intake.
2. Methods and Materials
2.1. Study Population
The KNHANES is conducted to obtain national estimates of the health and nutrition status
of Koreans by the Korea Centers for Disease Control and Prevention (KCDC) that uses a stratified,
multistage clustered probability-sampling design [21]. KNHANES is a nationwide, population-based,
cross-sectional study to assess the health and nutrition status of the Korean civilian, noninstitutionalized
population. Each survey consists of three sections: health interview, health examinations, and
nutritional survey.
We selected from the total population (n = 22,938) after the exclusion of <19 years (n = 4914),
subjects with thyroid cancer (n =135), pregnant and lactating women (n = 239), subjects reporting
unrealistic daily total energy intakes (<500 kcal, >5000 kcal) (n = 2251), subjects who did not test UIC
(n = 9312), and subjects with missing weight variables (n = 2). As a result, a total of 6095 subjects were
included in the final analysis (men=2852, women=3243). This subsample of KNHANES VI (2013–2015)
consisted of 6095 participants who underwent the thyroid function test (serum TSH and FT4) and UIC
stratified subsampling with consideration of sex and age.
This study protocol was approved by the Institutional Review Board of the KCDC and the
KNHANES (2013-07CON-03-4C, 2013-12EXP-03-5C, and 2015-01-02-6C). All participants gave written
informed consent.
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2.2. Measurement of TSH, FT4, and UIC
Serum TSH and FT4 levels analyzed via electrochemiluminescence immunoassay were used.
Serum TSH (reference range 0.35–5.50 mU/L) and FT4 (reference range 0.89–1.76 ng/dL) levels were
analyzed using E-TSH kit (Roche Diagnostics, Mannheim, Germany) and E-Free T4 kit (Roche
Diagnostics, Mannheim, Germany), respectively. UIC, analyzed through inductively coupled plasma
mass spectrometry (ICPMS; PerkinElmer, Waltham, MA, USA) using iodine standard (Inorganic
Venture, Christiansburg, VA, USA), was used [22].
2.3. Estimated Iodine Intake
The estimated iodine intake in populations was calculated by measuring the UIC and urine
creatinine (Ucr) level and the following equation (1) [6,23,24]:
Estimated of iodine intake (μg/day) = UIC (μg/L) × {879.89 + (weight (kg) × 12.51) −
[(6.19 × age) + (34.51 if black) − (379.42 if female)]} / (Ucr × 0.92 × 10). (1)
2.4. Establishment of Iodine Database of Commercial Foods in Korea
The iodine content of foods was based on the values shown in the Food Values of the Korean
Nutrition Society [25], Food Composition Tables, 9th revision by the Korean National Institute of
Agricultural Science, Rural Development Administration [26], a thesis that established the iodine
database for common Korean foods [2], and the Standard tables of food composition in Japan (7th
revised version) of the Ministry of Education, Culture, Sport, Science, and Technology, Tokyo, 2015 [27].
The value was selected if the food source existed on the database; however, if there was no
matching food, it was replaced by something a similar food item from the database. If there were
variations in terms of the processing method for certain foods, such as drying methods, we calculated
the iodine values based on the values of the existing source of the foods. Moreover, if there were
multiple values from different sources of data for one specific food, the mean value for the specific
food was used. The total number of food items was 837, and the number of foods with iodine content
was 559, which provided 66.8% coverage.
2.5. Measurement of Dietary Iodine Intake Using 24-hr-Dietary Recall
The nutrition survey data were collected using the 24-h dietary recall method and face-to-face health
interviews by trained dietitians and health examination [28]. The daily intake of energy was calculated
using the Korean Foods and Nutrients Database of the Rural Development Administration [26].
To calculate the dietary iodine intake, we established an iodine database by merging the data on food
items from the 24 h diet recall in the KNHANES database (2013–2015) with the established iodine
value for each food item.
2.6. Statistics
As the KNHANES data is based on stratified multistage probability extraction rather than simple
random extraction data, this study analyzed the weight (2013, KNHANES; Wt_hmnt, 2014, 2015
KNHANES; Wt_trnt), the stratification variable (KSTRATA) and the primary sampling unit (PSU).
To test for significant differences, the t-test was used when calibration was not performed using
the surveyreg procedure, and the general linear model was used when calibration was performed
using the surveyreg procedure. Additionally, the age and total daily energy intake were used as
calibration variables. In addition, the correlation between each of the iodine intake and thyroid function
tests was analyzed using Pearson correlation. Using the paired t-test, associations were determined
with weighted measures among the estimated iodine intake, dietary iodine intake, and UIC. Lastly,
to examine the effect of iodine intake on thyroid disease, this study divided iodine intake into Korean
Dietary Reference Intakes (KDRI) groups [4], and logistic regression analysis was performed via the
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surveylogistic procedure to obtain odds ratios (OR) and 95% confidence intervals (CI). All statistical
analyses were performed using SAS Ver. 9.4 (SAS Institute, Cary, NC, USA).
3. Results
3.1. Iodine Nutrition Status
The mean estimated iodine intake for all subjects was 790.1 μg, which was higher than the mean
dietary iodine intake (551.0 μg). These results were identical for both the male and female groups
(Figure 1).
Figure 1. Mean of dietary iodine intake vs. estimated iodine intake.
The results of the analysis of the iodine nutrition status of the subjects are shown in Table 1.
The thyroid disease group was higher in the total subjects’ energy than in the non-thyroid disease group
(unadjusted p < 0.0001, adjusted for age p = 0.001). In total subjects, the mean dietary iodine intake of
the non-thyroid disease group was 554.0 ± 35.8 μg, which was higher than that of the thyroid disease
group of 458.8 ± 93.6 μg. However, the mean of estimated iodine intake of the non-thyroid disease
group was 780.0 ± 56.1 μg, which was lower than that of the thyroid disease group of 1108.1 ± 195.8 μg.
In total subjects, the mean UIC of the non-thyroid disease group was 883.2 ± 92.1 μg, which was lower
than that of the thyroid disease group of 1085.9 ± 183.9 μg, but there was no significant difference.
Additionally, the same result was obtained in the female group (non-thyroid disease 849.8 μg, thyroid
disease group 1145.5 μg), but the result of the male group was the opposite (non-thyroid disease
913.5 μg, thyroid disease group 745.1 μg), and there were no significant differences between these
groups. Moreover, there were no significant differences in all groups with UIC, dietary iodine intake,
and estimated iodine intake.
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3.2. TSH and FT4 of the Subjects
The TSH and FT4 levels of the non-thyroid disease group vs. the thyroid disease group are shown
in Figure 2. The mean TSH of the non-thyroid disease group was 2.8 ± 0.1 mIU/L, which was lower
than that of the thyroid disease group (3.7 ± 0.4 mIU/L) (adjusted for age and energy intake p = 0.029).
As a result, TSH in the total subjects was significantly higher in the thyroid disease group than in
the non-thyroid disease group. Male and female groups showed similar results, but there were no
significant differences. Additionally, the mean FT4 of the non-thyroid disease group was lower than
that of the thyroid disease group, but there was no significant difference.
Figure 2. TSH and FT4 of thyroid disease status by sex.
3.3. UIC, TSH, and FT4 According to KDRI of the Estimated Iodine Intake
The estimated iodine intake was divided into KDRI groups, and the results of UIC, TSH, and FT4
tests for each group are presented in Table 2.
The KDRI groups were as follows: “<EAR (estimated average requirement)”, <95 μg/day; “≥EAR,
<RNI (recommended nutrient intake),” ≥95 μg/day, <150 μg/day; “≥RNI, <UL (tolerable upper intake),”
≥150 μg/day, 2400 μg/day; and “≥UL,” ≥2400 μg/day by KDRI [4]. The mean and median values of
the UL group were dramatically higher than those of the other groups (Figure 3). In total subjects,
both unadjusted and adjusted for age and energy intake, as iodine intake increased, age (p for trend <
0.0001), TSH (p for trend = 0.009) (Figure 3), and UIC (p for trend < 0.0001) tended to increase, but FT4
showed a tendency to decrease (p for trend < 0.0001) (Figure 4). In addition, in both male and female
groups, as iodine intake increased, age, TSH, and UIC tended to increase, but FT4 showed a tendency
to decrease. All results are significant except for TSH in the female group.
38












































































































































































































































































































































































































































































































































































































































































































































































Nutrients 2019, 11, 2757
Figure 3. Correlation of TSH and age with the estimated iodine intake.
Figure 4. Correlation of UIC and free thyroxine (FT4) with the estimated iodine intake.
3.4. Prevalence of Thyroid Disease and Distribution of Iodine Intake According to the Estimated Iodine Intake
by KDRI
The intake range, median, and mean of the estimated iodine intake classified by KDRI groups are
shown in Table 3.
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The population distribution with respect to the dietary iodine intake and estimated iodine
intake of all the subjects was divided into KDRI groups. The “≥RNI, <UL” group had the largest
population—65.1% with respect to dietary iodine intake and 63.5% with respect to estimated iodine
intake, while the “UL” group had the smallest population (Figure 5).
Figure 5. Population distribution of iodine intake by KDRI in the total subjects.
3.5. Relation between Thyroid Disease and the Estimated Iodine Intake by KDRI
The results of the relationship between the estimated iodine intake and the risk of thyroid disease
incidence according to KDRI groups using logistic regression analysis are presented in Table 4.
In relation to the thyroid disease according to the estimated iodine intake, as the estimated iodine
intake increased in Model 1, which was the unadjusted model in the female group, the odds ratio of
the “≥UL” group was 2.940 (95% CI: 1.267–6.823), which showed a tendency to increase the risk of
thyroid disease incidence (p for trend = 0.014). Additionally, as the iodine intake increased in Model
2 adjusted for age and energy intake, the odds ratio of Model 2 was 2.773 (95% CI: 1.198–6.420) in
the “≥UL” group compared with the “<EAR” group, and the risk of thyroid disease tended to be
increased (p for trend = 0.023). In Model 3, adjusted for age, energy intake, weight status, exercise
status, smoking status, and alcohol consumption, the odds ratio was 2.686 (95% CI: 1.161–6.215) in the
“≥UL” group compared with the “<EAR” group, and the risk of thyroid disease tended to be increased
(p for trend = 0.026). Also, in Model 4 adjusted for age, energy intake, weight status, exercise status,
smoking status, alcohol consumption, breakfast, and frequency of eating out, the odds ratio was 2.554
(95% CI: 1.113–5.861) in the “≥UL” group compared with the “<EAR” group, and the risk of thyroid
disease tended to be increased (p for trend = 0.34). Lastly, in Model 5, adjusted for age, energy intake,
weight status, exercise status, smoking status, alcohol consumption, breakfast, frequency of eating
out, education level, region of residence, household income level, and occupation, the odds ratio was
2.418 (95% CI: 1.010–5.787) in the “≥UL” group compared with the “<EAR” group, and the risk of
thyroid disease tended to be increased (p for trend = 0.038). However, there was no risk of iodine
intake incidence and thyroid disease in the male group and in the total subjects.
This might support the idea that iodine intake by >UL (≥2400 μg/day) can increase the risk of
thyroid disease in females (Figure 6). However, the same results were not observed in the male group.
Also, dietary iodine intake did not indicate any risk of thyroid disease incidence.
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(≥150, 2400) ≥UL (≥2400)
Total
Model 1 1 e 0.832(0.409–1.692) f 1.084(0.634–1.854) 1.788(0.820–3.898) 0.059(+)
Model 2 1 0.854(0.416–1.750) 1.092(0.631–1.891) 1.692(0.773–3.704) 0.096(+)
Model 3 1 0.887(0.428–1.838) 1.144(0.657–1.992) 1.796(0.815–3.960) 0.076(+)
Model 4 1 0.891(0.422–1.882) 1.166(0.662–2.056) 1.846(0.840–4.058) 0.066(+)
Model 5 1 0.847(0.390–1.836) 1.095(0.612–1.957) 1.726(0.760–3.923) 0.085(+)
Male
Model 1 1 0.499(0.095–2.620) 0.440(0.108–1.792) 0.414(0.051–3.359) 0.720(−)
Model 2 1 0.474(0.089–2.528) 0.390(0.095–1.609) 0.325(0.041–2.568) 0.607(−)
Model 3 1 0.397(0.075–2.098) 0.317(0.073–1.378) 0.251(0.034–1.839) 0.549(−)
Model 4 1 0.405(0.080–2.054) 0.353(0.079–1.566) 0.278(0.036–2.161) 0.582(−)
Model 5 1 0.419(0.084–2.084) 0.311(0.070–1.378) 0.240(0.029–1.954) 0.5573(−)
Female
Model 1 1 1.056(0.492–2.263) 1.667(0.908–3.061) 2.940(1.267–6.823) 0.014(+)
Model 2 1 1.054(0.490–2.267) 1.629(0.887–2.989) 2.773(1.198–6.420) 0.023(+)
Model 3 1 1.063(0.488–2.315) 1.608(0.873–2.961) 2.686(1.161–6.215) 0.026(+)
Model 4 1 1.048(0.479–2.292) 1.561(0.846–2.881) 2.554(1.113–5.861) 0.034(+)
Model 5 1 0.979(0.438–2.192) 1.426(0.766–2.654) 2.418(1.010–5.787) 0.038(+)
a KDRI group was classified based on the estimated iodine intake; b Standard error; c EAR: Estimated average
requirement; d p for trend was calculated by surveylogistic procedure of SAS; e Reference; f Odds ratio (95% CI,
confidence interval); Model 1: Unadjusted model; Model 2: Adjusted for age and energy intake; Model 3: Adjusted
for age, energy intake, weight status, exercise status, smoking status, and alcohol consumption; Model 4: Adjusted
for age, energy intake, weight status, exercise status, smoking status, alcohol consumption, breakfast, and frequency
of eating out; Model 5: Adjusted for age, energy intake, weight status, exercise status, smoking status, alcohol
consumption, breakfast, frequency of eating out, education level, region of residence, household income level,
and occupation.
Figure 6. The odds ratio for thyroid disease by the estimated iodine intake in female.
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4. Discussion
In this study, we investigated the relationship between iodine intake status and thyroid
disease-related functions, and we found that as the estimated iodine intake increased, TSH increased
and the risk of thyroid disease also increased. In Korea, iodine-replete areas generally have a high risk
of thyroid disease and autoimmune thyroid disease tends to develop into hypothyroidism. Excessive
iodine intake is considered to be an important factor in thyroid disease; however, the mechanism or
cause is uncertain at present.
Currently, the iodine nutrition status is measured by dietary iodine intake or UIC. The dietary
iodine intake is calculated by the iodine content of the food ingredient composition and measured
using the 24 h dietary recall method, food record, and food frequency questionnaire. However, the 24 h
dietary recall and food record methods do not accurately reflect the amount of iodine in soup stocks
such as salt and kelp. In addition, the iodine content of the food composition varies greatly depending
on the production area and production period. Also, the amount of iodine in the food is so low [3], and
the dietary intake of iodine-rich foods also varies widely among individuals. Hence, it is very difficult
to measure the amount of iodine in food and to obtain individual iodine intakes for meals [29,30].
Furthermore, iodine is mainly supplied by meals or drugs. The intake level is highly influenced
by the environment, and iodine—which is a micronutrient—is present in a small amount in most foods
and is concentrated in specific foods. It is difficult to accurately measure the iodine status [31,32].
Despite these limitations, the 24 h recall method is still valid for measuring dietary iodine intake in
individuals. Hence, the UIC method is used more than the dietary iodine intake [8].
One of the most commonly used methods for measuring iodine nutrition status is the UIC as an
epidemiologic criteria for the status of the population in the WHO [33]. Since, after metabolization
in the body, more than 90% of iodine is excreted in the urine, UIC can estimate the recent intake of
iodine by urinary iodine excretion amount and is used as a biomarker to determine the iodine status at
the population level, which is a valuable and useful index [34,35]. However, UIC is inappropriate for
evaluating the prevalence of iodine deficiency or excessive intake [16]. Therefore, in this study, we
calculated and used the estimated iodine intake based on UIC.
Kim et al. [36] showed that 27 patients with Grave’s disease showed higher urinary iodine excretion
than the normal group, and in a similar article [37], urinary iodine excretion was higher in patients
with simple goiter (n = 17; 2.88 mg/L), hyperthyroidism (n = 42; 4.90 mg/L), hypothyroidism (n = 15;
4.57 mg/L), and thyroid cancer (n = 11; 6.18 mg/L) than in the normal group (2.11 mg/L). Additionally,
in our study, the mean UIC based on prevalence was higher in the thyroid disease group than in the
non-thyroid disease group, and the estimated iodine intake showed the same result, although the
difference was not significant. These results indicate that UIC concentration is higher in the thyroid
disease (such as goiter, hypothyroidism, and hyperthyroidism) group than in the disease-free group.
In this study, the correlation between UIC and dietary iodine intake showed a significant correlation
with the total subject (r = 0.014, p < 0.001) and also in the female group (r = 0.089, p < 0.001), but,
as mentioned, the male group showed the opposite result (r = −0.005, p < 0.001). Also, in another
study [38], UIC was associated with dietary iodine intake (r = 0.60, p < 0.01), and as iodine intake
increased, the UIC gradually increased, which indicates a positive correlation between iodine intake
and UIC. Additionally, the correlation between the estimated iodine intake and dietary iodine intake
also showed a significant correlation with the total subjects (r = 0.021, p < 0.001) and also in the female
group (r = 0.095, p < 0.001), but the male group showed the opposite result (r = −0.001, p < 0.001).
Comparing the dietary iodine intake and UIC between these groups and understanding the differences
will enable us to determine the iodine nutrition status of the population more accurately.
In this study, the estimated iodine intake, which was calculated from UIC and dietary iodine
intake, was divided into KDRI intervals to determine the risk of thyroid disease. These results show
that the intake of iodine in Korea is higher than that in other countries, but there were more subjects
who consume <95 ug (<EAR) and ≥2400 ug (UL) (Figure 2). Most subjects consumed >150 μg and
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<2400 μg, and 2.6% of them consume >2400 μg (dietary iodine intake) and 6.2% (estimated iodine
intake) of iodine.
Furthermore, many other studies have shown that the median and upper limit of TSH increases
with age [39–41]. In NHANES III, a higher TSH concentration was found to be associated with a higher
UI/Cr excretion [42]. Additionally, TSH and FT4 levels were compared based on the presence of the
disease. Moreover, similar results were found in the reference population: TSH levels were lower than
that of the disease-free population. Therefore, a more in-depth study is required to clarify the link
between TSH and iodine status; however, it has been confirmed that the excessive intake of iodine may
be correlated with TSH.
In this study, the relationship between the estimated iodine intake, which was divided into KDRI
intervals, and thyroid disease incidence was evaluated using the logistic regression analysis. It was
found that the incidence of thyroid disease increased with increasing iodine intake. The correlation
between the risk of thyroid disease according to the estimated iodine intake and the correlation between
UIC and dietary iodine intake were significant only in the female group, but not in males.
These results support that the degree of response to iodine intake is higher due to the role of
estrogen in women than in men, but more research is required on the concentration of estradiol and
other cofactors [43–47].
One advantage of the study is that KNHANES VI (2013–2015) introduced TSH, FT4, TPOAb, and
thyroid disease-related items, making it possible to observe the correlation of the iodine nutrition
status with TSH and FT4 levels and to evaluate the effects of excessive iodine intake on thyroid disease.
Additionally, the study cohort provided the most recently released nationally representative data of
the Korean population.
However, there are some limitations to this study. First, KNHANES is a cross-sectional database;
therefore, it cannot demonstrate the relationship between iodine intake and TSH or FT4 levels and
thyroid disease, and it does not prove causality. Second, even though we have constructed a new
iodine database for commercial foods in Korea, there is a limitation in the accurate determination of
iodine intake by the food intake method. Finally, we did not consider various thyroid diseases.
The present study had limitations and further research is necessary to identify the factors
contributing to the findings and to build accurate dietary sources. Despite these limitations and despite
the need for further studies to identify the mechanisms involved in these findings and to build accurate
dietary sources, this study provided important information. The study demonstrated the relationship
between dietary iodine intake, UIC, and TSH along with a higher risk of thyroid disease-related
hormone levels in groups with estimated iodine intake by over the UL (≥2400 μg/day).
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Abstract: Iodine, a micronutrient that plays a pivotal role in thyroid hormone synthesis, is essential
for proper health at all life stages. Indeed, an insufficient iodine intake may determine a thyroid
dysfunction also with goiter, or it may be associated to clinical features such as stunted growth and
mental retardation, referred as iodine deficiency disorders (IDDs). Iodine deficiency still remains
an important public health problem in many countries, including Italy. The effective strategy for
the prevention and control of IDDs is universal salt iodization, which was implemented in Italy in
2005 as a nationwide program adopted after the approval of an Italian law. Despite an improvement
in the iodine intake, many regions in Italy are still characterized by mild iodine deficiency. In this
review, we provide an overview of the historical evolution of the iodine status in the Calabria region,
located in the South of Italy, during the past three decades. In particular, we have retraced an itinerary
from the first epidemiological surveys at the end of the 1980s to the establishment of the Regional
Observatory of Endemic Goiter and Iodine Prophylaxis, which represents an efficient model for the
surveillance of IDDs and monitoring the efficacy of iodine prophylaxis.
Keywords: iodine deficiency; iodine prophylaxis; goiter; urinary iodine concentration
1. Introduction
Iodine deficiency and related disorders are still a public health problem that affects most countries,
including industrialized and developing regions [1,2]. At the end of 2018, a global survey on iodine
status, covering more than 97% of the world’s population, indicated that 21 countries remain vulnerable
to iodine deficiency. Specifically, nationally-representative surveys revealed insufficient iodine intake
in 14 countries (Burkina Faso, Burundi, Finland, Haiti, Israel, Iraq, the Democratic People’s Republic
of Korea, Lebanon, Mali, Madagascar, Mozambique, Samoa, Vanuatu, and Vietnam). Moreover, in
sub-national surveys, seven other countries, including Angola, Italy, Morocco, Norway, Russia, South
Sudan, and Sudan were reported as being iodine insufficient [3].
Iodine deficiency impairs thyroid hormone production and has many adverse effects during the
course of life, which are collectively termed the iodine deficiency disorders (IDDs). The frequency
and severity of IDD manifestations are related to the degree of iodine deficiency and the age of the
affected subjects. Although thyroid enlargement (goiter) is the classic sign of iodine deficiency, and can
take place at any age, the most serious adverse effects of iodine deficiency occur during pregnancy,
including impaired fetal growth and brain development [4–6]. The iodine status of the population can
be assessed by using four methods: urinary iodine (UI) concentration, the goiter rate, serum thyroid
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stimulating hormone (TSH), and serum thyroglobulin (Tg) levels [7–10]. UI is the most sensitive
indicator of current iodine intake because >90% of dietary iodine is excreted in the urine [11]. UI
concentration can be measured in spot urine samples and the median UI values were used to assess
iodine nutrition among school-age children, as recommended by World Health Organization (WHO),
United Nations International Children’s Emergency Fund (UNICEF), and the Iodine Global Network
(IGN) [7]. The cut-off values for urinary iodine levels were used to define iodine deficiency (<100 μg/L)
were classified as mild (50–99 μg/L), moderate (20–49 μg/L), or severe (<20 μg/L). Daily iodine intake
for population can be extrapolated from UI concentration using the following formula: urinary iodine
(μg/L) × 0.0235 × body weight (Kg) = daily intake (μg) [12].
This allows us to assume that a median UI concentration of 100 μg/L corresponds roughly to an
average daily iodine intake of 150 μg.
An important indicator of IDDs is represented by the goiter rate measured by ultrasound in
school-age children. However, a standardized approach should be adopted worldwide to improve the
reliability of thyroid volume in the context of IDD monitoring [8]. Supplementary indicators of iodine
deficiency include blood-spot TSH measurement only in neonates [13], while Tg measured in a dried
blood spot has been reported to be a good marker of iodine intake in infancy [14].
Universal salt iodization is the most cost-effective strategy for IDDs and the WHO, UNICEF, and
IGN recommend that iodine is added at a concentration of 20–40 mg per kg salt, dependent on local
salt intake [15].
Over the last decades, intensive efforts have been made by the governments of IDD-affected
countries to implement and control salt iodization program [9,16–19]. India was one of the first
countries in the world to initiate and maintain a sustained increase in the coverage of adequately
iodized salt, achieving the goal of universal salt iodization levels of greater than 90% in urban areas of
the Central, North, and North-East zones of its territory in 2015 [20–22]. Following the introduction
of mandatory salt iodization in 1995, Madagascar showed a swift growth in iodized salt coverage,
however a recent national survey reported that iodine deficiency remains a serious public health
problem there [23]. This implies that to maintain an effective program on salt iodization over the long
term, it is necessary to set up a system that coordinates and monitors the sale trend of iodized salt and
communicates the health benefits of consuming iodized salt. A good example of national progress is
represented by Ethiopia in which the national coverage of iodized salt increased from 4.2% in 2005
to 95% in 2014. These results stem from multi-level and multi-sector efforts involving public-private
partnerships that focused on enforcing iodization legislation [24,25]. Also in Italy, a nationwide salt
iodization program was implemented in 2005 with the approval of the law n. 55/2005 that requires
the addition of potassium iodate to table salt at 30 mg/kg and the mandatory availability of iodized
salt in food shops and supermarkets. The law also permits the use of iodized salt in the food and
catering industries. To the aim of evaluating the efficiency and effectiveness of the nationwide program
of iodine prophylaxis, in 2009 the Italian National Observatory for Monitoring Iodine Prophylaxis
(OSNAMI) was established at the Italian National Institute of Health [26]. Although a significant
improvement of iodine nutrition has been observed over the years, some regions in Italy still remain at
risk of deficiency.
In this review we provide an overview of the iodine status in Calabria, a region of Southern
Italy, over the past three decades. Particularly, we report data obtained from the first epidemiological
surveys up to the establishment of the Regional Observatory of Endemic Goiter and Iodine Prophylaxis
(Figure 1), that represents an efficient model for the surveillance of IDDs and monitoring the efficacy of
iodine prophylaxis.
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Figure 1. Schematic representation of the key steps of epidemiological surveys conducted from the late
1980s to the present for assessing and monitoring iodine status in the Calabria region.
2. History of Goiter and Iodine Deficiency in Calabria: Epidemiological Surveys during the
1980–2000 Period
The Calabria region located in the Southern of Italy is a peninsula of irregular shape, referred to
as the “toe” of the Italian “boot”, with a coastline of 738 km on the Ionian and Tyrrhenian coasts of
the Mediterranean Basin. The regional orography highlights mountainous features: 42% of the land
is mountainous, 49% is hilly, and only 8% is completely flat with an average elevation of 597 m [27].
This region, comprising five provinces with a total population of about 2 million inhabitants, has been
historically exposed to iodine deficiency.
Data obtained from epidemiological surveys carried out between 1987–1996 allowed us to draw a
first map of iodine deficiency and endemic goiter in Calabria by evaluating the mean of UI excretion
and the size of thyroid gland. Since ultrasonography was not easy to perform in a large scale of
epidemiological screening and the reference values for ultrasound thyroid volume measurement in
children living in iodine-sufficient areas were not well established, the goiter rate was assessed using
WHO’s 1960 palpation system [28].
The first study was conducted by our research group [29] in 1987–1989 on 34 villages of extraurban
areas of Catanzaro (A) and Cosenza (B) provinces. In this survey, 4468 and 2721 schoolchildren (aged
between 6–12 years) of area A and area B, respectively, were examined. The prevalence of endemic
goiter was 53% in the population living in Catanzaro’s province with the highest percentage found in
Zagarise (67%), while the rate in schoolchildren from Cosenza’s province was 44% with the highest
percentage found in Laino Castello (69%). Interestingly, in both areas the goiter prevalence was
independent from area altitude as well as the distance of the villages from the main town, and was
significantly higher than that observed among the 1170 age-matched schoolchildren living in the urban
area of the Calabria region (7.7%). Mean UI concentration was 49.7 ± 5.3 μg/L and 70.7 ± 3.1 μg/L in
area A and B, respectively, indicating the presence of a mild iodine deficiency respect to the UI values
of urban area that reflect an iodine sufficiency (104 ± 6.6 μg/L).
After two years of voluntary iodine prophylaxis (1991–1992) 855 schoolchildren from five small
villages (Laino Borgo, Laino Castello, San Basile, Saracena and Mormanno) of Cosenza province
were examined. These five villages were chosen since their drug-stores carried iodized salt and the
population was advised to use it. As shown in Figure 2, an increase of UI concentration along with a
reduced goiter prevalence were found, suggesting that an effective program of iodine prophylaxis is
urgently needed in this region [29].
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Figure 2. Urinary iodine concentration (UIC) and goiter prevalence before and after iodine prophylaxis
in schoolchildren of the Cosenza province.
Another epidemiological study, which are useful to better define the map of endemic goiter and
to characterize iodine deficiency in the whole Calabrian territory, was performed during the years
1990–1996 by Costante et al. [30]. A total of 13,984 schoolchildren, aged 6–14 years, was examined for
the goiter prevalence, while UI excretion was evaluated in 284 samples that were randomly collected.
Goiter prevalence ranged from 19% to 64% and from 5.3% to 25.7% in the inland territory and at the
coastal area, respectively, while the mean of UI excretion was 53.8 ± 43.4 μg/L in the inland territory
and 89.6 ± 59.8 μg/L at sea level, confirming that moderate levels along with pockets of severe iodine
deficiency was present in the inland region, while iodine supply varied from sufficient to marginally
low in the coastal areas. Moreover, the presence of mild to moderate iodine deficiency was also
established by the results of neonatal TSH levels from the congenital hypothyroidism regional screening
program. Indeed, the authors reported 14.8% frequency of TSH levels >5 μU/mL in newborns from the
inland territory and 14.1% frequency from coastal areas [30].
Overall, these first epidemiological surveys clearly indicate that at the end of the 1990s, the whole
Calabria region was a mild to moderate iodine deficient area. Interestingly, the data obtained in the
Calabria region were in line with a series of surveys carried out from 1978 to 1991 in different regions of
Italy, in which a total number of 72,112 schoolchildren was examined, including 5046 controls living in
urban areas and 66,066 subjects residing in rural endemic areas. Surveys were carried out throughout
Italy in predominantly hilly and mountainous areas. Globally, the goiter prevalence ranged from 14%
to 73%, which inversely correlated with urinary iodine excretion (10–122 μg/g creatinine) and was
more prevalent in Central and Southern Italy (reference [31] and references therein).
At the end of the 1990s, as part of a European project entitled “Eradication of endemic goiter and
of disorders of iodine deficiency in Southern Italy” with cooperation between the National Research
Council and the Ministry of Health, and financed by the European Union, a survey to assess the iodine
nutrition was conducted in eight regions of Southern Italy, including Calabria [32]. The grade of
iodine deficiency was assessed through the measurement of UI excretion in 23,103 samples randomly
collected from the schoolchildren population aged 11–14 years living in urban and rural areas and in
different geographic locations. Median UI excretion in the all studied population was 74 μg/L, showing
significantly higher values in urban areas compared to rural areas (81 μg/L vs. 73 μg/L, p < 0.0001).
Besides, median UI excretion was significantly lower in inland mountainous/hilly areas respect to
coastal mountainous/hilly areas (68 μg/L vs. 79 μg/L, p < 0.0001). The results of this extensive survey
indicated that in Southern Italy, mild to moderate iodine deficiency still persisted [32]. Particularly in
the Calabria region, data obtained from a total of 2693 spot urinary samples expressed as median as
well as mean (±SD) displayed insufficient iodine intake in all five provinces of the Calabria region
(Table 1, data unpublished).
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Table 1. Mean (±DS) and median urinary iodine concentration (UIC) in schoolchildren in the
Calabria region.
Provinces Samples (n) UIC Mean (±SD) μg/L UIC Median μg/L
Catanzaro 1024 85 ± 71 65
Cosenza 701 91 ± 71 73
Crotone 257 84 ± 78 54
Reggio Calabria 346 91 ± 69 75
Vibo Valentia 365 83 ± 64 67
Similar results were obtained in Campania, another region of Southern Italy, in which UI excretion
from 10,552 schoolchildren were determined. The analysis of frequency distribution showed values
below 50 and 100 μg/L of UI in 32% and 61% of children, respectively, highlighting the Campania
region as a mild iodine deficiency area [33].
As a part of the same European project, another important challenge was to implement the use
of iodized salt through interactive meetings with schoolchildren. In the Calabria region, we have
interviewed 49,840 subjects in their classrooms, providing detailed information on the beneficial effects
of iodine salt prophylaxis along with informative materials consisting of leaflets and table-games about
iodine deficiency disorders. A final goal of this project was to establish an Observatory for Monitoring
Iodine Prophylaxis in each Italian region.
3. Status of Iodine Intake Over the Last Two Decades in the Calabria Region: The
Epidemiological Observatory for Endemic Goiter and Iodine Prophylaxis
Based on our extensive studies carried out in the entire regional territory and taking into account
the final goal of the European project, the Epidemiological Observatory and Promotion of Health of
the Calabria Region, Section “Goiter Endemic and Iodine Prophylaxis” (OERC) was established by
the Calabria region (regional law n. 755/2003) at the Health Center of the University of Calabria. The
OERC represents the epidemiological structure through which the regional-scale surveillance of the
iodine prophylaxis program is carried out using: (i) epidemiological surveys to periodically evaluate
the iodine intake and the prevalence of goiter in the adolescent and to verify the prevalence of thyroid
diseases in the adult population; (ii) a promotional campaign on the advantages of iodine prophylaxis;
(iii) the sale trend of iodized salt.
3.1. Epidemiological Surveys
The first survey was carried out in the years 2007–2009 on 11–14 year old children recruited
from long standing iodine sufficient urban areas (U) and from rural areas (R) in which an iodine
insufficiency was previously documented [29,30]. In agreement with the guidelines of WHO, UNICEF,
and International Council for Control of Iodine Deficiency Disorders (ICCIDD) [9], monitoring was
based on both the percentage of goiter and the median value of UI concentration in schoolchildren.
A total of 2733 subjects (1686 U and 1047 R) from the five provinces of Calabria were examined to
evaluate thyroid volume by ultrasonography, while 1358 (794 U and 565 R) spot-urine samples were
collected to determine adequacy of iodine intake. The prevalence of goiter, calculated on the basis of
the reference values proposed by WHO [8], and the median values of ioduria are shown in Figure 3
(data unpublished).
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Figure 3. Goiter prevalence and median urinary iodine concentration in schoolchildren population
from iodine sufficient urban areas (U) and rural areas (R) of the Calabria region.
Our data indicated that a mild iodine deficiency was still present in the rural areas of the provinces
of Cosenza, Reggio Calabria, and Crotone, whereas all the areas in which the prevalence of goiter was
less than 10% showed an adequate iodine status.
On the basis of these findings, we focused our attention on a vast territory of mild to-moderate
endemic area of Cosenza province, including four villages (Laino, San Basile, Saracena, and Mormanno).
In particular, we assessed both goiter prevalence and UI concentration in children aged 11–14 years.
Using WHO criteria, the goiter prevalence was 7.1% and 10.95% normalized for body surface area
(BSA) and age, respectively, while median UI excretion was 113 μg/L. Moreover, we also evaluated
the efficacy of the iodine prophylaxis in an adult population living in Laino. We observed reduced
goiter prevalence in the studied population that was subjected for two decades to a program of salt
iodization. More interestingly, the beneficial effects of iodine prophylaxis were also observed in the
youngest adult population investigated (ranged 18–27 years), which showed almost an absence of
thyroid enlargement, whereas the older adult population (>58 years), which have mostly lived in a
severe iodine deficient area before beginning iodine supplementation, were less responsive in reducing
goiter prevalence [34].
The epidemiological studies on iodine status by OERC continued until 2012 in the context of the
activities carried out by OSNAMI. Median UI concentration and goiter prevalence in 729 schoolchildren
recruited in Calabria region were 87 μg/L and 7.5%, respectively, which showed that further efforts
were still required to encourage the use of iodized salt [35].
Despite the clear benefits of iodine prophylaxis, continuous surveillance of adverse effects induced
by iodine intake needs to be carefully maintained. Thus, the frequency of thyroid disorders along
with the levels of antithyroid antibodies (TgAb and TPOAb) in 560 adult subjects from Laino and
from the urban area of Cosenza were evaluated [36]. As expected, the prevalence of subjects affected
by goiter was significantly higher in the rural area than in the urban area, but interestingly it was
significantly lower compared with that reported in the adult population living in the same rural area
in 2007 (42.6% rural area in 2007 vs. 13.8% rural area in 2015, p< 0.0001). Moreover, we have observed
a significant increase of TgAb levels in subjects living in a long-standing iodine sufficient area that may
be an epiphenomenon with no pathogenic significance [37]. Interestingly, no changes were detected for
concentrations of TPOAbs, the levels of which are typically high in thyroid autoimmune disease [38].
More recently, preliminary data from the national program of iodine deficiency monitoring
activities of OSNAMI have reported an increased UI concentration in rural areas as well as urban areas
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together with a reduction in goiter prevalence in schoolchildren population of most Italian regions,
including Calabria [39].
3.2. Promotional Campaign
An intense and widespread iodine prophylaxis campaign was carried out during 2007–2009. At
the end of the promotional survey, the OERC medical team visited 1012 primary schools involving
more than 100,000 children in all provinces of Calabria, outlining the health benefits of iodine through
the distribution of information materials, pamphlets, gadgets, and posters. Besides, other strategies to
increase consumer awareness towards iodized salt and its beneficial health effects have been developed
and are currently ongoing. These include a promotional campaign using mass media (newspaper,
TV), billboards on buses, and a website [40] that offers a useful platform containing national and
international links to other reliable sources of information about iodine nutrition.
3.3. Sale Trend of Iodized Salt
The activities of the OERC also include an assessment of the iodine content in salt on the market.
Salt samples, taken from the subjects screened (131 subjects from the rural area and 235 subjects from
the urban area) during our epidemiological surveys, were found to be compliant with the iodine
content permitted by Italian law (30 mg/kg) [36]. The data on sale trends of iodized salt in Calabria,
supplied by the Italian Salt Company, one of the most important sales producers/distributors in the
region, showed an increasing trend over the last few decades, reaching a coverage rate of approximately
65% [36]. These data are in line with those obtained from the national salt producers and collected by
the Italian National Institute of Health that specifically reported an increase in the percentage of sold
iodized salt from 34% in 2006 to 65% in 2017 [39]. However, since a usage rate of iodized salt of at least
90% is recommended by WHO, UNICEF, and the ICCIDD [3] for effective prevention of IDDs, further
efforts should be made to better inform the population on the benefits of using iodized salt.
4. Conclusions
The IDD control program in Calabria is one of the success stories of public health in Italy. The
epidemiological data over the last three decades clearly indicate the improvement of iodine status in
the Calabria region also due to the commitment of the Regional Observatory of Endemic Goiter and
Iodine Prophylaxis. Although substantial progress has been made, efforts should focus on ensuring
there is adequate iodine intake in the entire population to achieve and maintain the IDD control goal.
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Abstract: The inhabitants of Lazio, similarly to those of other Italian regions, have been historically
exposed to the detrimental effects of an inadequate intake of iodine. The latter is a micronutrient
essential for the biosynthesis of thyroid hormones (TH). Iodine deficiency is responsible for a number
of adverse effects on human health known as iodine deficiency disorders (IDD), the most common of
which worldwide are goiter and hypothyroidism. In order to reduce IDD, a national salt iodination
program was started in Italy in 2005. In this article we reviewed the available data regarding iodine
intake in the Lazio population before and after the introduction of the national salt iodination
program, in order to evaluate its efficacy and the eventual problem(s) limiting its success. On the
whole, the information acquired indicates that, following the introduction of the program, the dietary
iodine intake in the Lazio population is improved. There is, however, still much work ahead to
ameliorate the iodine prophylaxis in this region. In fact, although a generally adequate iodine intake
in school-age children has been observed, there are still areas where a mild iodine insufficiency is
present. Moreover, two independent epidemiological surveys on pregnant women evidenced a low
urinary iodine concentration with respect to the reference range conceived by the World Health
Organization. These findings demonstrate the need for greater attention to the iodine prophylaxis by
health care providers (i.e., obstetricians, gynecologists, pediatricians, etc.), and the implementation of
effective advertising campaigns aimed at increasing the knowledge and awareness of the favorable
effects of iodine supplementation on population health.
Keywords: iodine deficiency; schoolchildren; pregnancy; iodine prophylaxis; iodine deficiency
disorders; goiter; hypothyroidism
1. Introduction
Iodine is an indispensable micronutrient required by the thyroid gland for the appropriate
synthesis of the thyroid hormones (TH), i.e., triiodothyronine (T3) and its prohormone thyroxine (T4) [1].
By modulating key cellular processes (i.e., proliferation, differentiation, apoptosis, and metabolism),
TH affect multiple body tasks from the early stages of prenatal life, when maternal thyroxinemia plays a
fundamental role in neural growth and differentiation, to adulthood, in which they regulate metabolism,
thermogenesis, feeding, memory/learning abilities, and cardiovascular and reproductive functions [2–5].
To guarantee an appropriate TH biosynthesis, the daily dietary iodine intake recommended by the
World Health Organization (WHO), the United Nations Children’s Emergency Fund (UNICEF), and the
International Council for the Control of Iodine Deficiency Disorders (ICCIDD) is 90 μg for preschool
children (0 to 59 months), 120 μg for schoolchildren (6 to 12 years), 150 μg for adolescents (above
12 years) and adults, 250 μg for pregnant and lactating women [6]. Failure to meet these requirements is
held responsible for a number of adverse effects on human health known as iodine deficiency disorders
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(IDD) [7]. These affect almost 1.9 billion people worldwide and constitute a major public health issue
in different countries, including Italy [6,8,9]. IDD may occur at all ages, from the early stages of fetal
life to adulthood. Of particular relevance are the detrimental effects of an insufficient maternal intake
of iodine on development and maturation of the fetal brain, which represents a foremost preventable
cause of mental defects [10]. Further adverse effects include abortion, stillbirth, impairment of cognitive
functions, delayed growth and puberty, hypothyroidism, goiter, and infertility [11–17].
The epidemiological criteria established by the WHO to evaluate the prevalence and severity
of iodine deficiency in a specific population refer to the median urinary iodine concentration (UIC)
in morning spot urine samples, along with the presence of goiter [6]. Assuming a daily diuresis of
1.5 liters, a given land area is considered iodine sufficient when the median UIC of the population is
comprised between 100 and 199 μg/L, and goiter prevalence in school-age children (≥6 years) is below
5% [6]. In pregnant women, median UIC should be comprised between 150 and 250 μg/L to guarantee
normal fetal development. Reported in Table 1 are the WHO reference values of UIC for classifying the
iodine status in a population.
Table 1. Median urinary iodine concentrations (UIC) and iodine status in school-age children and
pregnant women according to the World Health Organization (see reference [6]).
School-Age Children Pregnant Women
UIC (μg/L) Iodine Status UIC (μg/L) Iodine Status
<20 Severe iodine deficiency <150 Insufficient
20–49 Moderate iodine deficiency 150–249 Adequate
50–99 Mild iodine deficiency 250–499 Above requirements
100–199 Adequate iodine nutrition ≥500 Excessive
200–299 More than adequate
≥300 Excessive
In the attempt to establish an efficient iodine prophylaxis and to eradicate IDD, the law n.55/2005,
introducing a national salt iodination program (30 mg of potassium iodate per kilogram of salt),
was promulgated in 2005 in Italy [9]. The rules laid down by this law make the sale of iodized salt
compulsory and favor the silent prophylaxis. Specifically, the sale points of salt for direct consumption
have to expose iodine enriched salt while ensuring the availability of non-iodized salt, which is
provided only upon specific request of the consumer. In the public catering sector, such as bars and
restaurants, and in workplace or community canteens, iodine-enriched salt should also be available
to consumers. Furthermore, the law recommends the use of iodized salt in the food industries as an
ingredient in preparation and food storage [9].
In the present manuscript, we will review the available information on iodine status in Lazio
(a region of central Italy) before and after the introduction of the Italian law n.55/2005, along with the
encountered problems hampering the actuation of the national iodine prophylaxis program. All papers
analyzed have been obtained from PubMed. Additional data are from the National Observatory for
the Monitoring of Iodoprophylaxis in Italy (OSNAMI) of the Italian National Institute of Health.
2. Iodine Status in the Lazio Region before the Introduction of the National Iodine
Prophylaxis Program
The Italian population, including the inhabitants of Lazio, has historically been exposed to the
negative effects of iodine food shortages [9,18–20].
In the seventies of the last century, epidemiological studies carried out in about 5700 school-age
children (6–13 years old) of southern Lazio documented the presence of iodine deficiency [21]. Reported
mean UIC values varied from 22 μg per gram of creatinine (μg/g Cr) to 40 μg/g Cr, consistent with an
iodine deficiency of moderate degree, as shown in Figure 1 and Table 1. In these children the prevalence
of goiter, evaluated by palpation, varied from 6.9% to 11.7%, as shown in Figure 1. In a subsequent
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case study, performed in 1998 in the city of Rome, UIC and goiter prevalence were investigated in
1040 school-age children (6–14 years old) [22]. A median UIC value of 92 μg/L (mean UIC value of
98 μg/L), consistent with a mild iodine deficiency, as shown in Table 1, was still observed, as shown
in Figure 1. On the other hand, goiter prevalence determined by ultrasound was 4.7% [22]. Hence,
before the introduction of the nationwide iodine prophylaxis program, the data collected indicated
a condition of mild to moderate iodine deficiency of children residing in Lazio. To the best of our
knowledge, no studies were performed on iodine status in pregnant women before 2005.
Figure 1. Urinary iodine concentrations (UIC) and goiter prevalence in the inhabitants of Lazio before
(A) and after (B) the introduction of the national salt iodination program.
3. Iodine Status in the Lazio Region after the Introduction of the National Iodine
Prophylaxis Program
Following the introduction of the iodine prophylaxis program, three independent studies were
performed in order to assess iodine status in both school-age children and pregnant women [23–25].
A first observational study was realized in 2006 in the city of Rome to evaluate iodine intake in
pregnant women compared to non-pregnant age-matched ones [23]. The study enrolled 51 clinically
healthy pregnant women in their first gestational trimester, and 100 clinically healthy non-pregnant
women [23]. The median UIC value observed in control women was 182μg/L, suggestive of an adequate
iodine intake, as shown in Figure 1. However, pregnant women showed poor iodine consumption,
attested by a median UIC value of 74 μg/L. In particular, the UIC was found below the normal range
only in 4% of control women but in 92% of pregnant women. These observations pointed out that,
despite the iodine sufficiency recognized in control women, the majority of pregnant women and their
fetuses were exposed to detrimental consequences of iodine deficiency.
61
Nutrients 2019, 11, 1647
After that, a new survey was performed in 2015 in the city of Cassino, located in the south of
Lazio, whose residents were previously found to have a moderate iodine deficiency, as shown in
Figure 1B [24]. In this study, UIC and thyroid volume measured by ultrasonography were evaluated in
234 school-age children (13–14 years old). At the same time an inquiry was conducted to estimate the
percentage of iodized salt sold in the preceding year by the major local retailers. The latter showed
only 42% of all salt sold in 2014 in this city was iodized. Despite that, a median UIC of 134 μg/L was
observed in the school children under examination, suggesting an adequate iodine intake. This result
was also corroborated by the low prevalence of goiter, encountered only in 3.8% of subjects. However,
when children were grouped based on the regular consumption of iodized salt or milk or both, those
referring no consumption of either iodized salt or milk had a median UIC value (96.4 μg/L), compatible
with a mild iodine deficiency. On the other hand, optimal median UIC values were found in school
children regularly taking either iodized salt (132.1 μg/L) or milk (131 μg/L) or both (147.9 μg/L).
Such evidence strengthens the importance of eating iodized salt and iodine-rich food to achieve the
right amount of iodine in the body for thyroid function [24].
A further study was aimed to analyze iodine intake in pregnant women from the same area of
Cassino [25]. Study participants were enrolled in the period from January 2016 to April 2017, for a total
of 96 pregnant women and 79 age-matched non-pregnant women. In the control group, median UIC
was nearby 98 μg/L, consistent with a mild iodine deficiency, while pregnant women had a median UIC
of about 110 μg/L, below the lower value (150 μg/L) recommended by the WHO for categorizing iodine
adequacy in a pregnant population. In agreement with this finding, a significantly increased thyroid
volume was recorded in pregnant women compared to non-pregnant ones, as shown in Figure 1 [25].
In this study the effects of iodized salt and/or milk consumption on UIC levels of both control and
pregnant women, considered as a whole, were also examined. The analysis showed an increasing
trend of UIC from women not using either iodized salt or milk (median UIC 79.8 μg/L) compared to
those using iodized salt (median UIC 94 μg/L) or milk (median UIC 112 μg/L) or both (median UIC
118 μg/L) [25]. Thus, once again the data obtained highlight the need to implement the national salt
iodination program, as well as the importance of inserting initiatives targeted at control of iodine
prophylaxis and prevention of IDD in regional health plans. It has to be mentioned, however, that the
aforementioned studies rely on a limited number of subjects analyzed and should be corroborated on
larger case studies.
4. Encountered Problems Hampering the Actuation of the National Iodine Prophylaxis Program
As reported above, the available epidemiological data demonstrated that, following the
introduction of the national salt iodination program, the iodine intake in the inhabitants of Lazio is
somewhat improved. However, prevention measures are still needed to fully avoid the risks of IDD in
this region. In particular, there are three main lines of action that should be pursued.
The first is devising strategies to increment the amount of iodized salt sold by retailers. In fact,
due to the lack of penalties related to non-compliance with the law n.55/2005, vendors are not
discouraged from exhibiting non-iodized salt on store shelves, and they sell both iodized salt and
or even just non-iodized salt [24]. This, at least in part, may explain the low percentage of iodized
salt sold (42%) in the city of Cassino, and why 45% of the school children and 50% of women of
child-bearing age do not use iodized salt. Moreover, the latest data provided by OSNAMI indicated
that the percentage of iodized salt used in collective catering is still very low (about 24%), and that
used by the food industry is even lower (3–8%) [26]. Thus, it is of great importance to encourage this
manufacturing sector to make more extensive use of iodized salt.
The second line of intervention should be to adequately inform the population on the beneficial
effects on human health deriving from the consumption of iodized salt. This task could be accomplished
by creating effective advertising campaigns able to reach every single citizen. In this context, an initiative
of the Ministry of Health is taking place that aims to provide all students with comprehensive
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information about the beneficial effects of the use of iodized salt through meetings with medical staff
organized by individual schools [27].
Finally, greater attention by the major health care providers of the National Health System is highly
desirable, especially obstetricians, gynecologists, and pediatricians. Different surveys, in fact, noticed
that obstetricians and midwives do not recommend iodine supplementation either to women planning
pregnancy or during pregnancy or lactation [28,29]. To this regard, a position statement on the use of
iodized salt in adulthood and children was signed by the Italian Ministry of Health, the National Institute
of Health, the Italian Society of Endocrinology, the Italian Thyroid Association, the Medical Association
of Endocrinologists, the Italian Society of Pediatric Endocrinology and Diabetology, the Italian Society
of Pediatrics, the Italian Society of Gynecology and Obstetrics, the Italian Association of Consultative
Gynecologists, the Italian Society of Human Nutrition, the Italian Society of Nutraceuticals, the Italian
Association of Dietetics and Clinical Nutrition, the Italian Society for the Study of Food Behavior
Disorders, the Italian Federation of Nutrition, and the National Federation of General Practitioners [30].
The joint implementation of all these actions should provide a consistent contribution toward the
eradication of iodine deficiency in Italy.
5. Conclusions
The available epidemiological data indicate that, following the introduction of the national salt
iodination program, the iodine intake of the inhabitants of Lazio has only partially improved. In fact,
although a generally adequate iodine intake in school-age children has been observed, pregnant women
still show an iodine deficiency. Thus, it is necessary to encourage compliance with the law in order
to reach optimal iodine nutrition and to completely eradicate the IDD in this region. The situation
recorded in Lazio corroborates the recent Krakow Declaration on Iodine reporting an increased concern
about the fading commitment of policymakers to address iodine deficiency in Europe and the poor
attention of policymakers, opinion leaders, and the public toward the resolution of IDD [31]. Thus, it has
become of primary importance to join forces with policymakers, public health officials, and scientists
to guarantee that existing European strategies to prevent IDD are fulfilled and implemented.
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Abstract: In the Republic of Moldova, more than half of all deaths due to noncommunicable diseases
(NCDs) are caused by cardiovascular disease (CVD). Excess salt (sodium) and inadequate potassium
intakes are associated with high CVD. Moreover, salt iodisation is the preferred policy to prevent
iodine deficiency and associated disorders. However, there is no survey that has directly measured
sodium, potassium and iodine consumption in adults in the Republic of Moldova. A national
random sample of adults attended a screening including demographic, anthropometric and physical
measurements. Sodium, potassium and iodine intakes were assessed by 24 h urinary sodium (UNa),
potassium (UK) and iodine (UI) excretions. Knowledge, attidues and behaviours were collected by
questionnaire. Eight-hundred and fifty-eight participants (326 men and 532 women, 18–69 years)
were included in the analysis (response rate 66%). Mean age was 48.5 years (SD 13.8). Mean UNa was
172.7 (79.3) mmoL/day, equivalent to 10.8 g of salt/day and potassium excretion 72.7 (31.5) mmoL/day,
equivalent to 3.26 g/day. Only 11.3% met the World Health Organization (WHO) recommended
salt targets of 5 g/day and 39% met potassium targets (>90 mmoL/day). Whilst 81.7% declared
limiting their consumption of processed food and over 70% not adding salt at the table, only 8.8%
looked at sodium content of food, 31% still added salt when cooking and less than 1% took other
measures to control salt consumption. Measures of awareness were significantly more common in
urban compared to rural areas. Mean urinary iodine was 225 (SD: 152; median 196) mcg/24 h, with
no difference between sexes. According to WHO criteria, 41.0% had adequate iodine intake. Iodine
content of salt table was 21.0 (SD: 18.6) mg/kg, lower in rural than urban areas (16.7, SD = 18.6 vs. 28.1,
SD = 16.5 mg/kg, p< 0.001). In most cases participants were not using iodised salt as their main source
of salt, more so in rural areas. In the Republic of Moldova, salt consumption is unequivocally high,
potassium consumption is lower than recommended, both in men and in women, whilst iodine intake
is still inadequate in one in three people, although severe iodine deficiency is rare. Salt consumed is
often not iodised.
Keywords: Republic of Moldova; salt; sodium; potassium; iodine; population
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1. Introduction
Non-communicable diseases (NCDs) are the leading causes of death globally [1] and their
reduction is a health priority [2], with reduction in population salt consumption a cost-effective
policy option (‘best buys’) [3]. In the Republic of Moldova, NCDs are the leading causes of death,
and cardiovascular disease (CVD) represents the main cause of population morbidity and mortality,
accounting for every second death in 2016 [4]. High blood pressure (BP) and unhealthy diets are major
causes CVD in the world and account for most of the disease burden in the Republic of Moldova [5].
High salt in the diet (i.e., sodium chloride, 1 g = 17.1 mmoL of sodium) causes high BP, a high risk of
vascular diseases [6–10] and other adverse health effects [11–13]. A lower salt intake reduces BP [7,8],
cardiovascular events and overall mortality [9,10].
The World Health Organization (WHO) currently recommends for adults a consumption not
higher than 5 g of salt daily [14]. However, in most countries in the world this recommendation is
unmet [15–17]. Salt enters our diet not only as added salt to food and cooking by the consumer, but,
in the Western diet, more often from processed food, food prepared in restaurants and other food
outlets [18,19]. There is no direct estimate of population dietary salt intake in Republic of Moldova.
However, it is likely to be high, as in neighbouring countries like Serbia (9.85 g/day) [20], Slovenia
(11.3 g/day) [21] and Montenegro (11.6 g/day) [22]. In the Republic of Moldova it is a common habit to
add salt to food at the table and when cooking, as well as eating processed food that have high salt
content. In 2013 a national survey indicated that 24.3% of those surveyed always or often added salt to
food, and 32.4% always or often ate processed foods that are high in salt [5]. Salt reduction strategies
in the European region, including the Republic of Moldova, include monitoring and evaluation actions
as one of their pillars [23].
In contrast to sodium, dietary potassium has beneficial effects on BP and cardiovascular
health [24–26]. The Republic of Moldova lacks data on actual potassium consumption. The WHO
currently recommends that adults should consume not less than 90 mmoL of potassium daily [27].
Finally, in the Republic of Moldova the prevention of iodine deficiency disorders recommends universal
salt iodization [28]. Starting in 2009, the Ministry of Health authorised the production and placing
on the market of iodized bottled water additionally to iodized salt. Since more than 90% of iodine
consumed is excreted in the urine within 24–48 hours [29,30], 24 h urinary iodine excretion is a good
marker of recent iodine intake and an ideal biomarker for estimating iodine status [31] in the entire
adult population.
The aim of the present study was to establish current baseline average consumption of sodium,
potassium and iodine by 24h urine collection, in a national random sample of men and women. The
study also aimed to explore knowledge, attitudes and behaviour towards dietary salt.
2. Materials and Methods
2.1. Participants and Recruitment
A total of 1307 randomly selected men and women participated in the survey. They were all aged
18–69 years. They comprised residents of all Districts and Administrative Territorial Units ‘Gagauz-Yeri’,
along with Chişinău and Bălti Municipalities. The survey did not cover the Districts from the left
bank of the Nistru River and the Municipality of Bender (Figure 1). A probabilistic master sample
from the National Bureau of Statistics’ Household Budget Survey was used to select the sample for the
survey which was extracted in three phases: 150 Primary Sampling Units (PSU—communes, cities or
sectors within cities) were selected; list of households from PSU were drawn; eligible individuals from
households were identified. Random sampling proportional to size were stratified by sex, geography
(north, centre, south and Chişinău), urban/rural, size of cities.
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Figure 1. Geographical sampling from the Republic of Moldova. National proportional random
sampling from 28 (marked with a star) of 37 Districts and Administrative Territorial Units ‘Gagauz-Yeri’,
along with Chişinău and Bălti Municipalities. The sampling was as follows: Anenii Noi (1.3%), Balti
(0.8%), Basarabeasca (1.4%), Briceni (4.7%), Cahul (3.5%), Călăraşi (2.4%), Cantemir (2.4%), Căuşeni
(0.8%), Chişinău (30.7%), Comrat/ATU ‘Gagauz-Yeri’ (4.4%), Criuleni (4.3%), Edinet, (3.1%), Făleşti
(2.4%), Floreşti (2.2%), Glodeni (1.2%), Hînceşti (0.7%), Ialoveni (4.4%), Nisporeni (3.0%), Ocnit,a (2.7%),
Orhei (4.8%), Rezina (1.7%), Rîşcani (0.6%), Sîngerei (1.9%), S, oldaneşti (2.6%), Soroca (2.2%), S, tefan
Vodă (0.6%), Străşeni (2.7%) and Ungheni (6.3%).
From the sampling frame and according to PAHO/WHO and EMRO-WHO Protocols [32,33],
we excluded the following groups: pregnant women, individuals with heart failure, severe kidney
disease, stroke, liver disease, people who had started diuretic therapy in the last two weeks, any other
conditions that would compromise the collection of 24 h urine samples or a reliable informed consent.
The survey took place between 21st July and 5th September 2016. From the 1307 participants
interviewed, 858 (66%) provided data for inclusion in the analysis. Thirteen had missing data,
263 admitted missing more than one void, 77 provided either under-collections (<23 h) or
over-collections (>25 h) and 37 had urinary creatinine excretion outside two standard deviations (SDs)
of the sex-specific distribution of urinary creatinine in the sample (Figure 2).
The survey was carried out in accordance with the Declaration of Helsinki and Good Clinical
Practice [34]. Ethical approval for the survey was obtained from the Committee of Research Ethics of
the National Agency for Public Health of the Republic of Moldova and participants provided written
informed consent to take part.
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Figure 2. Stepwise procedure for the selection of valid participants according to protocol adherence,
quality control and completeness of 24 hour urine collections.
2.2. Data Collection
The full methodology is reported in the supplementary material (Text S1). In brief, there were
three stages: (a) questionnaire, (b) physical measurements and (c) 24 h urine collections.
The questionnaire (adapted version of the WHO STEPS Instrument for NCD Risk Factor
Surveillance) [35] obtained demographic and socio-economic status, frequency of salty food, fruit and
vegetable consumptions, knowledge attitudes and behaviour on dietary salt.
Anthropometry, blood pressure (BP) and heart rate were measured in all participants with
standardized protocols and validated equipment, as also described elsewhere [22,32,33]. Hypertension
is defined as systolic and/or diastolic BP ≥ 140/90 mmHg or regular antihypertensive treatment [36].
After detailed and careful instructions (Text S1), participants provided a 24 h urine collection [32,33].
Sodium, potassium and creatinine determinations were carried out immediately [37,38]. Sodium and
potassium concentration in the urine samples were determined using a Ion Selective Electrode with a
Beckman Coulter Synchron CX5PRO system (High Wycombe, UK) and expressed in mmoL/L [37].
Creatinine concentration was determined through the Creatinine (urinary) Jaffé kinetic method and
expressed in mg/dL [38]. These determinations were carried out at the ICS Medical Laboratory Synevo
SRL in Chişinău. Urinary iodine was measured separately at the National Agency for Public Health of
the Republic of Moldova using the ammonium persulfate digestion method with spectrophotometric
detection by Sandell–Kolthoff reaction, expressed as mcg/L [39]. Iodine determinations in table salt
were carried out by the titration method [40].
2.3. Statistical Analysis
With a standard deviation of 75 mmoL/24 h (alpha = 0.05, power = 0.80) in urinary sodium
excretion, the study was designed to detect a reduction in salt consumption over time of around
1 g per day (~20 mmoL sodium/24 h). Considering an attrition rate of 50%, we aimed to select
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240 participants per age and sex group [32,33]. The population was stratified in groups by sex (men and
women), age (18–29 years, 30–44 years, 45–59 years, 60–69 years) and urban/rural areas. Therefore,
1920 individuals were originally needed to be selected (total n = 120 × 8 groups/0.5 attrition = 1920).
T-test for unpaired samples or analysis of variance (ANOVA) was used to test differences between
groups. The chi-square test was used for categorical variables. To convert urinary output into dietary
intake, the urinary excretion of sodium (UNa) or potassium (UK) in mmoL/day were first converted to
mg/day (for sodium 1 mmol = 23 mg of sodium, for potassium 1 mmol = 39 mg). The conversion from
dietary sodium (Na) intake to salt (NaCl) intake was made by multiplying the sodium value by 2.542.
Then, sodium values were multiplied by 1.05 (assuming that aproximately 95% of sodium ingested is
excreted) [41]. For potassium dietary intake was calculated assuming 80% of the potassium ingested
is excreted in the urine [42]. Urinary iodine was expressed in mcg/day. We used the cut-off targets
for iodine consumption set by WHO (based on urinary iodine concentrations in mcg/L derived from
24h collections) [31]. Statistical analyses were carried out using SPSS, version 20 (SPSS Inc., Chicago,
IL, USA). The results were reported as mean (SD and/or 95% CI) or as percentages, as appropriate.
Two-sided p below 0.05 were considered statistically significant.
3. Results
The final population sample included 858 participants between 18 and 69 years old (n = 326 or
38% men and n = 532 or 62% women), recruited nationally (Figure 1).
3.1. Characteristics of the Participants
Mean age was similar in men and women, but men were taller and heavier than women and had
a higher systolic BP (Table 1). The point prevalence of hypertension was 45.5% (385/858), comparable
in men (148/326 or 45.8%) and women (237/532 or 45.2%; p > 0.05).
Table 1. Characteristics of the participants.
Variable
All Men Women
(n = 858) (n = 326) (n = 532)
Age (years) 48.5 (13.8) 47.3 (13.6) 49.2 (13.9)
Height (cm) 166.7 (8.8) 172.8 (8.1) 162.9 (7.0) †
Weight (kg) 78.2 (15.8) 82.0 (15.8) 75.8 (15.3) †
B.M.I. (kg/m2) 28.1 (5.4) 27.4 (4.9) 28.6 (5.7) ‡
Waist circumference (cm) – 93.8 (15.5) 91.8 (15.1)
Hip circumference (cm) – 100.5 (12.3) 106.5 (14.0)
Systolic BP (mmHg) 134.3 (21.2) 136.1 (18.5) 133.1 (22.6) *
Diastolic BP (mmHg) 86.8 (11.9) 87.1 (10.8) 86.6 (12.6)
Pulse rate (b/min) 76.2 (9.5) 78.0 (10.3) 75.2 (8.8)
Hypertension # n (%) 385 (45.5) 148 (45.8) 237 (45.2)
Results are mean (SD) or as percentage; † p < 0.001; ‡ p = 0.002; * p = 0.04 vs. men. # SBP ≥ 140 mmHg and/or
DBP ≥ 90 mmHg or on anti-hypertensive medications.
3.2. Daily Urinary Excretions of Volume, Sodium, Potassium and Creatinine and Salt and Potassium Intake
Urinary volume excretion was, on average, 1441 mL per day, higher in men than women, and
higher in urban than rural areas (Table 2). Urinary creatinine excretion was 11.7 mmol per day, higher
in men than women, but lower in urban than rural areas (Table 2). Mean urinary sodium was 172.7
(SD 79.3, median 161.9) mmoL/24h (Table 2), equivalent to a mean consumption of 10.8 (4.9) g of salt
per day (Table 2). Men excreted more sodium than women (mean difference 18.1 mmoL/24h, p < 0.001),
equivalent to ~1.1 g of higher salt consumption than women. WHO recommended levels of 5 g or less
were met by just 97 participants (11.3%), with no difference between sex and area of residence. Mean
urinary potassium was 72.7 (SD 31.5, median 68.8) (Table 2), equivalent to a mean consumption of
3.40 (1.47) g of potassium per day (Table 2).
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Table 2. Daily urinary excretions of volume, sodium, potassium and creatinine and estimates of salt
and potassium intake.
Variables
All Men Women Rural Urban
(n = 858) (n = 326) (n = 532) (n = 531) (n = 327)
Volume (mL/24 h) 1441 (529) 1505 (536) 1401 (521) ˆ 1333 (427) 1616 (624) #
Sodium (mmoL/24 h) 172.7 (79.3) 183.9 (86.0) 165.8 (74.1) † 180.4 (80.2) 160.1 (76.2) #
Salt intake (g/day) 10.8 (4.9) 11.5 (5.4) 10.3 (4.6) # 11.3 (5.0) 10.0 (4.8) #
Potassium (mmoL/24 h) 72.7 (31.5) 76.0 (33.4) 70.7 (30.1) * 73.8 (31.6) 71.0 (31.2)
Potassium intake (g/day) 3.40 (1.47) 3.55 (1.56) 3.31 (1.41) * 3.45 (1.47) 3.32 (1.46)
Creatinine (mmol/24h) 11.7 (5.0) 13.3 (5.6) 10.7 (4.2) # 12.3 (4.8) 11.4 (5.0) †
Results are mean (SD). # p < 0.001; ˆ p < 0.005; † p < 0.01; * p < 0.02 vs. men or vs. rural
Men excreted more potassium than women. Thirty-nine per cent of particiants met the levels of
potassium excretion of 90 mmoL/day or more recommended by the WHO, with no difference between
sexes and areas of residence.
3.3. Daily Intake of Iodine and Use of Iodised Salt
Urinay iodine excretion (as measure of intake) was adequate in 40.9% of participants, irrespective
of sex or area of residence (Table 3). Iodine consumption was above requirement or excessive in 30.3%
of the participants, irrespective of sex or area of residence. Of the 28.6% who fell into the category
indicating insufficient consumption (equally distributed by sex or area of residence), only 2.3% had
severe deficiency (Table 3).
Table 3. Proportions of participants meeting WHO targets for iodine consumption (based on urinary
iodine concentrations in mcg/L derived from 24 h collections).
Group (mcg/L)
All Men Women Rural Urban
(n = 858) (n = 326) (n = 532) (n = 531) (n = 327)
n (%) n (%) n (%) n (%) n (%)
Insufficient (<100) 245 (28.6) 95 (29.1) 150 (28.2) 104 (31.8) 141 (26.6)
Severe (<20) 20 (2.3) 6 (1.8) 14 (2.6) 4 (1.2) 16 (3.0)
Moderate (20–49) 60 (7.0) 24 (7.4) 36 (6.8) 28 (8.6) 32 (6.0)
Mild (50–99) 165 (19.2) 65 (19.9) 100 (18.8) 72 (22.0) 93 (17.5)
Adequate (100–199) 351 (40.9) 132 (40.5) 219 (41.2) 131 (40.1) 220 (41.4)
Above requirement (200–299) 152 (17.7) 59 (18.1) 93 (17.5) 58 (17.7) 94 (17.7)
Excessive (≥300) 108 (12.6) 40 (12.3) 68 (12.8) 34 (10.4) 74 (13.9)
Results are number (%).
Average urinary iodine excretion was 225 (SD: 152, median 196) mcg per day (Table 4), with no
difference between sexes or areas of residence. Iodine salt content was, on average 21.0 (18.6) mg/kg,
with no difference between men and women. However, participants in rural areas consumed table salt
with significantly less iodine concentrations than those samples consumed in urban areas (p < 0.001;
Table 4).
Table 4. Daily urinary excretions of iodine and iodine content of household salt samples.
Variables
All Men Women Rural Urban
(n = 858) (n = 326) (n = 532) (n = 531) (n = 327)
Iodine (mcg/24 h) 225 (152) 232 (154) 221 (150) 225 (145) 224 (128)
Iodine in table salt (mg/kg) 21.0 (18.6) 22.1 (18.2) 20.3 (18.9) 16.7 (18.6) 28.1 (16.5) #
Results are mean (SD). # p < 0.001 vs. rural.
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There were weak correlations between the amount of sodium excreted in the urine and the amount
of excreted iodine in men and women or rural and urban settings (Figure 3).
Figure 3. Correlations between urinary sodium and urinary iodine excretions by sex (left) and areas
of residence (right). Left: men r = 0.087, p = 0.207, women r = 0.095, p = 0.029; right: rural r = 0.087,
p = 0.045, urban r = 0.090, p = 0.106.
There were also weak correlations between the amount of urinary iodine excreted in a day and
the amount of iodine present in the table salt sampled from the households of individual participants
(Figure 4).
Figure 4. Correlations between urinary iodine excretions and iodine content of household’s table salt
by sex (left) and areas of residence (right). Left: men r = 0.025, p = 0.662, women r = 0.021, p = 0.630;
right: rural r = 0.061, p = 0.164, urban r = −0.055, p = 0.325.
3.4. Knowledge, Attitude and Behaviours Towards Salt Intake
Knowledge, attitude and behaviours toward the consumption of salt was assessed by asking
participants about the frequency, quantity and type of salt used in the household, as well as their
cooking habits and their attitudes towards dietary salt. A total of 35.4% of respondents mentioned that
they added salt always or often before or while eating. The percentage of men who added salt always
or often to their meal was significantly higher than that of women (47.8% vs. 27.7%; p < 0.001). A total
73
Nutrients 2019, 11, 2896
of 61.3% of respondents reported that they always or often added salt when cooking or preparing food
at home; this was the case more often in rural than in urban areas (69.8% vs. 47.5%; p < 0.001). More
than half of the respondents (64.4%) mentioned that they used iodised salt when cooking or preparing
food at home. Consumption of iodised salt, however, was higher in urban than in rural areas (86.1% vs.
52.9%; p < 0.001). About a quarter (26.7%) felt they consumed too much or far too much salt, women
being more likely (32.1% vs. 23.3%; p < 0.01). More than half (67.2%) acknowledged that consuming
too much salt could cause serious health problems; however, only 28.2% considered lowering salt
intake in the diet to be very important. More than a quarter of respondents (27.8%) mentioned that
they consumed processed foods high in salt, with more men than women doing so (34.9% vs. 23.5%;
p < 0.001), and more often in urban than rural settings (39.2% vs. 20.8%; p < 0.001).
Participants were asked about actions they take to control salt intake on a regular basis. A total of
81.7% limited their consumption of processed food high in salt (Table 5). A total of 22.3% would use
spices rather than salt, one in three would not add salt when cooking. Only 8% looked at salt/sodium
content on food labels and 14.3% bought alternatives to salt. One in three avoided eating food prepared
outside home and 0.8% took any other measure to reduce salt intake.
Table 5. Knowledge, attitudes and behaviour towards the consumption of salt.
Participants Who:
All Men Women Rural Urban
(n = 858) (n = 326) (n = 532) (n = 531) (n = 327)
Limit their consumption of processed food 81.7 79.7 82.4 80.4 83.9
Look at salt/sodium content in foods 8.8 10.1 8.2 3.8 17.2 *
Buy low salt/sodium alternatives 14.3 17.4 13.2 3.8 24.7 *
Do not add salt at the table 77.3 69.6 80.2 75.9 79.6
Do not add salt when cooking 31.1 24.6 33.5 13.3 61.3 *
Use spices instead of salt when cooking 22.3 15.9 24.7 25.3 17.2
Avoid eating food prepared outside a home 33.1 27.5 35.2 43.7 15.1 *
Take other measures to control salt intake 0.8 1.4 0.5 1.3 0
Results are expressed as % of column total. * p ≤ 0.001 vs. rural by Fisher’s exact test.
4. Discussion
This is the first national survey on sodium, potassium and iodine consumption ever carried
out in adults in the Republic of Moldova, using the gold standard measure of 24 h urinary sodium,
potassium and iodine excretions as biomarkers of intake. The results show unequivocally that salt
consumption is high, potassium consumption is lower than recommended, both in men and in women.
Furthermore, iodine intake is still inadequate in one in three people, although severe iodine deficiency
is rare. However, universal salt iodization cover is still inadequate in many households both in urban
and rural areas, where the use of iodized salt is still limited in the Moldovan diet.
4.1. Salt Consumption
Average salt intake was nearly 11 g per day, over two-fold of the WHO recommended maximum
population target of 5 g per day [14]. Only 11.3% of the participants met the WHO salt targets. Men
excreted more sodium than women, and in rural areas salt consumption was higher than in urban areas.
Discretionary use of salt is common in the Republic of Moldova, with a third of participants adding
salt regularly to food and half also using it regularly when cooking. The majority of participants knew
that high salt causes serious health problems. However, only less than half thought it would be useful
to reduce its consumption, and even fewer felt their own intake was not excessive and were doing
anything to reduce it. The answers to these questions reveal an insufficient level of knowledge of
the problem associated with high salt consumption amongst the participants and the unreadiness to
transfer this knowledge to behavioural changes in using discretionary salt.
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4.2. Potassium Consumption
Average population potassium intake was estimated at around 3.26 g per day, still lower than the
WHO recommended minimum population target of 3.51 g per day (equivalent to 90 mmol per day [27].
Between 31% and 50% met WHO potassium targets. Men ate more potassium than women, likely due
to the larger body size and volume of food eaten, rather than the quality of it. Salt and potassium are
expressed as total quantities rather than consumption per calorie intake, hence the gender difference is
mainly explained by the larger body size of men compared to women and the corresponding total food
consumption compared to women. No difference in potassium intake was detected between rural and
urban areas.
4.3. Iodine Consumption
Average daily iodine consumption was 225 mcg per day, with no difference between sexes or areas
of residence. Severe iodine deficiency (<20 mcg/L according to WHO criteria [31]) was rare. However,
more than a quarter had levels below 100 mcg/L (insufficient), and a quarter had levels either above
requirement or excessive (above 300 mcg/L). The Republic of Moldova has adopted for a long time
a policy of universal salt iodization for the control of iodine deficiency disorders [28]. It should be
mentioned that as from 2009 the production and placing on the market of iodized bottled water was
authorised by the government, which may have contributed to the increasing iodine supply, especially
among more affluent population groups. By measuring the iodine content of the table salt used in
the households visited for the screening, we were able to detect a significant lower iodine content in
rural compared to urban areas (16.7 vs. 28.1 mg/kg). Moreover, the percentage of households with no
iodized salt was greater in rural than urban areas (30.9% vs. 9.8%; p < 0.001). These results seem to
suggest a variety of barriers, including possibly deterioration of iodized salt before reaching the users,
reduced access, lower use, lack of awareness, costs, lack of use of iodized salt in food preparation
by local producers, street vendors and the food industry. Another finding in our study was the lack
of strong relationships between urinary sodium and iodine excretions and between urinary iodine
excretion and iodine content in households’ table salt. These findings may, in part, indicate that some
salt in diet derives from non-iodized sources. Assuming that the food eaten in the households is
prepared with iodized salt (since the country has a national policy of universal salt iodization), a major
component of the salt consumed may derive from food eaten outside the household prepared with
non-iodized salt. It is also possible that the use of iodized bottled water has become an important
source of iodine, not captured in the correaltions with iodized salt.
4.4. Comparison with Other European Countries
Our main findings show that the salt intake in the Republic of Moldova is as high or higher
than that reported in many other European and neighbouring countries, both in men and women.
In the recent MINISAL study in Italy, the daily salt intake of Italians was 10.9 g for men and 8.5 g
for women [43], with large variations by region and socio-economic status [44]. In Northern Greece
average intakes were 11.1 and 9.1 g per day for men and women, respectively [45]. In the national
survey of salt consumption in Slovenia men ate 13.0 g and women 9.9 g per day [21]. Recently, in the
city of Podgorica, in Montenegro, salt consumption was measured at 13.9 g in men and 9.9 g per day in
women [22]. In the SALTURK II survey in Turkey, men consumed 15.7 g of salt per day and women
14.0 g per day, with higher salt consumption in rural compared to urban areas [46]. Finally, in Portugal
a national survey as estimated the consumption of salt at 10.7 g per day in men and 10.2 g per day
in women [47]. Potassium intake in the Republic of Moldova was lower than in Portugal [47] and
higher than that measured in Italy [43], Greece [45], and Montenegro [22]. Men eat more potassium
than women.
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4.5. Strengths and Limitations
Our study included a large random sample of men and women representative of the Republic of
Moldova. Salt and potassium intake were measured using the gold-standard method of 24 h urine
collections [33]. We applied a rigorous quality control and used a highly standardized protocol to
ensure completeness of urine collections, and a strict protocol of inclusion only of those fulfilling the
quality control criteria, such as length of collection time and urinary creatinine excretion, markers of
the accuracy of the collection. Our study is one of few studies having carried out at the same time a
population based evaluation of daily iodine excretion in an adult population using 24 h urinary iodine
excretion as a biomarker (rathe than spot urine samples), to assess the iodine status of a group of
individuals who, whilst being supplemented with the universal salt iodization program, is not usually
included in the population monitoring and surveillance on the effects of such policy.
Selection bias remains a possibility that we cannot rule out. We excluded a third of the participants
as a result of the robust quality control for completeness of urine collections. Participants not delivering
complete urines had lower weight, BMI, waist and hip circumferences and lower diastolic BP than those
complying. No other differences were seen in their general characteristics (Table S1). Urinary sodium
and potassium excretions were only assessed once. Whilst we cannot characterise an individual’s
intake [48], there is less likelihood that group estimates be biased. Finally, the absence of measurements
of thyroid hormones does not allow a full assessment of the impact of both insufficient and excessive
iodine intake on the adult population.
4.6. Impact and Policy Implications
The population of the Republic of Moldova is of just over 4 million, of whom approximately 75%
over the age of 25 years. According to national health statistics from 2016, the mortality rate from
diseases of the cardiovascular system is 617.3 per 100,000 population [49]. To meet the 30% reduction
in population salt consumption set by WHO, the Republic of Moldova should aim at a 3.24 g per day
reduction nationally. This reduction would be expected to avert 7.9% CVD events and 10.7% strokes
every year, approximately 1460 CVD deaths per year.
The Republic of Moldova adopted the National Strategy on Prevention and Control of
Noncommunicable Diseases 2012–2020 and its Action Plan [50]. Part of this pledge is to continue
on the awareness campaigns already in place and to establish a comprehensive strategy involving
legal measures, mandatory reformulation, nutritional labelling, efficient enforcement and good
leadership [28]. Furthermore, a feasibility study of implementation and evaluation of essential
interventions for the prevention of CVD in primary healthcare is currently under way in the Republic
of Moldova, with a view towards a national scale-up [51].
The evidence of the level of sodium and potassium intake in the Republic of Moldova provides
robust evidence to support action and to facilitate evaluation. Awareness, attitudes and behaviours
about salt and its implication for health suggest that there is an intensification of public awareness
campaigns and health promotion to improve the take up of preventive strategies aiming at reducing salt
consumption, whilst at the same time increasing potassium intake by encouraging higher consumption
of potassium-rich food. Awareness about hidden salt in processed food should be highlighted. The
national program for reducing salt intake in the Republic of Moldova needs a multisectoral collaborative
approach including not only public awareness and behaviour-change communication (including via
health care professionals), but, more importantly, structured programs for reformulation that set the
framework for the food industry to reduce salt in bread and bakery products and processed foods,
major source of salt intake.
4.7. Conclusions
The present study provides valuable insights into ways to improve and adapt the universal salt
iodization program. From one hand our results suggest that there are improvements to be made for a
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comprehensive take up of the policy nationally. On the other hand it confirms that both iodization
and salt reduction policies are fully compatible, as agreed in a WHO Consensus Statement [31] and
more recently confirmed in case studies in Italy [52] and China [53] where a moderate salt reduction in
unlikely to compromise iodine status. Our data provides a useful baseline against which to monitor
the impact of future initiatives.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/11/12/2896/s1
Table S1: Characteristics of the excluded participants and comparison with those included in the study, Text S1:
Data collection.
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Abstract: In breastfed infants, human milk provides the primary source of iodine to meet demands
during this vulnerable period of growth and development. Iodine is a key micronutrient that plays an
essential role in hormone synthesis. Despite the importance of iodine, there is limited understanding
of the maternal factors that influence milk iodine content and how milk iodine intake during infancy
is related to postnatal growth. We examined breast milk samples from near 2 weeks and 2 months
post-partum in a mother-infant dyad cohort of mothers with pre-pregnancy weight status defined
by body mass index (BMI). Normal (NW, BMI < 25.0 kg/m2) is compared to overweight/obesity
(OW/OB, BMI ≥ 25.0 kg/m2). The milk iodine concentration was determined by inductively coupled
plasma mass spectrometry. We evaluated the associations between iodine content at 2 weeks and
infant anthropometrics over the first year of life using multivariable linear mixed modeling. Iodine
concentrations generally decreased from 2 weeks to 2 months. We observed no significant difference
in iodine based on maternal weight. A higher iodine concentration at 2 weeks was associated with a
larger increase in infant weight-for-age and weight-for-length Z-score change per month from 2 weeks
to 1 year. This pilot study shows that early iodine intake may influence infant growth trajectory
independent of maternal pre-pregnancy weight status.
Keywords: iodine status; human milk; lactation; infant growth
1. Introduction
Iodine is a key micronutrient required for adequate growth and development through its critical
role in thyroid hormone synthesis [1]. Deficiency in iodine during the neonatal and infant periods may
result in impairments in brain development, cognitive outcomes, motor function, and growth stunting.
Exposure to excess iodine can lead to iodine-induced hyperthyroidism or hypothyroidism [2–5].
Newborns are a particularly vulnerable population for iodine related disorders given their low storage
of iodine in the thyroid at birth and their relatively high requirements for iodine relative to their body
size [2,3,6–9].
Exclusively breast-fed infants depend primarily on breast milk iodine to meet their daily iodine
needs [7,10]. The United States Institute of Medicine recommends 110 μg/day iodine intake for infants
from birth to 6 months of age, while the World Health Organization (WHO) recommends 90 μg/day to
achieve adequate intake [11,12]. In order to support fetal and neonatal development, the American
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Thyroid Association recommends all pregnant and lactating women supplement their iodine intake
with 150 μg/day iodine [3,13]. Iodine supplementation for mothers is intended to achieve the United
States Institute of Medicine recommendation of 290 μg/day iodine intake and WHO recommendation
of 250 μg/day. Through this degree of supplementation during lactation, the goal is to reach a sufficient
breast milk iodine concentration (BMIC) to support a breast-fed infant’s daily requirements [5,13].
However, the exact BMIC needed to meet infant needs is not universally defined [3,14].
BMIC is impacted by the maternal degree of iodine sufficiency from dietary iodine sources or
supplementation. BMIC also varies based on the time point during lactation, maternal smoking,
maternal health conditions, and with day to day fluctuation [3,15–19]. In establishing maternal
iodine insufficiency, iodine is thought to be secreted into breast milk rather than excreted into the
urine, to promote adequate levels of intake for offspring. The concentrating ability of mammary
epithelial cells has been modeled with in vivo rat studies showing that the sodium/iodine symporter
(NIS) mediates transport; however, published studies on the activity of the NIS in human mammary
epithelial cells remain limited [20]. BMIC is a stronger marker of maternal iodine status than urine
concentration [7,10,14,21–25]. BMIC is the greatest in the colostrum and then decreases in early
lactation, with an over 40% reduction over the first 6 months of lactation [2,3,6,7,10,15,16]. To date,
the impact of maternal health factors on BMIC has not been well described.
In pregnant and non-pregnant women, body mass index (BMI) has been negatively associated
with urinary iodine concentration, which is measured as an indicator of iodine status [26–28]. Iodine
deficiency has also been reported to be higher in those with morbid obesity [29]. The evaluation of
BMIC in the establishment of obesity during pregnancy and lactation has not been well studied. Given
the documented relationship with BMI, BMIC may have an important connection with rising levels of
obesity in adulthood, as well as a potential contributing factor to childhood obesity. Iodine studies in
mother-infant cohorts have shown mixed results regarding birth anthropometric outcomes, with some
studies associated with an increased mean birth weight with improved maternal iodine status [30–34].
Postnatal studies of iodine levels have shown an impact on growth factors but have not shown a
consistent association with infant growth [1,31,35–38].
With this study, we aimed to determine maternal BMIC over the first 2 months of lactation in
mothers with normal weight compared to mothers with elevated pre-pregnancy BMI to characterize
the impact of maternal metabolic factors on BMIC. We also assessed the impact of BMIC on infant
growth trajectory over the first year of life while taking into account maternal pre-pregnancy weight
status to gain a greater understanding of the impact of iodine on post-natal growth.
2. Materials and Methods
2.1. Subjects and Methods
This pilot study included a subset of 57 mother-infant dyads recruited in 2016 to 2018 at the
University of Michigan and St. Joseph Mercy Ann Arbor Hospital during hospital admission at the
time of infant delivery as part of the prospective Infant Metabolism and Gestational Endocrinopathies
(IMAGE) cohort. This study was developed to detect differences in breast milk insulin concentration.
This is a secondary analysis of the collected breast milk samples. The mothers included in this study
were enrolled if they (1) planned to breastfeed their infant, (2) were > 18 years of age, and (3) had
a healthy singleton infant delivered at ≥ 35 weeks gestation. Maternal health conditions, including
obesity, gestational diabetes, and polycystic ovary syndrome were included. Maternal demographics
and health history were obtained through an electronic medical record review and paper surveys.
The maternal pre-pregnancy weight status was determined through a calculation of BMI using obstetrics
recorded pre-pregnancy or the early first trimester weight and height as documented in the medical
record. Mother-infant dyads were categorized by maternal pre-pregnancy weight status as normal
weight (NW, BMI < 25.0 kg/m2) or overweight/obese (OW/OB, BMI ≥ 25.0 kg/m2).
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The study was approved by the institutional review boards at the University of Michigan
(HUM00107801, approved 01/05/2016) and St. Joseph Mercy Ann Arbor Hospital (HSR-17–1686,
approved 03/07/17). Mothers gave written informed consent for themselves and assent for their infants
prior to participation in the study. The study was conducted in accordance with the protocol approved
by the institutional review boards. Participants received reimbursement for their involvement in
this study.
2.2. Milk Collection
A written milk collection protocol was provided to the mothers, and in person verbal instruction
was given by the study team. Mothers were instructed to collect a 25 mL milk sample on the morning
of their infant’s 2 week (transitional milk) and 2 month (mature milk) routine well-child visit. The milk
collection protocol was based on the published methods by Fields and Demerath, with modifications as
described [39]. Mothers collected milk samples between 8:00 and 10:00 am and at least 2 h after feeding
their infant by hand expression or pumping of an entire breast based on the maternal preference of
expression type. Mothers expressed milk into a large container and then mixed the milk by inversion
before the milk was transferred to five glass vials (5 mL each). Samples were immediately placed
in the mother’s home freezer and then transported on ice to the clinic for storage at −20 ◦C prior to
transport on ice to the final storage location at −80 ◦C within one week. The milk was thawed on
ice for subsequent analyses, at which time 250 μL was aliquoted for further iodine assessment after
refreezing at −80 ◦C and shipment on dry ice.
2.3. Laboratory Analysis
Frozen whole milk 250 μL aliquots were shipped on dry ice to the Mayo Clinic Metals Laboratory
(Rochester, MN) for iodine analysis. PerkinElmer Sciex ELAN Dynamic Reaction Cell (DRC) II
Inductively Coupled Plasma Mass Spectrometer (ICP-MS), manufactured in Waltham, Massachusetts,
USA was used for testing. The gold standard of ICP-MS was used [3]. All samples had one freeze-thaw
cycle additional before dilution and were tested within an International Standards Organization (ISO)
class 7 cleanroom. The analysis performed followed the standard operating procedure of a test that was
developed and consistent with Clinical Laboratory Improvement Amendments (CLIA) requirements.
The method used commercially prepared calibrators (Inorganic Ventures, Christiansburg, VA, USA) in
1% TMAH, 7.5 g/L NaCl and 0.5 g/L CaCl2 matrix with iodine concentrations at 0, 10, 100, 500, 1000,
5000 μg/L, having an analytical measurement range (AMR) from 10 to 40,000 μg/L, with the use of 10,000
μg/L and 40,000 μg/L linearity standards. Results above linearity were diluted with SRW (≥18 MΩ cm
Special Reagent Water using a NANOpure system, Thermo Scientific, Waltham, MA, USA).
To assess the degree of error for the test method, a recovery study was performed on 3 breast milk
samples by spiking them with iodine calibration standards (0, 100 and 500 μg/L) and two levels of
Quality Control UTAK Serum Trace Element (UTAK Laboratories, Inc. Valencia, CA, USA), as shown in
Table 1. Initial dilutions were repeated five times in duplicate for an intra-assay coefficient of variation
(CV). Samples were then run with subsequent loads over a period of five days for an inter-assay CV.
The average percentages of recovery were all within 10% of the expected values and <10% for the intra
and inter-assay CV.
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Table 1. Performance characteristics of the iodine assay.
Breast Milk Precision and Recovery
Target 0 Standard 100 μg/L 500 μg/L NR UTAK QC HR UTAK QC
Mean 42.89 145.56 μg/L 551.52 μg/L 49 ng/mL 186 ng/mL
CV% 9.32% 6.65% 0.43% 9.6% 2.5%
Recovery 97.40 μg/L 450.9 μg/L 46 μg/L 179 μg/L
% Recovery 97.40% 90.18% 93.88% 96.24%
The same levels of UTAK Serum Trace Elements were used for the Quality Control Analysis;
levels were analyzed identically to those of the patient samples in duplicate. QC was run after every
20 samples and at the end of each load. During the sample preparation step each specimen was
thoroughly vortexed immediately before performing a two-step dilution using a Hamilton MicorLab
diluter (Hamilton Company, Reno, NV, USA) to aspirate 60 μg/L of the sample and 60 μg/L of the
Iodine 0 Solution, combined with Iodine Diluent (50 μg/L Te (30% HCl v/v) and 10 μg/L Rh (21% HCl
v/v) in 1% TMAH) for a total of 3 mL. The iodine concentration was measured in ng/mL. Samples were
analyzed in duplicate, and the results were averaged for reporting.
One milk sample at 2 weeks had a significantly elevated iodine concentration upon initial analysis,
which was consistent on repeat analysis at a separate run time point; given this outlier concentration
of >7000 ng/mL without biological plausibility, this value was truncated to the next highest iodine
concentration value in our cohort (649.1 ng/mL). A potential etiology may include iodine exposure
peri-partum through antiseptics; however, this was unable to be verified.
2.4. Infant Anthropometric Measurements
Infant health history was reviewed from the electronic medical record, including documentation
of birth history during hospital admission and follow-up routine outpatient well-child pediatric visits.
The type of nutritional intake, such as human milk, formula, or combinations, was determined from
the pediatrician notes at the well-child visits. Infant growth anthropometric measures were extracted
from the medical record measurements for weight and length obtained in the hospital at birth and
during outpatient well-child visits at 2 weeks, 2 months, 6 months, and 1 year. Age and sex specific
WHO Z-scores for weight-for-age (WFA), length-for-age (LFA), and weight-for-length (WFL) were
extracted from the medical record [40].
2.5. Statistical Analysis
The statistical analysis was completed using R version 3.6.1 (R Foundation for Statistical Computing,
Vienna, Austria) and the package nlme version 3.1–140 for this pilot study. Descriptive statistics,
comparisons of overweight and obese mothers, and unadjusted comparisons of log(BMIC) were done
using Fisher’s exact tests or t-tests, as appropriate, on all dyads with complete data for each test (n = 49
for comparisons involving 2 week BMIC; n = 50–57 for all other covariates).
Linear mixed models with random intercepts at the subject level were fit using the 35 dyads that
had exclusively breast milk feedings at 2 weeks and 2 months, with BMIC measured at 2 weeks. WFA
Z-score (WFAZ), LFA Z-score (LFAZ), and WFL Z-score (WFLZ) were considered dependent variables.
Estimates were obtained for the fixed effects for the following independent variables: 2 weeks BMIC,
time (in months, 0.5, 2, 6, 12), birth anthropometric Z-score, maternal BMI, gender, interaction of
maternal BMI and time, and interaction of 2 week BMIC and time. The interaction of BMIC and time
was used to test the association between BMIC and infant growth, and the interaction of maternal BMI
and time was included to control for the effects of maternal BMI on infant growth. An initial time
point of 2 weeks was used due to the anticipated fluid shift in the first 2 weeks of life in newborns.
Parameter estimates were considered statistically significant at p < 0.05.
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3. Results
This mother-infant cohort included 57 dyads with infant growth measures from birth to 1 year
of age, with the descriptive analysis shown in Table 2. Of the 57 dyads, 25 mothers provided milk
samples only at 2 weeks, 8 mothers provided milk samples only at 2 months, and 24 mothers provided
milk samples at both 2 weeks and 2 months. Mothers in our Midwestern population were primarily
Caucasian in the OW/OB maternal group compared to the NW maternal group. Infants were delivered
at term gestational age, with 47% male infants. At the 2 week time point of milk collection (mean 16.5
days, SD 3.0 days), 49 milk samples were available for analysis. At the 2 month time point of time
collection (mean 63.0 days, SD 5.6 days), 32 milk samples were available for analysis. At the 2 week
time point with milk samples collected, 86% of the infants were reported to be exclusively breastfed,
10% received breast milk and formula, 4% did not have their nutrition intake reported, and no infants
were exclusively formula fed. By the 2 month time point after the milk samples were collected, 81%
of infants received exclusively breast milk, 12% of infants received breast milk and formula, 6% of
infants did not have their nutritional intake documented, and no infants were exclusively formula fed.
Higher rates of formula supplementation were seen among mothers with OW/OB at 2 weeks (17%)
and 2 months (20%). The exact amount of formula supplementation was not quantified.
Table 2. Participant demographics.
Participant Characteristics
NW OW/OB p
(n = 24) (n = 33)
Maternal Age: years, mean (SD) 31.00 (3.66) 31.61 (3.06) 0.5
* Maternal Pre-Pregnancy BMI: kg/m2, mean (SD) 21.25 (1.99) 30.95 (4.69) <0.001
* Maternal Race/Ethnicity
0.002
Caucasian, no. (%) 11 (46) 28 (85) *
African American, no. (%) 2 (8) 1 (3)
Hispanic/Latino, no. (%) 4 (17) 1 (3)
Asian/Pacific Islander, no. (%) 6 (25) 1 (3)
Indian, no. (%) 1 (4) 0 (0)
N/A, no. (%) 0 (0) 2 (6)
Gestational Age: weeks, mean (SD) 39.5 (1.0) 39.1 (1.3) 0.16
Mode of Delivery
0.39Vaginal, no. (%) 18 (75) 20 (60)
C-section, no. (%) 6 (25) 13 (40)
Country
0.1Washtenaw, no. (%) 18 (75) 17 (52)
Other, no. (%) 6 (25) 16 (49)
Maternal income: dollars, mean (SD)
0.04
<60,000, no. (%) 21 (88) 19 (68)
>60,000, no. (%) 3 (12) 9 (32)
Unknown, no. (%) 0 (0) 5 (15)
Smoker
>0.99
Yes, no. (%) 1 (4) 1 (3)
No, no. (%) 19 (80) 27 (82)
N/A, no. (%) 4 (17) 5 (15)
Infant birth weight: kg mean (SD) 3.42 (0.36) 3.52 (0.42) 0.35
Infant birth weight: Z-score mean (SD) 0.33 (0.78) 0.42 (0.81) 0.68
Infant sex
>0.99Male, no. (%) 11 (54) 16 (49)
Female, no. (%) 13 (54) 17 (51)
Infant age at 2 week time point: days, mean (SD) 15.9 (3) 16.9 (3) 0.27
Infant age at 2 month time point: days, mean (SD) 62.0 (7.2) 62.5 (6.7) 0.8
Descriptive statistics on maternal and infant demographics from the cohort of 57 mother-infant dyads presented as
the mean (standard deviation) or number (percentage). The sample size is slightly smaller than the totals presented
for infants aged at 2 weeks (missing data for 9 infants). Statistical analysis using a t-test or Fischer’s exact test.
* represents statistical significance, with a p-value < 0.05. Abbreviations: normal weight (NW), overweight and
obesity (OW/OB), not available (N/A) number (no.). BMI p < 0.001, Maternal race/ethnicity p = 0.002.
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BMIC ranged from 16.0 to 649.1 ng/mL in samples collected near 2 weeks and 2 months. The median
BMIC at 2 weeks was 160.7 ng/mL, and, by 2 months, it was 86.0 ng/mL. For comparisons of the mean
BMIC, we used a log-transformation BMIC to satisfy the normality assumptions (p = 0.73 and 0.56
for the 2 week and 2 month BMIC, respectively, with a Shapiro-Wilk test). There was no significant
difference in the log-BMIC between NW and OW/OB mothers at 2 weeks (p = 0.54) or at 2 months
(p = 0.57). The log-BMIC decreased from 2 weeks to 2 months by 0.59 (39%, p = 0.007) in the 24 mothers
who had iodine measurements at both time points. There was no impact of infant sex, maternal county
of residence, or maternal income on BMIC. Untransformed BMIC is shown by the weight status and
time of measurement in Figure 1.
Figure 1. Breast milk iodine concentration (based on the maternal pre-pregnancy weight status for
normal weight (NW) compared to overweight and obese (OW/OB) mothers) in transitional milk at
2 weeks (NW n = 20, OW/OB n = 29) and mature milk at 2 months (NW n = 12, OW/OB n = 20). Data are
represented as a box plot, with the box showing median (IQR) and the whiskers equal to the farthest
observation less than 1.5 times IQR from the box edge.
We then explored the impact of maternal weight and BMIC on infant growth from 2 weeks to 1 year
using linear mixed models, with a subset of dyads who had complete data for all variables included
in the model, and who were exclusively breastfed at 2 weeks and 2 months (n = 35). We evaluated
infant growth by testing the interactions of maternal BMI with time, and BMIC at 2 weeks with time,
using an anthropometric Z-score through the first year of life, with the WFA, LFA, and WFL Z-scores
as dependent variables. We found no significant interactions between maternal pre-pregnancy BMI
and time for WFA (β = −0.00126, p = 0.534), LFA (β = 0.00359, p = 0.118), or WFL (β = −0.00452,
p = 0.089) Z-score changes per month from 2 weeks to 1 year. A higher milk iodine concentration at
2 weeks was associated with a larger increase in infant WFA (β = 0.00033, p = 0.0007) and WFL Z-score
(β = 0.00029, p = 0.0212) change per month from 2 weeks to 1 year, with no significant association with
LFA (β = 0.00015, p = 0.154), as shown in Table 3. Figure 2 represents the model interaction terms of
BMIC and time, showing the predicted WFAZ, LFAZ, and WFLZ for a male infant with a mean birth
Z-score, breastfed by a mother with mean BMI based on a 2 week BMIC mean, mean +1 standard
deviation (SD), and −1 SD.
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Figure 2. Infant growth anthropometric Z-score from 2 weeks to 1 year, with BMIC predicted by
linear mixed models (model n = 35). Graphs depict the difference in the predicted growth lines
for the mean ± 1 standard deviation BMIC as measured at 2 weeks for dyads with a male infant,
the mean birth anthropometric Z-score, and the mean maternal BMI. Interaction effect of BMIC and
time (months) on infant WFA (β = 0.00033, p < 0.001), infant LFA (β = 0.00015, p = 0.154), and infant
WFL (β = 0.00029, p = 0.021). Abbreviations: weight-for-age Z-score (WFA), length-for-age Z-score
(LFA), and weight-for-length Z-score (WFL); breast milk iodine concentration (BMIC).
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Table 3. Association of maternal weight status and 2 week breast milk iodine concentration with
change in weight-for-age, length-for-age, and weight-for-length Z-score across the first year of life.
Variables WFAZ LFAZ WFLZ
Model n Difference (β (p-value)) in change in infant
anthropometry Z-score
BMIC at 2 weeks (ng/mL) 35 −0.1883 (0.706) 1.23581 (0.028) * −1.1945 (0.053)
Time (months) 35 −0.0011 (0.170) −0.00056 (0.527) −0.0015 (0.136)
Birth WFAZ 35 0.53027 (0.0006) * −0.18117 (0.002) * 0.16434 (0.016) *
Maternal BMI (kg/m2) 35 −0.00532 (0.769) 0.42163 (0.0004) * 0.24395 (0.022) *
Infant sex 35 0.23087 (0.247) −0.03543 (0.080) 0.01866 (0.411)
Maternal BMI interaction with time 35 −0.00126 (0.536) 0.00359 (0.118) −0.00452 (0.089)
BMIC at 2 weeks interaction with time 35 0.00033 (0.0007) * 0.00015 (0.154) 0.00029 (0.021) *
* Statistical significance based on an estimation of the fixed effects in linear mixed models, with a significance threshold
at p < 0.05. Abbreviations: weight-for-age Z-score (WFAZ), length-for-age Z-score (LFAZ), weight-for-length Z-score
(WFLZ), body mass index (BMI), and breastmilk iodine concentration (BMIC).
4. Discussion
In the maternal-infant dyads in this study, transitional milk BMIC was positively associated
with infant WFA and WFL Z-score changes over the first year of life, and these iodine-related
growth differences were not related to maternal pre-pregnancy weight status based on this pilot
study. The importance of early milk iodine may point to a critical period of offspring development
during high vulnerability and a time during which formula fed infants may consume less iodine than
breastfed infants.
Milk iodine concentrations were not associated with maternal pre-pregnancy weight status in our
cohort. While literature on adult obesity has described iodine deficiency as associated with elevated
BMI, we did not find similar findings related to BMI as a marker of iodine status [26–29]. Limited
literature on BMIC during lactation has focused on the maternal health influences on milk iodine
concentration [26,27,29]. A study by Dumrongwongsiri, in Thailand, showed an association of BMIC
with maternal weight; however, there was no association with maternal age or lactation stage [41].
This study did not define the time point of maternal weight measurement and may not reflect the
weight prior to pregnancy, as assessed in our study. It is important for future studies on BMIC to
include an analysis of maternal pre-pregnancy weight status in order to understand the role of maternal
health on milk micronutrient composition.
The milk iodine concentrations in our cohort showed considerable variability. The BMIC to
achieve adequate iodine delivery to infants is debated, with the lower most BMIC proposed to range
from 60 to 150 ng/mL [3,13,14,22]. While exact values of the ideal BMIC for sufficient infant intake
ranges are not well described, a goal of 150 ng/mL in breast milk has been reported [3]. The levels in
our study showed a high degree of values below 150 ng/mL at 2 weeks (47%) and even more below
150 ng/mL at 2 months (81%). These results are higher than those of a study from the Netherlands,
showing that 33% of infants were anticipated to be iodine deficient based on BMIC <1.1 μmol/L
(139 ng/mL) [42]. Mothers with low BMIC may signify a population with iodine insufficiency, as BMIC
has been shown to be positively correlated with maternal urinary iodine concentration, the standard
measure of iodine sufficiency [43]. Currently, the United States has salt iodization programs, with a
reported use near 90% due to a decline in iodized salt into the 1990s, based on National Health and
Nutrition Examination Survey (NHANES) data [44]. Additionally, the NHANES reports on iodine
status during pregnancy showed a concerning degree of iodine insufficiency (56.9%) in 2005–2008 [45].
Previous cohorts from Boston have shown a similar degree of iodine insufficiency (47%) based on
estimated infant milk intake; however, this group had higher milk iodine concentrations (median
155 ng/mL) at a median of 48 days collection compared to BMIC at our 2 month time point (median
86 ng/mL) [43]. A meta-analysis by Nazeri described overall lower mature milk iodine level in iodine
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sufficient countries (mean 71.5 ng/mL) [46]. This difference may represent population, geographic,
or nutritional intake differences.
While our cohort may be a population at risk for infant iodine insufficiency based on BMIC,
we also noted some elevated BMIC levels in both NW and OW/OB throughout the first 2 months of
lactation. The level of BMIC that may lead to iodine excess has not been defined in the same manner
that urinary iodine concentration >300 ng/mL in children and >500 ng/mL in pregnancy is defined
as iodine excess [47]. Prior studies of high iodine exposure through elevated water iodine levels by
Liu identified a BMIC >200 ng/mL in mothers with high iodine intake [48]. A further evaluation of
excessive iodine exposure through breast milk is necessary to determine the safe levels of exposure,
particularly in mothers at risk for iodine excess, including those with high dietary, oral, or topical
iodine exposure [49].
Our data on BMIC overall, independent of maternal pre-pregnancy weight status, suggests a
relationship between infant iodine exposure and growth, with a higher BMIC at 2 weeks associated
with an increased change in Z-score for WFA and WFL over the first year of life. However, the clinical
implications of these small growth changes are unclear, and future long-term studies into childhood
growth and adiposity are needed. Prior literature has focused on the impact of iodine status
and supplementation on prenatal growth, with a systematic review showing low quality evidence
for increased birth weight in infants of mothers with severe iodine deficiency who are receiving
iodine supplementation [31]. Postnatal growth studies are limited in both observational and iodine
supplementation intervention studies during lactation [31]. In a study performed in China by Yang,
a maternal iodine deficiency based on urinary iodine levels <50 μg/L during lactation was linked
to a decreased infant WFA and LFA for infants <6 months of age, with positive effects of maternal
iodine status on infant weight; however, BMIC was not measured to determine infant intake [1].
A review of survey data by Mason showed a positive relationship with iodine salt use and increased
infant WFA and mid-upper-arm-circumference at 2 years. This study also assessed maternal BMI,
showing that the positive relationship between iodinated salt use and WFA was increasingly greater
with a lower maternal BMI [50]. However, there have been opposing trials and systematic reviews
showing no impact of iodine intake on infant growth. In a multicenter randomized control trial of
iodine supplementation during infancy in breastfeeding infants compared to placebo or formula fed
infants, there was no difference found for 12 month WFA Z-score or WFL Z-score in infants receiving
high or low iodine supplementation; however, infants receiving no intervention had higher LFA
Z-scores and formula fed infants had higher WFA, WFL, and LFA Z-scores [51]. In a systematic review
by Farebrother, on the impact of iodine supplementation on postnatal growth outcomes based on
limited supplementation studies during pregnancy and one randomized clinical trial of preterm infant
formula supplementation, there was no difference at 12 and 24 months in infant weight, length, or head
circumference with maternal iodine supplementation [31].
Our prospective observational cohort study without specific iodine supplementation evaluated
the association of BMIC with infant anthropometrics and found positive associations between growth
over the first year and early BMIC near 2 weeks. The potential mechanisms for iodine related infant
growth may be related to the role of iodine in the endocrine pathways of the thyroid hormone (TH)
and growth hormone-insulin-like growth factor (GH-IGF) axis [31,32]. Zimmerman showed in a
prospective intervention of iodine repletion in school age children that there was improved somatic
growth in the WFA and head circumference-for-age Z-score associated with increased IGF-I and
IGF binding protein-3 (IGFBP-3) concentrations in children [38]. Future work evaluating the link
between BMIC, infant somatic growth, and growth related hormone levels (TSH, free thyroxine, IGF-1,
and IGFBP-3) may provide further insight into mediators and identify areas for intervention for the
promotion of iodine sufficient status during lactation.
This study provides insight into longitudinal BMIC in a United States Midwestern population,
with corresponding assessments of infant growth through the first year of life in this pilot study.
The strength of this study is that the population was selected for their initial plans to breastfeed
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without selection for predetermined maternal iodine status. This pilot study is limited by the small
sample size used for its secondary analysis, which the initial study was not powered for; the mixed
modeling involved a large number of parameters for the sample size, which could raise questions
about the generalizability of these models among the larger population. However, the significant
associations with BMIC and infant growth seen with these small numbers highlights the importance
of consideration for BMIC analysis in more expansive mother-infant lactation focused cohorts to
further understand this potential early programming influence. Additional limitations, including
the assessment of infant growth outcomes, were measured by medical staff at pediatrician well-child
visits, possibly resulting in inaccurate anthropometrics. Infant growth is complex, and this study is not
able to address the numerous factors contributing to infant growth, which are not limited to genetic,
environmental, later formula supplementation quantity, complimentary feedings, milk volume intake,
and the complex composition of human milk, including macronutrients, micronutrients, bioactive
factors, growth hormones, and immune factors [52,53]. Our cohort did not assess iodine status during
pregnancy, which could impact fetal growth and development. Maternal iodine intake was also not
quantified in this study. This will be important in future studies to provide a further explanation for
the high BMIC among the population of lactating mothers. An assessment of infant iodine status
will also be an important addition to future work to determine the relationship with BMIC based on
detailed 24 h infant breast milk volume intake.
5. Conclusions
While the importance of maternal health during pregnancy and lactation in promoting infant
growth and development cannot be understated, this study did not show the impact of maternal
pre-pregnancy BMI on BMIC. We have identified a positive association between transitional BMIC and
infant weight and weight-for-length growth over the first year of life based on a Z-score irrespective
of maternal pre-pregnancy weight status. These findings highlight the critical need for knowledge
of breast milk composition, particularly in micronutrients (such as iodine), which play a key role in
infant growth. A further evaluation of the complex components in breast milk and the impact of
these components during ongoing organ development in infancy is necessary to promote targeted
interventions to support optimal childhood health.
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Abstract: Normal maternal thyroid function during pregnancy is essential for fetal development and
depends upon an adequate supply of iodine. Little is known about how iodine status is associated
with preterm birth and small for gestational age (SGA) in mildly iodine insufficient populations.
Our objective was to evaluate associations of early pregnancy serum iodine, thyroglobulin (Tg),
and thyroid-stimulating hormone (TSH) with odds of preterm birth and SGA in a prospective,
population-based, nested case-control study from all births in Finland (2012–2013). Cases of preterm
birth (n = 208) and SGA (n = 209) were randomly chosen from among all singleton births. Controls
were randomly chosen from among singleton births that were not preterm (n = 242) or SGA (n = 241)
infants during the same time period. Women provided blood samples at 10–14 weeks’ gestation for
serum iodide, Tg and TSH measurement. We used logistic regression to estimate odds ratios (ORs)
and 95% confidence intervals (CIs) for preterm birth and SGA. Each log-unit increase in serum iodide
was associated with higher odds of preterm birth (adjusted OR = 1.19, 95% CI = 1.02–1.40), but was
not associated with SGA (adjusted OR = 1.01, 95% CI = 0.86–1.18). Tg was not associated with preterm
birth (OR per 1 log-unit increase = 0.87, 95% CI = 0.73–1.05), but was inversely associated with SGA
(OR per log-unit increase = 0.78, 95% CI = 0.65–0.94). Neither high nor low TSH (versus normal) were
associated with either outcome. These findings suggest that among Finnish women, iodine status is
not related to SGA, but higher serum iodide may be positively associated with preterm birth.
Nutrients 2019, 11, 2573; doi:10.3390/nu11112573 www.mdpi.com/journal/nutrients95
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Keywords: iodine; thyroid hormones; thyroglobulin; thyroid stimulating hormone; pregnancy;
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1. Introduction
Normal maternal thyroid function during pregnancy is essential for fetal development [1].
Hypothyroidism is associated with adverse pregnancy outcomes including pregnancy loss,
preeclampsia, and preterm birth, as well as cognitive deficiencies and cretinism in the offspring [2].
Iodine, found in fish, eggs, dairy products, and iodized salt [3], plays an essential role in the production
of thyroid hormones. Thyroid hormone production is regulated by the hypothalamic-pituitary-thyroid
axis via thyroid-stimulating hormone (TSH) and requires the iodination of thyroglobulin (Tg) in the
follicular lumen of thyrocytes [1]. Pregnant women are especially vulnerable to iodine deficiency due
to fetal dependency on the maternal iodine supply and to a lesser extent, hemodilution, increased renal
clearance of inorganic iodide, and estrogen-stimulated production of Tg, which collectively necessitate
higher iodine intake [4].
Despite increased risk of iodine deficiency during pregnancy, even in developed countries [5,6],
and ample data indicating that thyroid dysfunction is associated with adverse neonatal and obstetric
outcomes, relatively few studies have evaluated how iodine status during pregnancy is related to
preterm birth and infants being born small for gestational age (SGA), and the results are conflicting [7–13].
Importantly, previous studies were conducted in populations with high prevalence of other nutritional
deficiencies and concurrent illnesses or included mostly iodine sufficient pregnant women [9,12].
Several of these studies also lacked information on thyroid hormones and therefore were unable to
evaluate whether associations of iodine with preterm birth and SGA may be different among potentially
hypo-or hyperthyroid women [9–11,13]. Additionally, prior studies used a single spot urinary iodine
measurement to classify iodine status, which has been shown to have high intraindividual variability
reflective of recent dietary intake, seasonal variation, urine dilution, and circadian rhythmicity [13–16].
Although urine iodine concentrations are useful for assessing the iodine status of whole populations,
serum iodide may be less sensitive to recent dietary intake and may, therefore, better reflect individual
long-term and bioavailable iodine status [17–19], reducing potential for misclassification.
The aim of the present study was to evaluate associations of serum iodide concentrations and
thyroid hormones indicative of iodine status (i.e., Tg and TSH) with risk of preterm birth and SGA
among pregnant Finnish women, a population considered to be mildly iodine deficient, but with
relatively low prevalence of other nutritional deficiencies [3].
2. Materials and Methods
2.1. Study Population
We conducted a population-based, nested case-control study within the Finnish Maternity Cohort
(FMC), using the Finnish Medical Birth Register (MBR) to ascertain pregnancy and perinatal outcome
data. Beginning in 1983, the FMC has collected more than 2 million serum samples from more than
950,000 pregnant women living in Finland, which reflects ~98% coverage of the pregnant population.
Blood samples were collected to screen for hepatitis B, human immunodeficiency virus (HIV), syphilis,
and rubella antibodies. The samples were drawn in general between 10 and 14 weeks gestation at local
maternity care units and sent to the prenatal serology laboratory of the Finnish Institute for Health and
Welfare in Oulu. There, sera were separated by centrifugation, screening analyses were performed and
the remaining serum (1–3 mL) was stored at −25 ◦C.
Biochemical data were linked to clinical data from the MBR via unique personal identification
numbers given to all Finnish citizens and residents at birth or at time of permanent residence. The MBR
includes data on all live births and stillbirths in Finland with a birth weight ≥500 g or a gestational age
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at birth ≥22 gestational weeks. Maternal data collected by the MBR includes age, height and weight,
socioeconomic status based on self-reported occupation, marital status, pregnancy history, smoking
status, and other factors. Data collected on infants included sex, gestational age at birth, and birth
height and weight.
Women gave written informed consent for their samples to be used for research purposes.
This study was approved by the steering committee of the FMC, the ethical review boards of the
Northern Ostrobothnia Hospital District and the Finnish Institute for Health and Welfare, Oulu,
Finland, and the Office of Human Subjects Research, National Institutes of Health, Bethesda, MD,
USA (#13459).
2.2. Case and Control Ascertainment
We randomly selected 200 cases of preterm birth (defined as a live birth <37 weeks gestation) and
250 potential controls from among all singleton births in Finland between 2012 and 2013 with available
serum samples in the FMC. Because the 250 potential controls were randomly selected without regard
to case/control status, 8 control pregnancies were delivered preterm and were thus reclassified as
cases. After reclassification, the final analytic sample included 208 cases and 242 controls. Similarly,
we randomly selected 200 cases of SGA (defined as birthweight <10th percentile for gestational age),
using the same control group. Nine control pregnancies were SGA and reclassified as such, resulting
in 209 SGA cases and 241 controls.
2.3. Measurement of Iodide, Thyroglobulin, and Thyroid-Stimulating Hormone
Details regarding the iodide measurement in this study population have been published previously
and are provided in Appendix A [20]. Briefly, serum samples were thawed at room temperature,
vortexed, and transferred to polypropylene tubes. Samples were pretreated, centrifuged, and analyzed
by high-performance liquid chromatography (Alliance 2695 HPLC) coupled with electrospray
triple-quadrupole mass spectrometry (Micromass, ESI–MS/MS; Waters Corporation, Milford, MA, USA).
Identification and quantification of 18O-labeled-perchlorate, 13C-labeled-thiocyante, and iodide was
performed using electrospray negative ionization (ESI-) and multiple reaction monitoring. Serum Tg
and TSH concentrations were measured using a commercial immunoassay (Siemens AG, Munich,
Germany), as they have been shown to be reliable markers of thyroid function in pregnant women [21].
The intra- and inter-assay coefficients of variation for Tg were <8% and <12%, respectively, and for
TSH <5% and <5%, respectively.
2.4. Statistical Analysis
Characteristics of the cases and controls were compared using t-tests for continuous variables
and χ2 tests for categorical variables. Equivalent non-parametric tests were used where appropriate.
For analyses evaluating continuous exposures, serum iodide, Tg, and TSH values were normalized by
log-transformation. Participants were divided into quartiles of iodide and Tg based on the distribution
of these biomarkers in the control group. For TSH, we categorized participants as having high TSH
(>3.1 and >3.5 mIU/L in the 1st and 2nd trimesters, respectively), normal TSH (0.1–3.1 and 0.2–3.5 in
the 1st and 2nd trimesters, respectively), or low TSH (<0.1 and <0.2 mIU/L in the 1st and 2nd trimesters,
respectively), according to previously defined reference ranges for this population [22].
Using logistic regression, we estimated unadjusted odds ratios (ORs) and 95% confidence intervals
(CIs) for preterm birth and SGA according to each biomarker. We then estimated adjusted ORs and
95% CIs adjusting for maternal age, maternal body mass index (BMI), socioeconomic status, smoking
status, parity, and marital status. Covariates were selected for inclusion in multivariable models based
on directed acyclic graphs [23]. Individuals with missing data on BMI (N = 7 for preterm birth and
N = 3 for SGA) were dropped from multivariable analyses.
We also examined possible non-linear associations of iodide with preterm birth and SGA
non-parametrically utilizing restricted cubic spline models. In these models, we specified 3 knots and
evaluated the individual spline term contributions to the model fit and overall test for nonlinearity.
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In sensitivity analyses, we excluded women with conditions associated with medically-indicated
preterm birth (i.e., chronic hypertension, gestational hypertension, gestational diabetes, pre-existing
diabetes, thyroid disease) to determine whether these conditions may have influenced the results.
All analyses were run using SAS, version 9.4 (SAS Institute Inc., Cary, NC, U.S.).
3. Results
3.1. Descriptive Characteristics
Characteristics of preterm birth and SGA cases and controls at blood draw are presented in Table 1.
For preterm birth, cases and controls were similar with regard to maternal age, BMI, smoking status,
marital status, parity, gravidity, and socioeconomic status (SES). Preterm birth cases and controls were
also similar in terms of gestational age at blood draw (10.9 weeks vs. 10.8 weeks). As expected, cases
were more likely to have chronic hypertension (10% vs. 3%), preeclampsia (30% vs. 3%), Type 1 or 2
diabetes (13% vs. 1%), and gestational diabetes (38% vs. 22%), compared to controls. For SGA, cases
had lower BMI (24 vs. 25 kg/m2), gravidity (1.3 vs. 1.4) and parity (0.8 vs. 1.1) than controls, and were
also more likely to be smokers (52% vs. 37%). SGA cases were also more likely than controls to have
preeclampsia during the pregnancy (16% vs. 4%). The Spearman rank correlation coefficients for each
biomarker were as follows: iodide and Tg, rs = 0.02 (P = 0.54); iodide and TSH, rs = 0.001 (P = 0.97);
and Tg and TSH, rs = −0.13 (P < 0.001).
Table 1. Maternal characteristics at blood draw according to preterm birth and small for gestational
age cases and controls in the Finnish Maternity Cohort and Medical Birth Register, 2012–2013.









(n = 209) P-value
2
Maternal age (years) 29.5 (5.3) 29.8 (5.5) 0.49 29.5 (5.3) 29.7 (5.6) 0.70
Body mass index (kg/m2) 24.6 (4.4) 25.3 (6.0) 0.75 24.8 (4.9) 23.6 (5.1) <0.001
Gravidity 1.4 (1.8) 1.4 (1.8) 0.80 1.4 (1.8) 1.3 (2.2) 0.03
Parity 1.1 (1.6) 0.9 (1.4) 0.19 1.1 (1.6) 0.8 (1.5) 0.01
Gestational age at screening (weeks) 10.9 (2.9) 10.8 (3.0) 0.89 10.9 (2.9) 11.4 (4.0) 0.12
Gestational age at birth (weeks) 39.7 (1.1) 34.1 (2.7) <0.01 39.6 (1.5) 38.4 (2.9) <0.001
Iodide (ng/mL) 28.1 (28.5) 32.8 (31.1) 0.02 28.2 (28.3) 27.7 (28.2) 0.82
Thyroglobulin (ng/mL) 29.6 (29.5) 31.5 (63.3) 0.36 29.9 (29.6) 27.9 (32.9) 0.05
Thyroid stimulating hormone (mIU/L) 1.2 (0.8) 1.3 (2.4) 0.25 1.2 (0.85) 1.4 (2.15) 0.68
Nulliparous 105 (43.4) 108 (51.9) 0.07 103 (42.7) 120 (57.4) <0.01
Smoking status 0.33 0.03
Nonsmoker 200 (82.6) 164 (78.8) 199 (82.6) 155 (74.2)
Smoker 37 (15.3) 35 (16.8) 37 (15.4) 52 (24.9)
Unknown 5 (2.1) 9 (4.3) 5 (2.1) 2 (1.0)
Socioeconomic status 0.32 0.11
Blue-collar 30 (12.4) 31 (14.9) 31 (12.9) 30 (14.4)
Lower white-collar 64 (26.4) 60 (28.8) 62 (25.7) 50 (23.9)
Upper white-collar 28 (11.6) 29 (13.9) 28 (11.6) 34 (16.3)
Entrepreneur 10 (4.1) 4 (1.9) 10 (4.2) 3 (1.4)
Student 25 (10.3) 12 (5.8) 24 (10.0) 10 (4.8)
Other/unknown 85 (35.1) 72 (34.6) 86 (35.7) 82 (39.2)
Diagnosed thyroid disease 0 (0) 7 (3.4) <0.01 0 (0) 1 (0.5) 0.28
Chronic hypertension 3 (1.2) 10 (4.8) 0.024 3 (1.2) 4 (1.9) 0.71
Preeclampsia 3 (1.2) 30 (14.4) <0.01 4 (1.7) 16 (7.7) <0.01
Gestational hypertension 6 (2.5) 11 (5.3) 0.12 6 (2.5) 11 (5.3) 0.14
Type I or type II diabetes 1 (0.4) 13 (6.3) <0.01 2 (0.8) 0 (0) 0.50
Gestational diabetes 22 (9.1) 38 (18.3) 0.02 23 (9.5) 23 (11.0) 0.64
Marital status 0.41 0.15
Married or cohabiting 215 (88.8) 176 (84.6) 211 (87.6) 177 (84.7)
Single or widowed 26 (10.7) 31 (14.9) 30 (12.5) 29 (13.9)
Unknown 1 (0.4) 1 (0.5) 0 (0) 3 (1.4)
1 Values are means (SD) for continuous data and N (%) for categorical data. 2 P-values were estimated using t-tests
for continuous data and χ2 tests for categorical data. Equivalent non-parametric tests were used where appropriate.
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3.2. Serum Iodine, Thyroid Hormones, and Preterm Birth
In unadjusted models, each 1 log-unit increase in serum iodide was positively associated with
preterm birth (unadjusted OR = 1.22, 95% CI = 1.04–1.42) (Table 2). After adjusting for age, BMI,
smoking, and other factors, the positive association persisted (adjusted OR = 1.19, 95% CI = 1.02–1.40),
and was robust to the exclusion of women with conditions related to preterm birth (OR = 1.29,
95% CI = 1.06–1.58). In unadjusted models evaluating quartiles of iodide, the OR for preterm birth
comparing women with high (quartile 4) versus moderate (quartiles 2+3) serum iodide was 1.32 (95%
CI = 0.86–2.04). The OR for preterm birth comparing low (quartile 1) versus moderate (quartiles 2 + 3)
serum iodide was 0.75 (95% CI = 0.46–1.22). In adjusted models, the ORs for preterm birth comparing
women with high (quartile 4) and low (quartile 1) versus those with moderate (quartiles 2 and 3)
serum iodide were 1.22 (95% CI = 0.78–1.93) and 0.76 (95% CI = 0.46–1.26), respectively. In spline
analyses, no signifcant departure of linearity was observed for serum iodide and preterm birth (P for
non-linearity > 0.05). No associations were observed for Tg and TSH and preterm birth (adjusted
OR = 0.87, 95% CI = 0.73–1.05 and OR = 0.97, 95% CI = 0.80–1.19, respectively).
Table 2. Unadjusted and adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for preterm
birth according to maternal serum iodide, thyroglobulin, and thyroid stimulating hormone in the
Finnish Maternity Cohort and Maternal Birth Register, 2012–2013 1,2.






Quartile (Q)1 38:60 3.4 0.75 (0.46–1.22) 0.76 (0.46–1.26)
Q2 + Q3 102:121 20.3 1 (referent) 1 (referent)
Q4 68:61 59.3 1.32 (0.86–2.04) 1.22 (0.78–1.93)
Log(iodide) 208:242 1.22 (1.04–1.42) 1.19 (1.02–1.40)
Log(iodide) 4 132:210 1.29 (1.07–1.57) 1.29 (1.06–1.58)
Thyroglobulin (ng/mL)
Q1 59:59 7.7 1 (referent) 1 (referent)
Q2 55:60 17.4 0.91 (0.55–1.53) 0.83 (0.49–1.41)
Q3 37:60 26.7 0.62 (0.36–1.07) 0.59 (0.34–1.04)
Q4 57:60 52.1 0.95 (0.57–1.58) 0.88 (0.51–1.50)
Log(thyroglobulin) 208:239 0.91 (0.76–1.08) 0.87 (0.73–1.05)
TSH (mIU/L)
Low 5:11 0.04 0.51 (0.18–1.50) 0.57 (0.19–1.70)
Normal 196:217 1.04 1 (referent) 1 (referent)
High 7:11 3.5 1.14 (0.32–3.95) 1.17 (0.31–4.38)
Log(TSH) 208:239 0.99 (0.82–1.20) 0.97 (0.80–1.19)
1 ORs and 95% CIs were estimated using logistic regression. 2 Data are missing for 3 controls. 3 Multivariable
models are adjusted for maternal age, maternal body mass index, socioeconomic status, smoking status, parity,
and marital status. 4 Analyses excluding women with conditions indicated for preterm birth (i.e., preeclampsia,
chronic hypertension, gestational hypertension, gestational diabetes, pre-existing diabetes, thyroid disease)
3.3. Serum Iodide, Thyroid Hormones, and Small for Gestational Age
Serum iodide was not associated with odds of having an SGA infant in unadjusted or adjusted
models. (Table 3) For example, the unadjusted OR for each log-unit increase in serum iodide was 0.99
(95% CI = 0.85–1.14). Similarly, in unadjusted models, the OR for SGA comparing high (quartile 4)
and low (quartile 1) versus moderate (quartiles 2 + 3) serum iodide was 1.15 (95% CI = 0.74–1.80) and
1.05 (95% CI = 0.85–1.14), respectively. Adjustment for age, BMI, and other factors resulted in similar
findings (OR per 1 log-unit increase in serum iodide = 1.01, 95% CI = 0.86–1.18). In unadjusted models,
log-transformed Tg was inversely associated with SGA (unadjusted OR = 0.84, 95% CI = 0.71-0.99).
This inverse association was somewhat stronger after adjustment in multivariable analyses (adjusted
OR= 0.78, 95% CI= 0.65–0.94). Likewise, in adjusted models, the OR comparing high (quartile 4) versus
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low (quartile 1) Tg was 0.45 (95% CI= 0.25–0.79). TSH was not associated with SGA (high versus normal
OR = 0.56, 95% CI = 0.14–2.22; low versus normal OR = 1.11, 95% CI = 0.44–2.79). Spline analyses
revealed no significant departures of linearity for serum iodide and SGA (P for non-linearity > 0.05).
Table 3. Unadjusted and adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for small for
gestational age according to maternal serum iodide, thyroglobulin, and thyroid stimulating hormone
in the Finnish Maternity Cohort and Maternal Birth Register, 2012–2013 1,2.






Quartile (Q)1 52:60 3.3 1.05 (0.85–1.14) 1.01 (0.68–1.79)
Q2 + Q3 99:120 19.3 1 (referent) 1 (referent)
Q4 58:61 59.3 1.15 (0.74–1.80) 1.28 (0.79–2.08)
Log(iodide) 209:241 0.99 (0.85–1.14) 1.01 (0.86–1.18)
Log(iodide) 4 162:206 0.91 (0.77–1.07) 0.91 (0.76–1.09)
Thyroglobulin (ng/mL)
Q1 75:58 8.3 1 (referent) 1 (referent)
Q2 50:61 17.7 0.63 (0.38–1.05) 0.52 (0.30–0.89)
Q3 36:59 28.2 0.47 (0.27–0.81) 0.41 (0.23–0.72)
Q4 45:60 52.3 0.58 (0.35–0.97) 0.45 (0.25–0.79)
Log(thyroglobulin) 206:238 0.84 (0.71–0.99) 0.78 (0.65–0.94)
TSH (mIU/L)
Low 10:11 0.04 1.04 (0.43–2.50) 1.11 (0.44–2.79)
Normal 193:221 1.4 1 (referent) 1 (referent)
High 5:6 4.1 0.95 (0.29–3.18) 0.56 (0.14–2.22)
Log(TSH) 208:238 1.05 (0.88–1.26) 1.04 (0.86–1.26)
1 ORs and 95% CIs were estimated using logistic regression. 2 Data are missing for 3 controls. 3 Multivariable
models are adjusted for maternal age, maternal body mass index, socioeconomic status, smoking status, parity,
and marital status.4 Analyses excluding women with conditions indicated for preterm birth (i.e., preeclampsia,
chronic hypertension, gestational hypertension, gestational diabetes, pre-existing diabetes, thyroid disease)
4. Discussion
In this population-based, nested case-control study, we found that neither low- nor high-serum
iodide was associated with SGA, and some suggestion that higher serum iodide may be associated
with increased risk of preterm birth. Levels of TSH, which were largely within the normal range,
indicated a mostly euthyroid population. Tg, which is generally higher during periods of both iodine
insufficiency and extreme excess [24–26], was inversely associated with risk of having an SGA infant,
but was not associated with preterm birth. Levels of TSH were not associated with either outcome,
although very few women had values considered to be above or below the normal range in this
population. Collectively, our findings suggest that iodine insufficiency, within the range observed
among pregnant Finnish women, likely does not play a role in preterm birth or SGA, but that higher
serum iodide may be associated with increased risk of preterm birth.
To date, only a handful of studies have evaluated associations of iodine status with preterm
birth and SGA, and data are mixed [7–13]. A recent prospective study of pregnant women in the UK
reported U-shaped relationships between urinary iodine concentrations and risks of preterm birth
and SGA, with elevated risks observed among women with urinary iodine concentration (UIC) <50
and ≥250 μg/L versus those with UIC in the 150–249 μg/L group; however, confidence intervals were
wide and included the null value [10]. Another prospective study of pregnant women in the UK
with low obstetrical risk reported a borderline significant increased risk of having an SGA infant with
increasing UIC, but no association with preterm birth [13]. Similarly, in a largely iodine deficient
population of pregnant women in Thailand, insufficient (UIC <150 μg/L) versus sufficient/excess (UIC
≥150 μg/L) iodine status was associated with increased risks of both preterm birth and low birth weight
(LBW) infants [9]. Similar associations were observed among pregnant Chinese women, in which UIC
100
Nutrients 2019, 11, 2573
<50 μg/L versus ≥50 μg/L was associated with a non-significant higher risk of LBW and SGA [12].
In another prospective study of Chinese women, both iodine insufficiency and excess were inversely
associated with fetal femur length, a measure of fetal growth [11]. Among Spanish women, lower rates
of SGA were observed among women with UIC 100–149 μg/L compared to those with <50 μg/L [8],
but no associations of UIC with birth weight, SGA, or preterm birth were observed in another study of
Spanish women [8]. In our study population of Finnish women, we found that higher serum iodide
was positively associated with preterm birth, but neither high nor low serum iodide was associated
with SGA.
Only a few previous studies have evaluated associations of Tg and TSH with preterm birth
and SGA. In two prospective studies of pregnant Spanish women, high TSH, which is indicative of
hypothyroidism, was associated with increased risk of SGA [7,8]. Similarly, in a prospective study of
U.S. women, Männistö et al. reported a positive association of hypothyroidism and risk of preterm
birth [27], which is consistent with findings of several other studies [28,29]. In our study of Finnish
women, we observed an inverse association of Tg and SGA, but no association with preterm birth.
TSH was not associated with either outcome, which was somewhat expected given that nearly all
women were within the normal range.
While our findings for iodine are somewhat difficult to compare directly with prior studies due to
our use of serum versus urine concentrations, the observed elevated risk of preterm birth associated
with higher levels of serum iodide in our data are compatible with the possibility of a true U-shaped
relationship observed in several previous studies, with both high and low levels of iodine being
associated with increased risk of preterm birth. However, because the women who comprised our
study population were only mildly iodine insufficient [3], and the prevalence of severe deficiency is
low, our results may only capture the right side of this U-shaped relationship. Some data suggest that
Tg levels may be sensitive indicators of iodine status among children and pregnant women [24,30],
with a U-shaped relationship between Tg and UIC. Thus, the inverse association for SGA observed in
analyses comparing high versus low Tg may be explained, at least in part, by mild iodine insufficiency
among women with Tg in the lowest quartile. Additional explanations for conflicting findings of
previous research and ours may relate to other underlying nutritional deficiencies (e.g., zinc or iron)
present in other countries, bioavailable iodine in soil, and genetic factors, as well as differences in the
underlying risk of obstetrical complications across study populations [3,31,32].
Potential biological mechanisms to explain our observed positive associations of serum iodide
with preterm birth and inverse associations of Tg with SGA are somewhat unclear. During periods of
iodine deficiency, TSH, which is secreted from the pituitary gland, increases and stimulates uptake of
circulating iodine by thyrocytes in the thyroid [1]. The iodination of Tg produces T3 and T4, which are
essential for fetal central nervous system and skeletal development. When iodine deficiency is severe
(UIC <50 μg/L), the production of T3 and T4 is impaired, and circulating levels of the thyroid hormones
decrease. Paradoxically, when iodine intake is excessive (defined as UIC>500μg/L), a transient decrease
in T3 and T4 also occurs, known as the Wolff–Chaikoff effect [33]. In normal, healthy individuals, this
effect lasts only a few days; however, fetuses <36 weeks’ gestation cannot escape this effect, resulting
in fetal hypothyroidism [34]. Although this phenomenon is not well understood, it is possible that
high levels of maternal serum iodide may induce this decrease in fetal thyroid hormones, which in
turn, could have implications for fetal skeletal development, placentation, and preterm delivery [33].
Strengths of our study include the population-based, nested case-control design, which ensures
minimal impact of selection and recall biases, and improves generalizability to the source population.
In addition, our study population included women who were mildly iodine-insufficient, but with
relatively low prevalence of other nutritional deficiencies that might otherwise confound the associations
between iodine status and preterm birth and SGA [3]. Furthermore, our study is the first to evaluate
associations of preterm birth and SGA with serum iodine, a measure of iodine hypothesized to be
more stable than urinary iodine concentrations over time. Single spot urinary iodine, which was used
to assess iodine status in all previous studies on this subject, exhibits considerable intraindividual
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variation owing to urine dilution, dietary intake, circadian rhythm, season, and other factors [14–16].
Because of this, UIC is considered an acceptable biomarker of iodine status for whole populations,
but not for individuals [35]. Serum iodine on the other hand, is less sensitive to recent dietary intake
and may better reflect individual iodine status over longer periods of time [19], possibly reducing
misclassification of exposure.
Our study also has limitations. First, we were limited to a single serum iodide measurement, rather
than longitudinal iodine measurements over the course of the pregnancy. Serum iodide decreases
during pregnancy, and as such, some women may have developed iodine deficiency later in pregnancy.
Additionally, serum iodide reference ranges have not been established in this population, making
it difficult to compare with prior research and World Health Organization iodine recommendations
established for pregnant women. We also cannot rule out potential confounding by unmeasured
factors such as dietary patterns, chronic thyroid conditions or iodine supplementation initiated after
blood collection. Residual confounding by measured factors such as smoking and socioeconomic
status is also possible, but the similarity between unadjusted and adjusted estimates suggest that this
is an unlikely source of substantial bias.
5. Conclusions
In conclusion, we found that in a mildly iodine insufficient population of Finnish women,
higher-serum iodide was positively associated with risk of preterm birth, but was not associated with
risk of having an SGA infant. High levels of Tg were inversely associated with risk of SGA. In light
of our findings, it appears that mild iodine insufficiency is unlikely to be a substantial contributor
to preterm birth and SGA in Finland. Findings of increased risk of preterm birth associated with
high-serum iodide warrant further investigation.
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Appendix A
The methods used to measure serum iodide have been described previously by Bell et al. [20].
After samples were thawed at room temperature and vortex mixed for 30 s, 200 μL were transferred to
polypropylenes tubes. For sample pretreatment, an internal standard mixture of 40 ng/mL of Cl18O4-
and 4 μg/mL of S13CN- was added and mixed. After the standard was thoroughly mixed, 20 μL of
acetic acid (HAc, 5% in water) and 10 μL of ascorbic acid solution (AA, 2.5 mg/mL in water) were added,
mixed, and incubated for 15 min in an incubator shaker at 37 ◦C (100 rpm). Following this, 100 μL
of tetramethylammonium hydroxide (TMAH) (2.5 weight % solution in water), mixed the solution,
and then digested in an oven at 90 ◦C for 2.5 h. Samples were then cooled to room temperature,
after which we added 115 μL of water and 30 μL HAc, and then were mixed and centrifuged for
10 min at 5000 rpm. Finally, 500 μL of the final sample supernatant was transferred to amber vial for
high-performance liquid chromatography-triple quadrupole mass spectrometry (HPLC–MS/MS).
An Alliance 2695 high-performance liquid chromatograph (HPLC) coupled with a Micromass
Quattro LC tandem mass spectrometer (MS/MS; Waters Corporation, Milford, MA, USA) was
used for sample analysis. Micromass MassLynx 3.5 software was used for data acquisition and
quantification. The IonPac AS-21 column (guard column; 50 mm × 2 mm, analytical column;
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250 mm × 2 mm, Dionex, Sunnyvale, CA, USA) was used to separate iodide. Identification and
quantification of 18O-labeled-perchlorate, 13C-labeled-thiocyanate, and iodide was performed
using electrospray negative ionization (ESI-) and multiple-reaction monitoring (MRM) mode at
107 (35Cl18O4-) > 89 (35Cl18O3-); 59 (S13CN-) > 59 (S13CN-), and 127 (127I-) > 127 (127I-).
A number of quality control checks were performed. A matrix matched calibration standard
with a range of concentrations from 0.02 to 100 ng/mL of iodide was used for each 100-sample
batch. Calibration curves had regression coefficients of >0.99. Each calibration standard had internal
standards (Cl18O4- and S13CN-) spiked into them at 2 ng/mL and 20 ng/mL. Both internal standards had
average recoveries of 70%. Estimated limits of quantification for iodide in blood sera was 0.25 ng/mL.
Each 100-sample batch included a procedural blank, a matrix blank, a duplicate, standard reference
material, and matrix spike of 25 ng/mL iodide. In analyses, no iodine was detected in procedural
blanks, <2 ng/mL of iodide was detected in matrix blanks, 90%–111% of iodine was recovered in
standard reference material, and 101%–122% of iodine was recovered in spiked serum matrices.
No carry-over was detected from water blanks injected every 20–25 samples. To measure instrumental
drift, a mid-point calibration standard was injected in every 10 h as initial calibration verification (ICV)
to monitor for drift in instrumental response.
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Abstract: Background: Perchlorate-induced natrium-iodide symporter (NIS) interference is a
well-recognized thyroid disrupting mechanism. It is unclear, however, whether a chronic low-dose
exposure to perchlorate delivered by food and drinks may cause thyroid dysfunction in the long term.
Thus, the aim of this review was to overview and summarize literature results in order to clarify
this issue. Methods: Authors searched PubMed/MEDLINE, Scopus, Web of Science, institutional
websites and Google until April 2020 for relevant information about the fundamental mechanism of
the thyroid NIS interference induced by orally consumed perchlorate compounds and its clinical
consequences. Results: Food and drinking water should be considered relevant sources of perchlorate.
Despite some controversies, cross-sectional studies demonstrated that perchlorate exposure affects
thyroid hormone synthesis in infants, adolescents and adults, particularly in the case of underlying
thyroid diseases and iodine insufficiency. An exaggerated exposure to perchlorate during pregnancy
leads to a worse neurocognitive and behavioral development outcome in infants, regardless of
maternal thyroid hormone levels. Discussion and conclusion: The effects of a chronic low-dose
perchlorate exposure on thyroid homeostasis remain still unclear, leading to concerns especially for
highly sensitive patients. Specific studies are needed to clarify this issue, aiming to better define
strategies of detection and prevention.
Keywords: perchlorate; Natrium/Iodide symporter; iodine; endocrine disruptors; review; drinking
and Food; Hypothyroidism
1. Introduction
Endocrine disrupting chemicals (EDCs) have been defined as a group of compounds or a mixture
of natural or man-housed exogenous chemicals which interfere with the hormonal network, or induce
endocrine cell damage [1]. Interference may be attributable to several mechanisms such as receptor
agonism or antagonism, modulation of receptor expression, modification of signal transduction,
hormone synthesis or incretion, plasmatic distribution and clearance [2]. Moreover, epigenetic effects
have been hypothesized for EDCs and concerns about a possible “transmission” of EDCs across
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the generations is a topic of debate [3,4]. To date, a wide range of environmental chemicals have
been identified as being involved in the pathogenesis of thyroid diseases [5,6] and several chemicals
or common pollutants may act as thyroid disruptors [7–9]. Perfluorooctanoic acid [10], a chemical
largely employed for the manufacturing of waxes, cosmetics, carpets, cleaning or waterproof products,
and bisphenols [11], hugely used as plasticizers, were found to increase the prevalence of thyroid
diseases in exposed patients [12], including thyroid autoimmunity [13]. Moreover, legacy pesticides
were experimentally shown to affect thyroid function [14] and, despite some controversy, they may
also induce hypothyroidism, thyroid autoimmunity, thyroid volume enlargement or nodules in
humans [15]. The bactericide triclosan was mostly found in personal hygiene products (oral care,
shampoos, hand sanitizers, soaps), and was proven to increase the risk of thyroid diseases, too [16].
Thyroid disruption includes different pathways, and may be due to either interference or synergism
among different EDCs [17]. The leading mechanisms of thyroid interference by pollutant agents
have been explored, and frequently include the inhibition of thyroperoxidase activity, competitive
natrium-iodide symporter (NIS) inhibition, impairment of binding protein transport and peripheral
deiodinase activity, enhancement of liver catabolism [18]. Since food and drinks are also a relevant
source of thyroid disruptors, a lifelong human exposure to these chemicals could induce potentially
harmful consequences on thyroidal homeostasis. Given this consideration, this review aims to
specifically focalize on NIS interference by specific agents, mainly perchlorate compounds, which are
commonly found in food and drinks.
2. Materials and Methods
The authors summarized iodine metabolism and its importance in thyroid homeostasis and
hormonal synthesis. Furthermore, the authors searched PubMed/MEDLINE, Scopus, Web of Science,
institutional websites and Google for relevant information about the fundamental mechanism of NIS
interference induced by perchlorate compounds orally assumed and the consequences on thyroidal
health status associated with chronic exposure to these chemicals.
3. Results
3.1. Overview on Iodine Metabolism in Healthy Humans
The primary source of iodine (I) is represented by natural food (seafood, milk, eggs, vegetables,
legumes, fruits), fortified food (salt) and mineral waters. I is basically available in two forms,
organic and inorganic (iodide); the latter form is absorbed at the level of stomach and duodenum [19]
through a specific natrium-iodide symporter (NIS) which regulates iodine homeostasis in human
body [20]. After gastrointestinal absorption, I enters the circulation, undergoing to a large distribution
into the plasma, red blood cell cytoplasm and extracellular fluid, and is finally intercepted by
tissues [21]. A wide range of tissues express the NIS, including salivary glands, breast, and thyroid [22].
Nevertheless, thyroid represents the most important reservoir of the ion considering that, in a healthy
human body, the gland normally stores up to 80% of the entire iodine pool (15–20 mg). The NIS is a
13-domain transmembrane protein which mediates transmembrane I and sodium (1 to 2 ratio) transport
at the level of thyrocyte’s basolateral membrane [23,24]. Transmembrane sodium gradient is generated
by the sodium-potassium ATPase pump which indirectly provides energy for an almost continuous
intrathyroidal I uptake (secondary active transport). Given this thyroid avidity, I concentration in
thyrocytes is 30 to 60 times higher than its plasmatic levels [25]. As a mean, thyroid secretes 80 μg a
day of I in the form of both levothyroxine and triiodothyronine [26]. Due to peripheral metabolism
of thyroid hormones, I circulates in bloodstream finally undergoing to both renal and hepato-biliary
clearance and thyroidal re-uptake, as well. An intrathyroidal I recycling has also been described [27].
Thyroidal uptake considerably fluctuates according to I intake, and ranges from 10% to over 80% of
the entire amount of ingested I. Contrariwise, urinary I excretion is inversely correlated with thyroid
uptake, and in the case of adequate I intake, more than 90% of the ion is cleared by the kidneys with
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urine [28]. Urinary I concentration is thus a reliable biomarker of I intake, and is a useful tool for
screening patients suspected for I deficiency [25]. Both the thyroid hormone synthesis and urinary I
excretion increase during pregnancy [29], while 126 to 269 μg of I could be excreted with each liter
of breast milk in lactating women [30]. Iodine intake is generally recommended at 150 μg per day
for adults in order to ensure the daily iodine recycle [31]. Thus, the recommended dose of iodine
intake raises at 200 - 250 μg per day during pregnancy and lactation for sustaining an increased
requirement [32]. I is an essential micronutrient for thyroid hormones synthesis [33,34]. Afterward the
transition into thyrocyte cytoplasm, I moves towards the apical surface of thyrocyte’s plasmatic
membrane into the follicular lumen. This transport is mediated by a ionic carrier belonging to the
SLC26A family, otherwise known as pendrin [35], and is also expressed at the level of the inner ear,
kidney and bowel. Specifically, pendrin is essential for favoring the efflux of iodine into follicular space
in exchange of chloride (1 to 1 ratio) and a defective synthesis or function of this carrier is responsible
for a the so called Pendred’s syndrome [36]. Once into follicular lumen, I undergoes oxidation by
thyroperoxidase, thus becoming promptly available for thyroglobulin’s organification. Thyroid I
content is the most important regulator of thyroid hormone synthesis. Indeed, I overload reduces the
expression of NIS, decreases both the thyroid peroxidase and deiodinases activities, and finally leads
to a transient impairment of thyroid hormone synthesis [37]. In predisposed patients, iodine excess
increases oxidative stress, and may induce or exacerbate thyroid autoimmunity and hypothyroidism
(Wolff–Chaikoff effect) [38]. Finally, I overload may exacerbate a latent hyperthyroidism in patient
with single thyroid nodule or multinodular goiter [39].
3.2. Perchlorate Compounds and Iodine Interference
The evidence that high doses of perchlorate (ClO4−) anion decreased thyroid hormone synthesis
has been known since the 1950s [40], and given this peculiarity, it has been used to effectively treat
hyperthyroidism such as in Graves’ disease and amiodarone-induced hyperthyroidism [41]. Specifically,
ClO4− competes with I at the level of the NIS (Figure A1), the former having a 30-fold higher affinity
for the symporter when compared to the latter [42]. A dose-response sigmoid curve has been reported
for describing NIS sensitivity to ClO4− inhibition in different species and the half maximal inhibiting
concentration in humans was found at 1.566 μM [43]. To confirm these experimental results, an orally
delivered acute exposure to up to 520 μg/kg of body weight (bw) induced a significant increase in
serum thyroid stimulating hormone (TSH) levels, with a relevant decline in serum-free levothyroxine
concentrations [44]. On the other hand, it is thought that a chronic low-dose exposure to ClO4−,
normally observed as the consequence of food and drink intake, could impair thyroid function by
reducing iodine uptake particularly in predisposed individuals, such as those with an underlying
iodine deficiency [45,46].
3.3. Perchlorate Compounds in Food and Water
ClO4− may naturally occur in the atmosphere from spontaneous photogenic reaction between
chloride and ozone, or arises from man-made products such as oxidizers, fertilizers, explosives,
propellants, fireworks, airbag inflators spread into environment. In addition, ClO4− can be
also produced from the degradation of the common water disinfectant hypochlorite [47].
Perchlorate compounds occur in different form, such as metal perchlorate, ammonium and alkali
metal forms, organic and inorganic forms and salts. Antarctic ice represents the most important
sediment of ClO4− in the planet, with different concentrations depending on drilling areas [48].
The Atacama desert (Chile, South America) is another important natural source of geogenic ClO4−,
and elevated concentrations of its compounds have been found in soil (290 to 2565 μg/Kg) and surface
waters (744 to 1480 μg/L) [49]. Other relevant sources of natural ClO4− have been discovered in
Alaska, Puerto Rico, New Mexico, Texas, California (United States of America, USA), and Bolivia
(South America). Anthropogenic ClO4− compounds have been found in soil, sea and rainwater,
surface and groundwaters, indoor and outdoor dust, ice and snow [50]. Given data from ice drilling
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analyses, anthropogenic ClO4− started to accumulate in Arctic ice from the 1980s [51]. In Devon Island
(Canada, North America), ClO4− compounds were found in ice and snow at variable concentrations
ranging from 1 to 18 ng/L [52]. A great variability in rainwater ClO4− levels was observed due to
differences in analyzed geographical sites and seasonality. In fact, ClO4− concentration ranges from
0.02 to 1.6 μg/L in Texas (USA) [53], 0.02 to 6.9 μg/L in India (Asia) [54], and 0.35 to 27.3 ng/mL in China
(Asia) [55]. Moreover, Munster et al. evaluated the levels ClO4− in total deposition from November
2005 to July 2007 in Long Island (New York State), relieving a mean concertation of 0.21 μg/L and with
a maximum level of 2.81 μg/L recorded after fireworks displays occurred during the Independence
day celebration [56]. Another observation reported different levels of ClO4− in wet deposition only,
ranging from <5 to 105 ng/L (mean 14 ng/L) with higher concentrations recorded in spring and
summer than winter [57]. Soil usually does not retain ClO4− and more than 90% is confined in the
aqueous phase [58] where ClO4− spreads and persists due to its high solubility and resistance to
photolysis and anaerobic bacterial biodegradation [59]. Fruits and vegetables represent a relevant
food source of ClO4−, particularly because of the widespread use of perchlorate-based fertilizers [60].
In particular, leafy vegetables, spinach, salad plants, raspberries, apricots, asparagus, cantaloupes,
and tomatoes accumulate ClO4− as a consequence of farming techniques [61]. The mean concentration
of perchlorate in tested food appears variable and the highest levels have been found in Guatemalan
cantaloupes (156 μg/Kg), spinach (133 μg/Kg), Chilean green grapes (45.5 μg/Kg) and Romaine lettuce
(29 μg/Kg) [62]. Vega et al. reported variable concentration of ClO4− in Chilean drinking waters
which ranged from 4 to 120 μg/L [63]. Conversely, lower levels of ClO4− in drinking water have been
observed in the USA [64] and Europe, including Italy (0.5–75 μg/L) [65].
3.4. Chronic Esposure to Perchlorate Compounds by Food and Drinking Water
The 2018 “Italian Institute for Food and Agriculture Market Services” ranking reported the
USA as the most valuable country in exporting fruits and vegetables, followed by Mexico and Chile.
Given the volume of exports, Spain (4th) and Italy (7th) are responsible for the 42% of the entire
European market of fruits and vegetables, ahead of Poland, France and Greece [66]. Chile has a
remarkable export economy [67], and usually exports several thousands of millions of kilograms of
fruits a year worldwide [68]. Specifically, the European Union is Chile’s third-largest trade partner
in the world, after China and the USA, and currently imports 19% of the Chilean global export of
vegetable products [69]. Cherries and table grapes, followed by apples, Chilean blueberries and
plums are the most exported vegetable products to Europe. Vegetables from Chile are notoriously
rich in ClO4− and the excessive consumption of these products could have chronically negative
consequences on thyroid homeostasis. Indeed, ClO4− food exposure is essentially driven by vegetables
and fruits and widely ranged according to geographical area as well as seasonality [70]. To confirm
this assumption, ClO4− was detected in a wide range of vegetable samples, ranging from 21 to
162 μg/kg [71]. Vegetables consumption in Italy seems to slightly but continuously increase over time
and some of the most consumed vegetable products, such as spinach, leaf vegetables and spices were
found to be a relevant source of ClO4− [72]. Normal consumption of these vegetables does not usually
lead to exceeding the maximal total daily dose according to the European Food Safety Authority
2014 (0.3 μg/Kg of bw). However, a higher daily consumption of these products led to a relevant
exceeding of the maximal tolerated dose by 32% in adults, 61% in children and 56% in infant [72].
In addition, tea and herbal infusions could represent another relevant source of ClO4−, oscillating from
630 to 730 μg/Kg for dark tea; 80 to 430 μg/Kg for black tea; and 250 to 500 μg/Kg for green tea [73].
Therefore, the consumption of the aforementioned products should be moderate and intermittent for
avoiding a consistent ClO4− overload. Indeed, acute exposure to high or very high levels of ClO4−
normally is not enough for overcoming thyroidal compensation and ability to maintain normal serum
concentration of thyroid hormones in healthy individuals [64]. Chronic consumption of ClO4− in
adults has been estimated as high as 0.07 to 0.34 μg/Kg of body weight per day in Europe [70], and 0.2
to 0.4 μg/Kg of body weight per day in the USA [74]. Despite ClO4− consumption being generally
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below the level of recommended reference dose in adults [75], it may become critical, especially
in some categories, such as children, high sensitive patients, cigarette smokers, iodine deficient
people, and pregnant and breast feeding women as well [76–78]. Indeed, the inhibition of I uptake
and any potential downstream effects induced by ClO4− are strictly dependent on the exposure to
other environmental NIS inhibitors, such as thiocyanates and nitrates, and iodine intake itself [79].
These potential confounders should therefore be considered in future studies and calculations for
risk assessment [80]. Finally, breast milk and infant formulas are the most significant sources of
ClO4− for newborns and infants [81–83]. Compared with adults, infants and children exhibited a
greater ClO4− exposure per Kg of bw per day [75,84], particularly breastfed children (0.22 μg/Kg of
bw/day) respective to those fed by cow milk-based formula (0.1 μg/Kg of bw/day) or soy-based formula
(0.027 μg/Kg of bw/day) [85]. Food intake more than drinking water is considered the main source of
ClO4− for children [81] and adults [86], since ClO4− exposure from drinking water alone is not able to
suppress thyroid function [87]. Nevertheless, this assumption is controversial considering that other
results suggest opposite conclusions [70,74].
3.5. Perchlorate Compounds Toxicity
From this point of view, concerns have been supposed in case of ClO4− exposure during fetal and
infantile life [88,89]. The placental NIS ensures maternal-to-fetal transition of I [90], therefore allowing
fetal uptake of ClO4− and other goitrogen chemicals, too. Blount et al. specifically analyzed the
perinatal exposure to goitrogen chemicals in 150 mothers from New Jersey (USA), showing that
the placental barrier was more permeable to I respective to goitrogens and maternal urinary ClO4−
concentrations were directly correlated with ClO4− concentration in amniotic fluid, thus resulting
an useful tool for assessing fetal exposure [91]. As observed in a Chinese population, ClO4− was
detected in infant’s urine (22.4 ng/mL) and cord blood serum (3.2 ng/mL) at a concentration about
22 times greater compared to that reported by Blount (0.14 μg/L) [92]. This finding is difficult to
explain, but could be attributable to different environmental exposures or dissimilarities in assay
or both. Several studies analyzed the impact of a mild-to-moderate exposure to ClO4− in early
pregnancy on both maternal thyroid function and several neonatal outcomes. In a cross-sectional trial
in Athens (Greece), 139 first-trimester pregnant women with mild iodine deficiency were chronically
exposed to dietary sources of ClO4− as suggested by median levels of urinary ClO4− concentration at
around 4 μg/L. The authors specifically found that ClO4− urinary concentration, possibly associated
with a moderate iodine deficiency, was inversely related with plasmatic levels of triiodothyronine
and thyroxin in this cluster of patients [93]. A cross-sectional study in 200 first-trimester Thai
pregnant women (<14 weeks of gestation age) confirmed a chronic low-level environmental exposure
to ClO4− compounds (and thiocyanates) and this exposure was positively associated with serum
TSH concentration and negatively related with serum levothyroxine levels [94]. Data from San Diego
(South California) reported a mean urinary ClO4− concentration of 8.5 μg/L in first-trimester pregnant
women, and the higher the level of ClO4−, the higher the level of TSH and the lower those of total
thyroxine and free thyroxine [95]. Pearce et al. analyzed the effects of environmental exposure to
ClO4− in a cohort of 1600 first-trimester pregnant women, with mild-to-moderate iodine deficiency,
who had been enrolled in the Controlled Antenatal Thyroid Screening Study (CATS) from Cardiff
(Wales) and Turin (Italy). The results of this observation displayed a low-level environment exposure
to ClO4− in all participants but no thyroidal impairment due to this contamination was noted [96].
These findings were also confirmed in first-trimester pregnant women from Los Angeles (California)
and Cordoba (Argentina) in whom a low concentration of urinary ClO4− were detected (mean of
7.8 and 13.5 μg/L, respectively) but no correlation with ClO4− exposure and thyroid function was
demonstrated [97]. A cross-sectional association between urinary ClO4−, thiocyanate and nitrate
concentration and thyroid function was also assessed in healthy pregnant women living in New York
City (New York State). The results confirm that a co-occurrent exposure to ClO4−, thiocyanate and
nitrate may possibly impair thyroid homeostasis leading to hypothyroidism and ClO4− specifically
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displayed the largest weight in driving this outcome [98]. Taylor et al. evaluated the relationship
between maternal ClO4− exposure and neurocognitive development in first-trimester pregnant women
with hypothyroidism or hypothyroxinemia and mild iodine deficiency. The results display that
maternal urinary ClO4− concentration in the highest 10% of the population were associated with
an higher risk of offspring’s verbal intellective quotient impairment [odds ratio 3.14 (1.38–7.13),
p 0.006] and levothyroxine replacement did not improve the outcome [99]. In addition, a high
risk of mild reduction in the verbal intellective quotient in 3-year-old children who were prenatally
exposed to ClO4− was observed irrespective of their mother’s thyroid function during pregnancy [100].
Furthermore, maternal ClO4− concentration was found to positively correlate with male infant
bodyweight, especially in preterm [101].
Several observations assessed the relationship between maternal perchlorate exposure and
neonatal or infant thyroid homeostasis with controversial results according to the different clinical
end-points used for the assessment of euthyroidism [102–104]. ClO4− may affect children growth as
reported by Mervish et al., who observed that girls with higher ClO4− exposure displayed lower body
mass index and waist circumference than controls [105]. In addition, the results of a cross-sectional
study in 3151 participants (12–80 years old) displayed for each logarithmic unit increased exposure to
both ClO4− and thiocyanate, the level of free thyroxine decreased by 8% in adolescent girls and 9% in
adolescent boys, respectively [106].
3.6. Overview on Other Halogenate Compounds
Other halogenated compounds may interfere with I uptake as similarly observed for ClO4−,
including bromine and brominated compounds [107] and fluoride and fluorinated compounds [108].
Bromine compounds naturally occur in marine and terrestrial plants, but industrial compounds account
for 80% of bromine production [109]. In particular, bromine compounds are essentially found in
phytochemical, pharmaceutics, pesticides, dyes, and photographic and water treatment chemicals [109].
Bromine has been found at higher concentrations in seawater (65 to 80 mg/L) compared to natural waters
(in mean 0.5 mg/L) and groundwaters (1 to several mg/L) [110]. In addition, potassium bromate is an
inexpensive oxidizing agent used as dough improver in the baking industry [111]. Specifically, it leads
to the formation of disulfide bonds between gluten proteins, ameliorating bread’s proprieties, such as
swelling and volume [112]. Chronic exposure to potassium bromate was associated with toxic
effects and carcinogenicity in animal models [113–115]. However, no data are currently available to
also confirm toxicity and carcinogenicity in humans, thus the International Agency for Research on
Cancer classified potassium bromate in group 2B (possibly carcinogen to humans) [116]. Given these
considerations, potassium bromate has been precautionarily banned from several countries, such as
those in Europe, the United Kingdom, Canada, Nigeria, China, South Korea, and several countries in
South America, but it is still considered safe in the United States. Indeed, according to the Food and
Drug Administration, no sufficient evidence of potassium bromate adverse effects has been collected
in humans thus allowing the use of additives in the bread baking industry not exceeding 75 parts per
million [117]. For this reason, bromate levels should be constantly and reliably monitored in bread
whether potassium bromate has been used as an additive in flour processing [112]. In one observational
study in Nanchang (China), bromine was detected in all 131 whole blood samples, thus suggesting
a higher prevalence of contamination among people [84]. The daily intake of bromide ranged from
2 to 8 mg in the USA and 9 mg in Europe (the Netherlands) [110]. Regulatory agencies defined
limits of concentration bromide in drinking-waters at 6 mg/L for adults and 2 mg/L for children and
acceptable daily intake currently ranges from 0 to 1 mg/Kg of bw [110]. Human exposure to brominated
compounds usually occurs by food intake and consistently increases over time, resulting particularly
higher in Occidental countries [118]. Breast milk as well as hair and adipose tissue may accumulate these
chemicals, thus resulting as reservoirs for further persistence of brominated compounds in the human
body [118]. Bromide may interfere with thyroid homeostasis, particularly competing with I uptake and
I clearance [119,120] however, human toxicity data demonstrated that polybrominated compounds
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may interfere with gonadal function and sexual steroids’ metabolism [118]. Fluoride and fluorinated
compounds has been found in different rock-forming minerals, fertilizers, pesticides, and propellants,
and has also been found in drinking water generally at acceptable levels according to regulatory
agencies (<1.5 mg/L or <4 mg/L) [121] and groundwater [122]. Considering that a low dose of
fluoride increases overall oral health, several countries add it to their public water supply at 0.7 to
1.5 mg/L [118]. In Italy, public waters are naturally rich in fluoride (1 mg/L), thus making fluoride
addition in public supply unnecessary [123]. However, fluoride concentration in public waters
differs among regions, and is particularly higher in Lazio, where an excessive consumption of public
drinking-water may lead to a fluoride overexposure [123]. Concerns over fluoride overexposure
through drinking water have been raised in several countries [124], in which the levels of fluoride
intake exceed safety limits, leading to a relevant increase in the prevalence of both dental and skeletal
fluorosis [125]. Fluoride has been found to block I uptake by two fundamental mechanisms: inhibition
of sodium-potassium ATPase and a cytokine-mediated reduction in NIS gene expression [126].
Indeed, fluoride exposure in early stages of life, mostly for preventing dental caries, is believed to
be linked with an higher risk of future development of several diseases, including hypothyroidism
and impaired intellective quotient [127]. Moreover, the exposure to fluoride concentration at 100 ppm
(mg/L) in experimental conditions were associated with apoptosis, organelle damage and oxidative
stress resulting in neurodegeneration, endocrine dysfunction and diabetes mellitus [128]. Due to
anthropogenic and industrial activities, a great number of pollutant entry in water systems leading to
possible concerns for wildlife and human health. Defluoridation of water may contribute in reducing
the level of fluoride contamination in water and different physicochemical and electrochemical methods
have been used for this purpose [129]. Among these, biosorption should be considered an easily
available, recyclable and inexpensive tool [129].
4. Discussion
I sufficiency and euthyroidism are essential for preventing negative neurodevelopmental [130]
outcomes and processing disorders [131], thus I deficiency or interference should be hazardous
particularly during pregnancy and earlier stages of life given the particularly vulnerable thyroid
function in this developmental phase. Conventionally, I deficiency has been defined as a 24-h urinary
excretion <100 μg/L [132]. Given this criteria, more than 2 billion people worldwide are at high risk of
iodine insufficiency and at least half of European citizens exhibit a mild to moderate I deficiency [133].
Italy has been historically defined as being endemic for I deficiency, particularly in the northern
mountainous regions. Strategies of implementation of iodine intake have been allowed by law
since 1972 through the use, on a voluntary basis, of fortified salt with an I content of 15 μg/Kg,
subsequently augmented to 30 μg/kg (law 55/2005). Supplementation provided a slow but progressive
improvement of iodine status over time but did not completely eradicate the risk [134,135] and the
prevalence of mild-to-moderate I deficiency remains a current matter [136], especially in pregnancy
and lactation [137]. Of note, patients with I deficiency should be considered as highly susceptible
for developing I interference by food intake. ClO4− has a short half-life (up to 8 h) due to a quick
renal clearance [138], thus its accumulation in human body is clearly due to chronic exposure to drinks
and food [139,140]. ClO4− exposure may be harmful for thyroid homeostasis, especially in childhood
and pregnancy. Two trials were performed to assess short term effects of a ClO4− acute exposure
(2 weeks) to either 0.5 or 3 mg daily, showing no effect on thyroid function [141,142]. However, 2 weeks
of ClO4− exposure at higher doses (10 to 30 mg per day) resulted in significantly reduced iodine
uptake, potentially affecting thyroid hormone synthesis [143,144]. The results of these studies should
be interpreted with caution, particularly considering that short-term exposure is usually insufficient
to affect thyroid secretion of levothyroxine. Moreover, to achieve these levels of exposure, it could
be necessary to have an extremely high daily consumption of ClO4− for a limited period of time
which is normally not reproducible in real life (i.e., 2 litres of drinking water at ClO4− content as
high as 200 μg/L). On the other hand, studies which assessed the effect of a chronic ClO4− exposure
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(i.e., occupational) on thyroid hormone synthesis reported inclusive or equivocal results, despite I
uptake being usually impaired in almost all participants [145–147]. Given these findings, it was
difficult to make an unequivocal conclusion. The National Research Council of the National Academics
sustained that, in healthy individuals, I uptake would be reduced by at least 75% for months in order
to significantly impair thyroid hormone synthesis [47]. Thus, a sustained exposure to 0.5 mg/Kg of
bw/day of ClO4- would be most likely to induce a significant decline in I uptake consequentlyaffecting
thyroid hormone synthesis [47]. However, the US Environmental Protection Agency adopted a
recommended reference dose for ClO4− at 0.7 μg/kg of bw/day [141]. This conservative decision was
based upon a non-observed effect level found by Greer et al. in 2002 (7 μg/Kg of bw/day) divided for
an uncertainty factor of 10 attributable to intra-human variability intended to calculate an acceptable
daily intake [144]. The Office of Environmental Health Hazards Assessment developed a public health
target for ClO4− in drinking water of 6 μg/L in 2002 to 1 μg/L in 2012 [148]. In 2011, the Joint Food
and Agriculture Organization—World Health Organization recognized a maximum tolerable daily
intake of 10 μg/kg of body weight [149]. In Europe (France and Germany), the acceptable level of
exposure to ClO4− was set at 0.7 μg/kg of bw with a tolerable concentration in drinking water of
15 μg/L, successively reduced to 4 μg/L [47]. Furthermore, the European Food Safety Authority in
2014 predisposed the maximum tolerable daily dose of 0.3 μg/Kg of bw/day [70]. Water and soil
contaminations have become a concern due to detrimental consequences for both wildlife and human
health. Efficient methods for reducing the levels of ClO4− in fruits and vegetables represent useful
tools to decrease the levels of exposure. Considering that the contamination of fruits and vegetables
should reflect ClO4− concentration in soil, water for irrigation and fertilizers, several processes found
application in this field [150]. As an example, ion exchangers, which replace ClO4− with other resident
anions, such as bicarbonate, sulfate and nitrate, are one of the most used methods for removing ClO4−
from water and may be considered as a tool for dropping ClO4− levels throughout soil watering [151].
Biological degradation by perchlorate-reductase producer bacteria [152] or plants [150] could be
counted as another useful method for reducing ClO4− in water and soil, respectively. Photocatalytic
reduction of aqueous oxyanions converts toxic anions (such as ClO4− or bromate) into harmless and
less and/or not toxic ions in contaminated waters [153]. However, several limitations have been
described for this method, which include high costs of technologies, sunlight harvesting capability and
generation of dangerous radical substances [153]. Physical methods include reverse osmosis coupled
with nanofiltration membrane systems [154], or a less expensive semipermeable membrane system
coupled with electrodialysis [155]. Moreover, iron-media adsorbent have been used for removing
ClO4− and other anions in aqueous solutions [156]. In particular, granular ferric hydroxide was
found to induce a rapid uptake of ClO4− in water, considering that its maximum absorption and
equilibrium were achieved in 30 and 60 min, respectively at 25 ◦C with optimal pH at 3–7 [157].
ClO4− contamination of soil and water is strictly related to geogenic ClO4− naturally occurred in
the atmosphere and subsequently precipitated. However, fertilizes may be considered a source of
ClO4− accumulated in food chain [158]. Among fertilizers, higher levels of ClO4− were detected
in nitrogenous fertilizers (32.6 mg/Kg) compared to natrium-phosphorus-potassium (12.6 mg/Kg),
non-nitrogen (10.2 mg/Kg) and phosphates (11.5 mg/Kg) fertilizers [159]. Thus, the type and the amount
of fertilizer may influence the source of entry for ClO4− in crops. Additionally, agronomic practices
of fertilization may also contribute in this risk. As an example, fertigation is an innovative and less
expensive methods of fertilization which allows for less water being wasted, better distribution of
fertilizers and superior micronutrient assimilation by crops, but given these principles, it may be easier
to foster more significant accumulations of ClO4- in fruits and vegetables [60].
5. Conclusions
In conclusion, acute exposure to ClO4− by food and drink should not be a harmful concern
for thyroid homeostasis in healthy individuals. Generally, chronic exposure to ClO4− by eating
and drinking does not exceed the safety reference levels. However, lifelong effects of a low-dose
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exposure to ClO4− are currently unknown and concerns remain, especially for highly susceptible
individuals such as pregnant and breastfeeding women, infants and children, cigarette smokers and
high vegetable consumers, such as vegans. These clusters of patients should be advised about this
worry, and encouraged to limit daily consumption of rich in perchlorate vegetables, as well as to
implement I intake.
On the other hand, producers should be encouraged to use specific culture systems,
fertilizers (as an example nitrate-free) as well as technologies for reducing the level of ClO4− in soil
and irrigation waters in order to prevent an unnecessary ClO4− enrichment of crops. For this purpose,
economic sustainment should be considered particularly for small and medium-size companies in
order to reduce management costs.
Finally, further and specific long-term studies are probably needed to better explore this issue,
aiming to clarify whether monitoring of perchlorate exposure over time, especially in individuals at
risk, could be of interest for endocrinologists for better defining strategies of detection and prevention
in exposed patients.
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(specifically at the level of thyroid gland).
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Abstract: Cadmium (Cd) damages the thyroid gland. We evaluated the effects of myo-inositol (MI),
seleno-L-methionine (Se) or their combination on the thyroids of mice simultaneously administered
with Cd chloride (CdCl2). Eighty-four male mice were divided into 12 groups (seven mice each).
Six groups (controls) were treated with 0.9% NaCl (vehicle), Se (0.2 mg/kg/day), Se (0.4 mg/kg/day),
MI (360 mg/kg/day), MI+Se (0.2 mg/kg) and MI+Se (0.4 mg/kg). The other six groups were treated
with CdCl2 (2 mg/kg), CdCl2+MI, CdCl2+Se (0.2 mg/kg), CdCl2+Se (0.4 mg/kg), CdCl2+MI+Se
(0.2 mg/kg) and CdCl2+MI+Se (0.4 mg/kg). An additional group of CdCl2-challenged animals (n = 7)
was treated with resveratrol (20 mg/kg), an effective and potent antioxidant. All treatments lasted
14 days. After sacrifice, the thyroids were evaluated histologically and immunohistochemically.
CdCl2 reduced the follicular area, increased the epithelial height, stroma, and cells expressing
monocyte chemoattractant protein-1 (MCP-1) and C-X-C motif chemokine 10 (CXCL10). CdCl2+Se at
0.2/0.4 mg/kg insignificantly reversed the follicular and stromal structure, and significantly decreased
the number of MCP-1 and CXCL10-positive cells. CdCl2+MI significantly reversed the thyroid
structure and further decreased the number of MCP-1 and CXCL10-positive cells. CdCl2+MI+Se,
at both doses, brought all indices to those of CdCl2-untreated mice. MI, particularly in association
with Se, defends mice from Cd-induced damage. The efficacy of this combination was greater
than that of resveratrol, at least when using the follicular structure as a read-out for a comparison.
We suggest that the use of these nutraceuticals, more specifically the combination of MI plus SE,
can protect the thyroid of Cd-exposed subjects.
Keywords: cadmium; nutraceuticals; myo-inositol; seleno-L-methionine; thyroid; MCP-1; CXCL10
1. Introduction
Thyroid disorders, including hypothyroidism, with its leading etiology (Hashimoto’s thyroiditis)
and cancer arising from the follicular epithelium, are very common diseases [1,2]. Indeed, with
a prevalence of 10%–12% in the general population, Hashimoto’s thyroiditis is the most common
autoimmune disease [1]. The prevalence of thyroid cancer has increased considerably in recent decades.
Thyroid cancer incidence was relatively stable until the 1990s, when it began to increase
dramatically. Overall, thyroid cancer incidence increased from 4.9 per 100,000 population to 14.7 per
Nutrients 2020, 12, 1222; doi:10.3390/nu12051222 www.mdpi.com/journal/nutrients125
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100,000 population in 2011 [2]. Dysfunction, autoimmunity and cancer of the thyroid are triggered
by environmental factors, including pollutants such as organochlorine compounds, polychlorinated
biphenyls, polybrominated diphenylethers, bisphenol A, triclosan, perchlorates, thiocyanates, nitrates
and heavy metals [3–8].
One such heavy metal is cadmium (Cd). Cd is found in food, cigarette smoke, mines, phosphate
fertilizers and nickel–cadmium batteries [9]. Cd enters the body through the gastrointestinal tract and
the alveolar epithelium [9] and passes through the systemic circulation, bound to albumin. Cd is then
transported to the liver, where it is released and induces the synthesis of metallothionein (MT), a stress
protein first discovered in 1957 in horse kidneys [10], which protects against Cd toxicity and oxidative
stress [11]. The complex MT–Cd accumulates in the liver, kidneys, skeletal muscles and thyroid.
With a biological half-life of 5 to 30 years, exposure over time to even environmentally low levels of
Cd is associated with several toxic effects on the liver, kidneys, bones, testes and the cardiovascular
system [12–15]. Persons living in Cd-polluted areas have an intrathyroid concentration of Cd that
is threefold greater than control persons [16]. Finally, Cd has been classified as a group 1 human
carcinogen, with evidence existing of its association with lung, prostate and kidney cancers [17], and a
possible association with other malignancies, such as breast [18], pancreas [19], and urinary bladder
cancer [20]. Concerning thyroid cancer, a recent study on 66 patients with papillary thyroid cancer
(PTC) showed that the content of selenium (Se) was significantly decreased (66 vs. 132 ng/g), while the
content of Cd (58 vs. 33 ng/g) and the resulting Cd/Se ratio (0.055 vs. 0.018) were significantly higher in
the cancerous tissue compared to the healthy, noncancerous thyroid tissue [21]. Furthermore, Cd and
the Cd/Se ratio were associated with the retrosternal thyroid growth of PTC [21].
Cd increases serum thyrotropin (TSH) concentration in rats [22,23] and humans [24]. After chronic
exposure to Cd, the presence of desquamated cells in the follicles, mononuclear cell infiltration in
the connective tissue and follicles lined by higher cells with light cytoplasm were observed [25].
In a similar manner to mercury (Hg), the interaction of Cd with Se, which is relatively abundant
in the thyroid [26], as the inorganic component of the deiodinases [27–29], results in formation of
insoluble complexes [27,28,30]. The consequence of such sequestration of Se is the impairment of
selenoprotein synthesis and activities [28]. In over 5000 Chinese adults, blood levels of both Cd and
lead (Pb) were directly correlated with both thyroid hypofunction and serum thyroid autoantibody
levels [31], even if the risk of hypothyroidism increased incrementally with blood cadmium in
men, but not in women [32]. In the study on 5628 Chinese adults, women showed a positive
correlation between log (ln)-transformed blood concentrations of Cd and log (ln)-transformed blood
concentrations of thyroglobulin autoantibodies (TgAb) [31]. In the adjusted logistic regression models,
the log (ln)-transformed blood concentrations of Cd of women were positively related to their TgAb
tertiles and hypothyroid status [31]. Cd exposure also causes increased susceptibility to testicular
autoimmunity [33]. Indeed, the role of Cd in autoimmunity is supported by studies on 24 individuals,
in whom the authors measured the blood levels of three heavy metals (Cd, Hg and Pb) and blood mRNA
expression of 98 genes that are implicated in stress, toxicity, inflammation, and autoimmunity [34].
Among the different mechanisms involved in Cd-induced thyroid damage (genome influence,
apoptosis, mitochondrial dysfunction, oxidative stress), the the last mechanism seems to play a relevant
role [24]. Indeed, the said depletion of Se stores leads to its decreased availability to form glutathione
(GSH) peroxidase, which is one of the main natural antioxidants [35]. Se supplementation exerts some
beneficial effects on the thyroid of Cd-exposed rats. Histopathological analysis of the thyroid of young
rats whose mothers received Cd during pregnancy demonstrated the presence of microfollicles lined
by a single layer of columnar epithelium; Cd administration resulted in a sharp decrease in the height
of epithelial cells [36]. Furthermore, treatment of Cd-exposed rats with Se partially attenuated the
Cd-induced decrease in serum T4 levels [22].
Beneficial effects against Cd-induced damage of the thyroid or other organs were also described
for other naturally occurring molecules that, like Se, are used as nutraceuticals. These molecules are
quercetin [37] and myo-inositol (MI) [38–40]. Quercetin significantly increased serum thyroid hormones
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in rats treated with CdCl2, even if levels were significantly lower compared to unchallenged rats [37].
In mice, a 14-day treatment with CdCl2 (2 mg/kg/day) plus MI (360 mg/kg/day) protected the testis [39]
and the kidney [40] from the damage induced by CdCl2. The Cd-induced testicular damage consisted
of smaller tubules, the discontinuity of the seminiferous epithelium, the detachment of spermatogonia
from the basal membrane, and reduced claudin-11 immunoreactivity [39]. The Cd-induced renal
damage consisted of alterations in glomerular and tubular morphology [40]. Concerning the testis,
experiments were also conducted with Se alone and with a combination MI plus Se-L-methionine [39],
with such a combination having the greatest protective effects on the seminiferous tubules, and in
particular on the blood–testis barrier.
Aside from the Cd setting, the beneficial effects of MI have been shown in human sperm [41,42]
and oocytes [43]. The antioxidant properties of MI are demonstrated by the MI-induced increase
in the intracellular levels of GSH, superoxide dismutase (SOD) and catalase (CAT) [44]. Starting
from the knowledge that chemokines are mechanistically involved in the initiation and maintenance
of Hashimoto’s thyroiditis [45,46], it was shown that MI and, to a greater extent, the combination
of MI plus Se-L-methionine, decreased serum levels and lymphocyte secretion of the investigated
chemokines [47,48]. These chemokines were chemokine (C-C motif) ligand 2 (CCL2; also known as
monocyte chemoattractant protein-1 (MCP-1)), C-X-C motif chemokine 9 (CXCL9; also known as
monokine induced by gamma interferon (MIG)), and C-X-C motif chemokine 10 (CXCL10). Such effects
on chemokines explain the benefits of the combination of MI plus Se-L-methionine in patients with
Hashimoto’s thyroiditis, in terms of decreased oxidative stress [38], decreased serum levels of thyroid
autoantibodies and an improved hormone profile [47–49].
Based on this background, considering (i) that no morphometric analysis has been conducted
in previous studies on protection from Cd-induced thyroid damage [24,36,50], (ii) the lack of data
regarding the effects of MI alone and the association of MI plus Se with Cd-induced thyroid damage,
and (iii) that MI, Se and other natural compounds are being increasingly used as nutraceuticals
in clinical practice [38], we aimed to demonstrate their protective role in the structure of thyroid
glands in mice exposed to Cd. We also wished to test whether Cd induced the expression of two
aforementioned chemokines (MCP-1/CCL2 and CXCL10) and, if so, to test whether this expression
could be counteracted by MI, Se or their combination.
2. Materials and Methods
2.1. Experimental Protocol
All procedures adhered to the standards for care and use of animals as per guidelines issued
by Animal Research Reporting in Vivo Experiments (ARRIVE); the procedures were evaluated and
approved by the Italian Health Ministry (project identification code: 112/2017-PR). Eighty-four male
C57 BL/6J mice (25–30 g) were obtained from Charles River Laboratories Italia Srl (Calco, LC, Italy) and
stored at the animal house faculty of our university hospital. A standard diet was provided ad libitum
and the animals had free access to water; they were kept on a 12-h light/dark cycle. The animals were
randomly distributed into twelve groups of seven mice each. Six groups (viz. 42 mice) were considered
as controls (0.9% NaCl (vehicle, 1 mL/kg), seleno-L-methionine (Se) (0.2 mg/kg), Se (0.4 mg/kg),
MI (360 mg/kg), MI (360 mg/kg) plus Se (0.2 mg/kg), MI (360 mg/kg) plus Se (0.4 mg/kg)). The other six
groups were challenged with CdCl2 (2 mg/kg) plus a vehicle, CdCl2 (2 mg/kg) plus MI (360 mg/kg),
CdCl2 (2 mg/kg) plus Se (0.2 mg/kg), CdCl2 (2 mg/kg) plus Se (0.4 mg/kg), CdCl2 (2 mg/kg) plus
MI (360 mg/kg) plus Se (0.2 mg/kg) and CdCl2 (2 mg/kg) plus MI (360 mg/kg) plus Se (0.4 mg/kg).
An additional group of CdCl2-challenged animals (n = 7) were given 20 mg/kg of resveratrol [51,52],
a biologically active compound with potent antioxidant properties [53]. CdCl2 and NaCl were
administered intraperitoneally (i.p.), while MI, Se and resveratrol per os. MI was ready for use, while
CdCl2 and Se were diluted in 0.9% NaCl before use. After 14 days of treatment, mice were sacrificed
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with an overdose of ketamine and xylazine, and their thyroids were collected and processed for
histological and immunohistochemical procedures.
2.2. Histological Evaluation
The thyroid glands were fixed in 4% paraformaldehyde in 0.2 M phosphate buffer saline (PBS),
dehydrated in ethanol, cleared in xylene and embedded in Paraplast (SPI Supplies, West Chester, PA,
USA). Blocks were cut in a microtome (RM2125 RT, Leica Instruments, Nussloch, Germany), and 5 μm
sections were cleared with xylene, rehydrated in ethanol and stained with hematoxylin and eosin (HE)
and Sirius red (SR). All samples were observed with a Nikon Ci-L (Nikon Instruments, Tokyo, Japan)
light microscope and the micrographs were obtained using a digital camera (Nikon Ds-Ri2) and saved
as Tagged Image Format Files (TIFF) with the Adobe Photoshop CS5 12.1 software.
2.3. Immunohistochemistry for Monocyte Chemoattractant Protein-1 (MCP-1) and C-X-C Motif
Chemokine 10 (CXCL10)
The same specimens used for histological evaluation were cut at 5 μm and the sections were placed
on polysine slides (Thermo Fisher Scientific, Waltham, MA, USA), cleared with xylene and rehydrated
in ethanol. Antigen retrieval was obtained in buffer citrate pH 6.0; endogenous peroxidase was blocked
with 0.3% H2O2 in PBS. Incubation with primary antibodies (MCP-1, 1:150, Santa Cruz, Dallas, TX,
USA; CXCL10, 1:100, Biorbyt, Cambridge, UK) was performed overnight at 4 ◦C in a moisturized
chamber; then, secondary antibodies (anti-mouse and anti-rabbit, Vectastain, Vector, Burlingame, CA,
USA) were added, and the reaction was evidenced with 3,3′-diaminobenzidine (DAB) (Sigma-Aldrich,
Milan, Italy). Slides were counterstained in Mayer’s hematoxylin. For each test, specific positive and
negative controls were prepared. Micrographs were taken with a Nikon Ci-L (Nikon Instruments,
Tokyo, Japan) light microscope using a digital camera (Nikon Ds-Ri2).
2.4. Morphometric and Immunohistochemical Evaluation
All micrographs were printed at the same final magnification (800×) and were blindly assessed by
two trained observers, without knowledge of the previous treatment. Five microscopic fields (MFs),
all including two entire thyroid follicles from ten non-serial sections stained with the HE of each group
were considered.
As for the follicular compartment, a Peak Scale Loupe 7× (GWJ Company, Hacienda Heights, CA,
USA) micrometer was used as a scale calibration standard to estimate the follicular diameters. The area
(A) of each follicle was calculated by measuring the smaller inner diameter (d) and the larger inner
diameter (D) of the follicle, both expressed in micrometers (μm). The estimated area of the follicular
lumen was obtained by the following formula:
A = π. (d/2. D/2). (1)
In each thyroid gland, we measured the area of 20 follicles. To calculate the epithelial height, a straight
line perpendicular to the epithelium was traced and measured, and the results were expressed
in micrometers.
For the evaluation of the stroma, a quantitative study of micrographs from 20 microscopic fields
of Sirius Red (SR)-stained not-serial sections for each group was performed with the Adobe Photoshop
CS5 12.1 software, acquiring the pink/red color of collagen fibers. Positive areas were automatically
calculated based on their pixel number. Values were indicated as the pixel number of the positively
stained area/unit area (UA). The area of the entire micrograph was evaluated as the UA.
For an assessment of the immunoreactivity of MCP-1/CCL2 and CXCL10, positive cells were
counted from 10 non-serial sections of the thyroid, selecting two unit areas (UA) of 0.1 mm2
(316 × 316 μm). Cells overlapping the right and top borders of the areas were not counted, while the
cells overlapping the left and the bottom borders were considered.
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2.5. Drugs and Chemicals
CdCl2, Se and resveratrol were bought from Sigma-Aldrich Srl (Milan, Italy). LO.LI. Pharma Srl
(Rome, Italy) kindly provided MI. All chemicals not otherwise mentioned were commercially available
reagent grade quality.
2.6. Statistical Analysis
Values are expressed as the mean ± standard error (SE). The statistical significance of differences
between group mean values was established using Student’s t-test. The statistical evaluation of
differences among groups was obtained with ANOVA. The statistical analysis of histological scores was





Images are presented in Figure 1A–G, with the quantification of the follicular area and the height
of the follicular epithelium (thyrocytes) summarized in Figure 1H–I.
All control animals had thyroids with normal morphologies (results not shown). Therefore,
for sake of simplicity, we present a single micrograph as representative of controls (Figure 1A). In the
thyroid of mice challenged with CdCl2, compared to controls, the follicular area was smaller and
thyrocytes were taller but poorly stained (Figure 1B). In the thyroid of mice treated with CdCl2 plus
either dose of Se, compared to controls, the follicular area was also dose-dependently significantly
smaller and the follicular epithelium was also dose-dependently significantly taller (Figure 1C,D),
though the area and height changed to a lesser degree compared to mice treated with CdCl2 alone
(compare Figure 1C,D with Figure 1B, and corresponding points in Figure 1H,I). In the thyroid of mice
treated with CdCl2 plus MI, compared to controls, the follicular area was also significantly smaller, and
the follicular epithelium was significantly taller (Figure 1E), while both the area and height changed to
an even lesser degree compared to mice treated with CdCl2 plus either dose of Se (compare Figure 1E
with Figure 1B, and corresponding points in Figure 1H,I). In mice treated with CdCl2 plus both MI and
Se at either 0.2 or 0.4 mg/kg, the follicular area and epithelial height were no longer statistically different
from the controls (Figure 1F,G), but both indices were statistically different from their counterparts in
the other treated mice (compare Figure 1F,G with Figure 1B,G, and corresponding points in Figure 1H,I).
Furthermore, the effect of the combination of MI plus Se on the follicular area and epithelial height
was greater than that brought about by resveratrol, used for its potent antioxidant properties (see
Supplemental materials Figure S1).
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Figure 1. Histological organization of the thyroid (hematoxylin–eosin stain; scale bar: 25 μm).
Mice groups (seven mice/group) are: controls (A), cadmium chloride (CdCl2) plus vehicle (B), CdCl2
plus seleno-L-methionine (Se) 0.2 mg/kg (C), CdCl2 plus Se 0.4 mg/kg (D), CdCl2 plus myo-inositol (MI)
(E), CdCl2 plus MI plus Se 0.2 mg/kg (F), CdCl2 plus MI plus Se 0.4 mg/kg (G). A: Control mice have a
normal thyroid structure, as demonstrated also by bar A in H and I. B: CdCl2-treated mice show small
follicles and less stainable follicular epithelium (thyrocytes), the height of which is increased, as shown
by bar B in (H,I). C-D: In mice treated with CdCl2 plus 0.2 mg/Kg Se or CdCl2 plus 0.4 mg/kg Se, small
follicles are present with thyrocytes of smaller height, as indicated by bars C and D in H and I. E:
In mice treated with CdCl2 plus MI, the follicles and thyrocytes show a tendency to acquire a normal
size and height, even though both indices are significantly different from the controls; see also bar E in
H and I. F-G: In mice treated with CdCl2 plus MI and 0.2 mg/Kg Se or CdCl2 plus MI and 0.4 mg/kg Se,
follicles and epithelial cells were close to normal, as demonstrated by bars F and G in H and I. H: Mean
± standard error values of follicular area in the different groups of mice. I: Mean ± standard error
values of epithelial cells height in the different groups of mice. * p < 0.05 versus control; § p < 0.05
versus CdCl2 plus vehicle and CdCl2 plus 0.2 or 0.4 mg/kg Se; † p < 0.05 versus CdCl2 plus MI alone.
3.1.2. Stroma
As indicated in the Materials and Methods, Sirius Red staining allowed us to quantify the thyroid
stroma, since stromal areas are positive to such staining. Positive areas were quantified by a software
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based on their pixel number. Data were expressed as the pixel number of the positively stained
area/unit area (UA), considered to be the entire micrograph area. Matching the illustration of data for
the epithelium (see above), images are presented in Figure 2A–G, with quantification also summarized
in Figure 2H.
Figure 2. Structural organization of the thyroid stroma based on staining with Sirius Red (scale bar:
25 μm). Mice groups are as in Figure 1. (A): Control mice have a normal architecture of interstitial
collagen, with well-stained fibrillary elements, as indicated by bar A in H. (B): In CdCl2-treated mice,
an increased amount of perifollicular connective tissue is present around the follicles, as indicated
by bar B in H. (C,D): In mice challenged with CdCl2 and 0.2 mg/kg Se or CdCl2 and 0.4 mg/kg Se,
stained areas are similar to mice challenged with CdCl2, as shown by bars C and D in H. (E): CdCl2
plus MI-treated mice have stained areas with a statistically significant decrease in the pink/red colored
collagen fibers, as evident in H, bar E. (F,G): In mice treated with CdCl2 plus MI and 0.2 mg/kg Se
or CdCl2 plus MI and 0.4 mg/kg Se, a significant reduction in the stained areas can be seen, as also
demonstrated by bars F and G in H. (H): Mean ± standard error values of pixel numbers of Sirius
Red (SR)-stained areas/unit areas (UA) in the different groups of challenged mice. * p < 0.05 versus
control; § p < 0.05 versus CdCl2 plus vehicle and CdCl2 plus 0.2 or 0.4 mg/kg Se; † p < 0.05 versus
CdCl2 plus MI.
When comparing Figure 2H with Figure 1H,I, it is evident that changes in the stroma were parallel
to changes in epithelial height and opposite to changes in follicular area. Compared to the amount of
stroma in the seven untreated mice (5912 ± 556 pixels/UA (data not shown)), in the other 42 control
mice, the variation was between −5.0% (mice treated with only 0.2 mg/kg Se) AND +2.1% (mice treated
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with vehicle) (data not shown). Accordingly, the value of 5833 ± 583 (mean ± SE of the 49 control mice;
Figure 2A and bar A in Figure 2H) was taken as the reference to evaluate the effects of CdCl2 alone
or CdCl2 co-administered with Se, MI, or their association. Exposure to CdCl2 alone increased the
amount of perifollicular connective tissue by almost threefold (compare Figure 2A,B, and bars A and B
in Figure 2H). The co-administration of CdCl2 and Se decreased—even though the CdCl2-induced an
insignificant increase in—thyroid connective tissue (compare Figure 2C,D with Figure 2B, and bars C
and D with bar B in Figure 2H). MI co-administration was more effective compared to either dose of
Se, since the increase in the amount of stroma was of a smaller magnitude (compare Figure 2E with
Figure 2C,D, and bar E with bars C-D in Figure 2H) or approximately 1.5-fold higher when compared
to controls (compare Figure 2E with Figure 2A, and bar E with bar A in Figure 2H). The association of
MI with either dose of Se in mice that were simultaneously treated with CdCl2 was even more effective,
resulting in an amount of stroma superimposable to that of the control mice (compare Figure 2F,G with
Figure 2A, and bars F-G with bar A in Figure 2H).
In summary, both the follicular epithelium and the connective tissue respond in a similar fashion
to the administration of Se, MI or their combination in CdCl2 co-treated mice. This response consists of
a benefit that is modest in the case of Se, moderate in the case of MI, and high (full protection) in the
case of MI combined with either dose of Se.
3.2. Immunohistochemical Expression of MCP-1/CCL2
To maintain the modality of illustrating results, images are presented in Figure 3A–G,
with quantification also summarized in Figure 3H for MCP-1/CCL2, and in Figure 4A–G, with
quantification also summarized in Figure 4H for CXCL10.
In the baseline condition represented by untreated mice, there were no cells at all that expressed
MCP-1/CCL2 (data not shown), a pattern that was also true for the vehicle-treated mice and the other
groups of control mice, except three groups. These three groups, in which only one cell was stained,
were those treated with either concentrations of Se alone and the group treated with 0.4 mg/kg Se
plus MI (data not shown). Overall, in the 49 mice from the seven control groups, the number of cells
immunostained by the MCP-1/CCL2 averaged 0.35 ± 0.34/UA (Figure 3A, and bar A in Figure 3H).
In contrast, CdCl2 plus the vehicle induced a marked expression of MCP-1/CCL2, with a 60-fold
increase in the number of thyrocytes immunostained (compare Figure 3B with Figure 3A, and bar
B with bar A in Figure 3H). In the mice from the remaining groups, the over-expression induced by
CdCl2 was counteracted significantly by all of the tested compounds (Figure 3C–G, and bars C-G in
Figure 3H). This antagonism was small with either the dose of Se alone (Figure 3C,D, and bars C-D in
Figure 3H), moderate with MI alone (Figure 3E, and bar E in Figure 3H), and great with the dose of Se
and MI (Figure 3F–G, and bars F-G in Figure 3H). Indeed, 0.4 mg/kg Se plus MI decreased the number
of cells to 0.44 ± 0.39, which is statistically similar to the above 0.35 ± 0.34 for the 49 control mice.
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Figure 3. Immunohistochemical expression of monocyte chemoattractant protein-1 (MCP-1) in the
thyroid (scale bar: 25 μm). Mice groups are as in Figure 1. (A): In controls, no MCP-1-positive cells
are present, as shown by bar A in H. (B): CdCl2-treated mice show a marked increase in MCP-1
immunoreactivity, as indicated by bar B in H; positive cells line the follicle wall with strong stains
on their cytoplasm. (C,D): In mice treated with CdCl2 plus 0.2 mg/kg Se or CdCl2 plus 0.4 mg/kg Se,
the number of MCP-1-positive cells is decreased, but still higher than controls, as evidenced by bars C
and D in H. (E): CdCl2 plus MI-treated mice, MCP-1-positive cells are fewer, as shown by bar E in H,
and show reduced cytoplasmic staining. (F,G): In the thyroid of mice treated with CdCl2 plus MI and
0.2 mg/Kg Se or CdCl2 plus MI and 0.4 mg/kg Se, MCP-1 immunoreactivity is significantly decreased,
as indicated by bars F-G in H. (H): The number of MCP-1-positive cells per microscopic field in the
different groups of mice (mean ± standard error). * p < 0.05 versus control; § p < 0.05 versus CdCl2 plus
vehicle and CdCl2 plus 0.2 or 0.4 mg/kg Se; † p < 0.05 versus CdCl2 plus MI.
133
Nutrients 2020, 12, 1222
Figure 4. Immunohistochemical expression of C-X-C motif chemokine 10 (CXCL10) in the thyroid
(scale bar: 25 μm). Mice groups are as in Figure 1. (A): In controls, no CXCL10-positive cells are
evident, as shown by bar A in H. (B): In CdCl2-treated mice, a large number of CXCL10-positive
cells is present among the follicle walls, as indicated by bar B in H. (C,D): In mice treated with CdCl2
plus 0.2 mg/kg Se or CdCl2 plus 0.4 mg/kg Se, the number of CXCL10-positive cells is decreased,
but still high, as evidenced by bars C and D in H. (E): In CdCl2 plus MI-treated mice, only a few
CXCL10-positive cells are present, as shown by bar E in H. (F,G): In the thyroid of CdCl2 plus MI
and 0.2 mg/kg Se or CdCl2 plus MI and 0.4 mg/kg Se, no CXCL10 immunoreactivity is detectable,
as indicated by bars F-G in H. (H): The number of CXCL10-positive cells per microscopic field in the
different groups of mice (mean ± standard error).* p < 0.05 versus control; § p < 0.05 versus CdCl2 plus
vehicle and CdCl2 plus Se 0.2 or 0.4 mg/kg Se; † p < 0.05 versus CdCl2 plus MI.
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3.3. Immunohistochemical Expression of CXCL10
When CXCL10 immunoreactivity was considered, the results mimicked those described above for
MCP-1/CCL2. Thus, in the 49 mice from the seven control groups, the number of cells immunostained
by the CXCL10 averaged 0.52 ± 0.27/UA (Figure 4A, and bar A in Figure 4H). The overexpression of
CXLC10 induced by CdCl2 plus the vehicle was fully counteracted by the combination of MI with
either dose of Se (Figure 4F,G, and bars F-G in Figure 4H).
4. Discussion
In the present work, we have confirmed that Cd exposure has negative consequences for the
murine thyroid. These consist of histologically demonstrable alterations in the follicular epithelium
and stroma, and in the induced expression of two chemoattractant chemokines, an expression that is
absent prior to Cd exposure.
In fact, after chronic exposure to Cd, desquamated cells into the follicles, mononuclear cell
infiltration in the stroma and follicles lined by higher cells with light cytoplasm were observed [25].
Therefore, these Cd-elicited thyroid changes have consequences in terms of both thyroid dysfunction
and autoimmunity [31,32,54].
Se is considered to exert an overall protection against toxicity induced by heavy metals such as Cd,
Pb, As and Hg [55], mainly through the sequestration of these elements into biologically inert complexes
and/or through the action of Se-dependent antioxidant enzymes [55]. This protection from Cd toxicity
occurs regardless of the Se form (as selenite, selenomethionine, nanoSe, or Se from lentils) [56].
Furthermore, it was recently demonstrated that Se alleviated oxidative stress in chicken ovari and rat
kidneys, and counteracted the endoplasmic reticulum stress able to induce apoptosis [57,58]. However,
in this paper, we found that the trace element Se was less potent than the carbocyclic sugar MI in
protecting mice from CdCl2 thyroid toxicity, though the co-administration of Se amplified the protection
conferred by MI alone. The complementary activity of the two antioxidants can be related to their
distinctive mechanism of action. While Se is a vital constituent of the enzyme glutathione peroxidase
that catalyzes the reaction between GSH and hydrogen peroxide, thus protecting against oxidative
stress, MI is a hydroxyl radical scavenger, preventing lipid peroxidation. The combined action of the
two compounds may enhance the antioxidant effect [39]. Interestingly the efficacy of this combination
was greater that that of resveratrol (used for its potent antioxidant properties), at least when using the
follicular area and the epithelial height as read-outs for a comparison evaluation.
One limitation of our work is the lack of hormone measurements. However, considering (i)
the aforementioned Chinese study on the direct relationship between blood Cd levels with thyroid
hypofunction and serum thyroid autoantibody levels [31], (ii) the association of insulin resistance with
either decreased thyroid hormone levels or increased serum TSH [59–61], with counteracting effects by
insulin-sensitizing agents [62–64], and (iii) the insulin-mimetic action of MI [54,65,66], we expected
that Cd-exposed mouse thyroids would display decreased thyroid hormone levels and increased TSH
compared to Cd-unexposed mice. We also expected that at least the combination of MI+Se would have
fully counteracted these hormone changes induced by Cd.
On the other hand, the strengths of this study are the findings that are consistent with the
previous literature concerning the benefits for the thyroid [38] and other endocrine organs, such as the
testes [39], including consistency in the hierarchy of benefits (MI+Se >MI >> Se). In particular, CdCl2
determined significant increase in MCP-1 and CXCL10-positive cell numbers. Our data clearly agree
with many in vitro and in vivo experiments by different groups, showing that the production of these
chemokines by thyrocytes may play a central role in the recruitment of monocytes and T-lymphocytes
at immune inflammatory sites in the thyroid gland from the blood in humans, thus providing a possible
mechanism by which thyrocytes themselves may participate in the processes of thyroid autoimmune
and inflammatory disease [45,46]. After treatment with Se, MCP-1 and CXCL10-positive cell numbers
were reduced. These data about the effects of Se on the thyroid gland, from our point of view, are
not particularly surprising. In fact, the recent literature indicates that, regarding thyroid pathology,
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selenium intake has been associated with autoimmune disorders [67]. Our experimental data indicate
the relative inefficacy of Se when administered alone, probably due to extensive detrimental effects of
Cd on thyroid structure and function, not adequately counterbalanced by micronutrient administration
alone. MI treatment significantly lowered MCP-1 and CXCL10-positive cell numbers, particularly in
association with Se, thus confirming that this nutraceutical compound could impact different molecular
pathways related to oxidative stress and inflammation, involving chemokines such as MCP-1 and
CXCL10 [46].
In view of the “prophylactic” benefit reported in the present paper, it will now be interesting
to investigate whether Se, MI and their combination (Se+MI) have “therapeutic” benefits.
The demonstration of the latter’s benefits requires that animals would be first exposed to CdCl2
for a time sufficient to induce thyroid toxicity (14 days, based on the present work), and then
administered Se, MI and Se+MI at doses equal to or greater than those used in the present work and for
the same or a longer time (≥14 days), in order to show the reversal of the alterations induced by prior
Cd exposure. Another translational implication of the data presented in this paper is that, because
several pollutants, such as organochlorine compounds, polychlorinated biphenyls, polybrominated
diphenylethers, bisphenol A, triclosan, perchlorates, thiocyanates, nitrates and heavy metals different
from Cd [3–8] disturb thyroid homeostasis and confer increased environmental susceptibility to thyroid
autoimmunity, it would be worthwhile to test whether the said molecules (particularly MI+Se) may
have prophylactic and/or therapeutic effects against the thyroid alterations caused by exposure to a
number of thyroid-disrupting chemicals.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/12/5/1222/s1,
Figure S1: Histological organization of the thyroid (hematoxylin–eosin stain; scale bar: 25 μm). Mice groups
(7 mice/group) are: (A) controls, (B) cadmium chloride (CdCl2) plus vehicle, (C) CdCl2 plus seleno-L-methionine
(Se) 0.2 mg/kg, CdCl2 plus Se 0.4 mg/kg, (E) CdCl2 plus myo-inositol (MI), (F) CdCl2 plus MI plus Se 0.2 mg/kg,
CdCl2 plus MI plus Se 0.4 mg/kg. A: Control mice have normal thyroid structure, as demonstrated also by bar A in
I and L. B: CdCl2-treated mice show small follicles and less stainable follicular epithelium (thyrocytes), the height
of which is increased, as shown by bar B in I and L. C-D: In mice treated with CdCl2 plus 0.2 mg/Kg Se or CdCl2
plus 0.4 mg/kg Se, small follicles are present with thyrocytes of smaller height, as indicated by bars C and D in I
and L. E: In mice treated with CdCl2 plus MI, the follicles and thyrocytes show a tendency to acquire the normal
size and height, even though both indices are significantly different from controls; see also bar E in I and L. F-G: In
mice treated with CdCl2 +MI + 0.2 mg/Kg Se or CdCl2 +MI + 0.4 mg/kg Se, follicles and the epithelial cells were
close to normal, as demonstrated by bars F and G in in I and L. H: In mice treated with CdCl2 plus resveratrol,
the follicles show an increased size and thyrocytes a reduced height, being both indices significantly different
from controls, as shown also by bar H in I and L histograms. I - Mean ± standard error values of follicular area in
the different groups of mice. L - Mean ± standard error values of epithelial cells height in the different groups of
mice. * p < 0.05 versus control; § p< 0.05 versus CdCl2 plus vehicle and CdCl2 plus 0.2 or 0.4 mg/kg Se; † p < 0.05
versus CdCl2 plus MI alone;  p < 0.05 versus CdCl2 +MI + 0.2 mg/Kg Se and CdCl2 +MI + 0.4 mg/kg Se.
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Abstract: Nutraceuticals are defined as a food, or parts of a food, that provide medical or health
benefits, including the prevention of different pathological conditions, and thyroid diseases, or the
treatment of them. Nutraceuticals have a place in complementary medicines, being positioned in
an area among food, food supplements, and pharmaceuticals. The market of certain nutraceuticals
such as thyroid supplements has been growing in the last years. In addition, iodine is a fundamental
micronutrient for thyroid function, but also other dietary components can have a key role in clinical
thyroidology. Here, we have summarized the in vitro, and in vivo animal studies present in literature,
focusing on the commonest nutraceuticals generally encountered in the clinical practice (such
as carnitine, flavonoids, melatonin, omega-3, resveratrol, selenium, vitamins, zinc, and inositol),
highlighting conflicting results. These experimental studies are expected to improve clinicians’
knowledge about the main supplements being used, in order to clarify the potential risks or side
effects and support patients in their use.
Keywords: nutraceuticals; thyroid; carnitine; flavonoids; melatonin; omega-3; resveratrol; selenium;
vitamins; zinc
1. Introduction
The term “nutraceutical” is placed in an area among food, food supplements, and
pharmaceuticals [1]. Nutraceuticals are considered complementary medicines, defined as a “food,
or parts of a food, that provide medical or health benefits, including the prevention and treatment
of disease” [2]. Most nutraceuticals are normal human metabolites (i.e., dehydroepiandrosterone
(DHEA) and S-adenoylmethionine (SAMe), carnitine, creatine, coenzyme Q10, lipoic acid, melatonin),
or bioactive plant dietary components [2]. Food categories and supplements are both described in
the European regulation (No. 1924/2006 of the European Parliament and of the Council, updated
by EU Regulation 2015/2283), even if an official mention or recognition of the term “nutraceutical”
does not exist [3]. The European Food Safety Authority (EFSA) does not distinguish clearly the terms
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“food supplements” and “nutraceuticals, while in America “medical foods” and “dietary supplements”
are regulatory terms, although “nutraceuticals” and “functional foods” are determined according to
consumer trends [1].
In the last years, interest and knowledge in nutraceuticals have been growing. Nutraceuticals can
be considered for the prevention of different pathological conditions, including thyroid diseases and
associated disorders [4–6].
In addition to iodine, which is a fundamental nutrient for thyroid function, other dietary
components (such as carnitine, flavonoids, melatonin, omega-3, resveratrol, selenium, vitamins, zinc,
and inositol) were found to have some role in thyroid homeostasis, so that they could have a role in
clinical thyroidology. The principal issue about the appropriateness and effectiveness of nutraceuticals
in prevention and treatment depends on the lack or scarcity of clinical data [1]. Moreover, there is the
problem of the not uncommon discrepancy between the concentration reported in the label and the real
one [1]. Conventional medicines are usually submitted to quality control to ensure that they contain
the claimed dose of active constituents, and that they have suitable disintegration characteristics and
bioavailability, enabling absorption in the gut tract. Composition of nutraceuticals is increasingly being
evaluated, the results of the analyses being that composition sometimes fails the relevant standards, or
the label claims are not respected [2].
Here, we aim to review various nutraceuticals that can influence human thyroid homeostasis,
addressing on the in vitro, and in vivo experimental animal studies reported in literature. We will
focus on nutraceuticals, other than iodine, that are more likely to be encountered in the clinical practice.
2. Search of the Literature
A PubMed search, run on March 2020, using the word “nutraceuticals” as the entry, yielded
74,935 results, indicating the great interest in general for this emerging class of natural compounds that
makes the line between food and drugs to fade. Interestingly, using the entry “nutraceuticals AND
thyroid” a total of 6622 published papers were obtained, highlighting that the scientific interest of
nutraceutical area covers the thyroid research field. Indeed, different nutraceuticals possibly influence
human thyroid function and/or thyroid tumor biology that will be reviewed and commented upon.
Particularly, using the filter “humans” to exclude “other animals”, and the filter “other animals” in
order to exclude “humans”, we have meticulously screened the in vitro and in vivo experimental
studies on thyroid and carnitine (“carnitine AND thyroid”), flavonoids (“flavonoids AND thyroid”),
isoflavonoids (“isoflavonoids AND thyroid”), soy (“soy AND thyroid”), melatonin (“melatonin AND
thyroid”), omega-3 polyunsaturated fatty acids (“omega-3 polyunsaturated fatty acids AND thyroid”),
resveratrol (“resveratrol AND thyroid”), selenium (“selenium AND thyroid”), vitamins (“vitamins
AND thyroid”), zinc (“zinc AND thyroid”), and inositol (“inositol AND thyroid”) (Table 1).
Table 1. Summary of number of articles on given nutraceuticals retrievable on PubMed as of
21 March 2020 *.
n. of Items. Entry Humans Other Animals
1 nutraceuticals 55,737 31,391
2 nutraceuticals AND thyroid 522 (0.9%) 224 (0.9%)
3 carnitine 8134 8778
4 carnitine AND thyroid 71 (0.8%) 95 (1.1%)
5 flavonoids 44,187 49,719
6 flavonoids AND thyroid 222 (0.5%) 248 (0.5%)
7 isoflavonoids 404 281
8 isoflavonoids AND thyroid 4 (0.9%) 4 (1.4%)
9 soy 7965 6531
10 soy AND thyroid 93 (1.2%) 75 (1.1%)
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Table 1. Cont.
n. of Items. Entry Humans Other Animals
11 melatonin 11,142 14,477
12 melatonin AND thyroid 200 (1.8%) 364 (2.5%)
13 omega-3 polyunsaturated fatty acids 17,168 12,783
14 omega-3 polyunsaturated fatty acids AND thyroid 37 (0.21%) 38 (0.3%)
15 resveratrol 5823 5961
16 resveratrol AND thyroid 54 (0.9%) 42 (0.7%)
17 selenium 13,794 13,888
18 selenium AND thyroid 600 (4.3%) 372 (2.7%)
19 vitamin A 32,637 22,296
20 vitamin A AND thyroid 495 (1.5%) 593 (2.7%)
21 vitamin D 61,418 20311
22 vitamin D AND thyroid 1280 (2.1%) 554 (2.7%)
23 vitamin E 22,004 18,811
24 vitamin E AND thyroid 96 (0.4%) 123 (0.6%)
25 zinc 58,247 50,628
26 zinc AND thyroid 503 (0.86%) 401 (0.7%)
27 inositol 17,144 27,226
28 inositol AND thyroid 147 (0.86%) 205 (0.75%)
* The PubMed search was run using the filter “humans” to exclude “other animals”, and the filter “other animals”
in order to exclude “humans”. Note how thyroidal studies account for a tiny fraction of total studies for any listed
nutraceutical, and with comparable percentages in humans and animals. For instance, “resveratrol AND thyroid”
accounted for 54 of 5823 studies in humans (0.9%) and 42 of 5961 studies in other animals (0.7%).
3. Carnitine
The naturally occurring quaternary amine, carnitine, is ubiquitous in mammalian tissues, and
according to studies of about 40 years ago, it was considered a peripheral antagonist of thyroid hormone
(TH) action [7].
Old studies published in German language showed that carnitine is capable of contrasting
TH-induced changes associated with the nitrogen balance in rats and metamorphosis of tadpoles [8,9].
In the more recent of such papers, carnitine contrasted the thyroxine (T4)-induced liver and circulating
concentration of both alanine aminotransferase (ALT) and aspartate aminotransferase (AST) [9].
Tissue culture experiments on human skin fibroblasts, human hepatoma cells HepG2, and mouse
neuroblastoma cells NB 41A3 demonstrated that L-carnitine inhibits cell entry, and overall nuclear
entry, of triiodothyronine (T3) and T4 [7]. There was no inhibition on TH efflux from cells, and no
inhibition of TH binding to isolated nuclei. These data confirm that carnitine is a peripheral antagonist
of TH action, and that one level of inhibition occurs at the nuclear envelope or before it [7].
Four experimental groups were formed starting from 21 male Sprague Dawley rats: hyperthyroidism
(n = 5), hyperthyroidism plus low dose L-carnitine (100 mg/kg/d for 10 days; n = 5), hyperthyroidism
plus high dose L-carnitine (500 mg/Kg/d for 10 days; n = 5), and controls (0.2 mL/100 g body weight,
subcutaneously, of 0.9% NaCl solution; n = 6) [10]. The injection of levothyroxine (L-T4) in a dose of
250 μg/kg body weight per day for 20 consecutive days was able to induce hyperthyroidism in rats.
The treatment with either dose of L-carnitine was by intraperitoneal injection, and it started on the 10th
day of hyperthyroidism continuing for the following 10 days. Activities of one marker of oxidative
stress (malondialdehyde (MDA)) and activities of three markers of antioxidant defense (namely, the
antioxidant enzymes catalase (CAT), glutathione peroxidase (GPX), and myeloperoxidase (MPO))
were measured in liver homogenates. MDA activity was increased by 59% in the carnitine-untreated
hyperthyroid group, but it decreased significantly and to levels comparable to the control rats in either
group of hyperthyroid rats receiving L-carnitine. Activities of the three enzymes were 21% to 76%
lower in the carnitine-untreated hyperthyroid rats with respect to the control group. Treatment of
hyperthyroid rats with either low or high dose of L-carnitine increased strongly the liver activities
of the antioxidant enzymes (with dose-dependency absent for CAT, moderate for GPX and great
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for MPO), indicating that even a low dose of L-carnitine was enough to prevent the oxidative stress
induced in the rat liver by L-T4 [10].
Some experimental data are available in the neoplastic setting of the thyroid. L-carnitine, the
biologically active form of carnitine, transports long-chain acyl groups from fatty acids into the
mitochondrial matrix to generate metabolic energy in living cells. Although, it has been reported that
treatment with L-carnitine efficiently induced ATP generation in normal cells, it has been found to
selectively inhibit cancer cell growth in vitro and in vivo models [11].
Controversially, the expression of the enzyme involved in this transport, the carnitine
palmitoyltransferase 1C (Cpt1c), has been detected at higher levels in papillary thyroid tissues
compared with normal ones and Cpt1c up-regulation has been found to promote cancer cell growth
and metastasis in human papillary thyroid carcinomas cell lines [12].
Recently, carnitine has been reported as a potential candidate biomarker able to discriminate
between normal and thyroid cancer cells, however, further studies are needed to confirm carnitine
as the thyroid cancer diagnostic oncometabolite [13]. Of interest, a recent Turkish study [14] used
40 guinea pigs to assess the protective effects of amifostine (200 mg/kg ip), L-carnitine (200 mg/kg ip),
or vitamin E (40 mg/kg im) against high dose radioactive iodine (131I) treatment-induced salivary gland
damage. Control animals received 131I was administered intraperitoneally at doses (555–660 MBq)
that ablate the thyroid and impair the parenchymal function of the salivary glands. The damage of
the salivary glands was evaluated one month after treatment, by salivary gland scintigraphy and
histopathology, in 40 guinea pigs. The three molecules gave different levels of protection against
radioactive iodine treatment injury in salivary glands; however, none of the agents could provide
absolute protection.
4. Flavonoids, Isoflavonoids, Soy
Flavonoids are the most common group of polyphenolic compounds in the human diet and are
widespread in plants [15], and they can be classified into flavonoids or bioflavonoids; isoflavonoids;
and neoflavonoids. It has been reported that flavonoids can interfere with thyroperoxidase (TPO)
activity, reducing TH synthesis with subsequent raise of thyroid-stimulating hormone (TSH) levels
and potential development of goiter. Goiter occurrence has been described among infants fed with
soy formula, while the thyroid profile was normal in post-menopausal women with regular soy diet.
Moreover, flavonoids seem to impair the peripheral action of TH, by the inhibition of deiodinase or
displacing T4 from transthyretin [16]. Recently, the debate on soy foods and diet has earned attention
among the healthcare and general public.
Since isoflavones from soy and other legumes showed to act on estrogen pathway, they are also
proposed as nutraceutical products to relieve women from symptoms of menopause [17]. However,
data regarding the impact of isoflavones on endogenous estrogens levels in women are still controversial.
To date, no health issue on isoflavones has been ratified by EFSA because of insufficient scientific
evidence, while the available human studies ruled out the hypothesis of adverse effects of isolated
isoflavones on mammary gland, uterus or thyroid health among postmenopausal women. Nevertheless,
there are many divergences to consider in term of metabolism of isoflavones, developmental stage at
time of consumption and in their temporarily restricted uptake during certain stages of life, that make
animal models not reliable for humans. Thus, potential adverse effects cannot be completely ignored,
especially among women with unknown diseases status (i.e., undetected precancerous lesions in the
mammary gland) [17].
In 2014, a review explored 5 health benefits-relieves of menopausal symptoms and prevention
of breast cancer, heart disease, osteoporosis, and prostate cancer, and 5 health risks-increased risk
of breast cancer, hypothyroidism, male hormonal and fertility problems, antinutrient content, and
harmful processing by-products [18]. The authors considered in their analysis prospective human trials,
systematic reviews of human trials, observational human studies, in vitro studies, laboratory analyses
of soy components, and animal studies. They noticed that isoflavones and soy foods may wane
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menopausal symptoms and protect from breast cancer and heart disease, but not from osteoporosis.
The impact on male fertility and reproduction was controversial. With regard to thyroid activity, data
are conflicting and there is uncertainty, demonstrating that soy may have unpredictable effect on
thyroid physiology [18].
In a study, adult female cynomolgus monkeys (Macaca fascicularis) were randomized in 2 groups,
according to diet: One to consume casein-lactalbumin (n= 44) and the other soy protein with isoflavones
(n= 41) [19]. All animals were ovariectomized after 34 months, and then, for other 34 months, half of the
monkeys from each diet treatment group continued to receive their preovariectomy diet. The remaining
animals were not considered furtherly. The authors concluded that soy protein and isoflavones do not
adversely affect thyroid function in females [19].
Anyway, studies of soy isoflavones in experimental animals suggest possible adverse effects as
well (i.e., anti-thyroid effects, modulation of endocrine function, and enhancement of reproductive
organ cancer) [20].
A study showed that rats fed with a diet containing soy (20% defatted soy bean) had a severe
hypothyroid state (low T4, increased TSH and thyroid weight), with evidence for increased thyroid cell
proliferation. This hypothyroidism was induced only when a dietary condition of iodine deficiency
was added [21].
Another paper indicated a dramatic synergism between soy intake and iodine deficiency on the
induction of thyroid hyperplasia in rats [22]. Female F344 rats were randomized into 8 groups, and for
a 5-week period received a diet containing: 1) 0.2% soy isoflavone mixture (SI); 2) 0.2% SI + iodine
deficiency (ID); 3) 0.04% SI; 4) 0.04% SI + ID; 5) 20% defatted soybean (DS) alone; 6) 20% DS + ID; 7) ID
alone; 8) basal diet alone. In the group receiving 20% DS, serum T4 and TSH levels increased inducing
thyroid growth in rats exposed also to the ID diet. In the ID diet groups, proliferating cell nuclear
antigen labeling indices (%) were elevated and increased by DS, but not SI, suggesting that isoflavones
may not participate in the mechanisms underlying the synergistic goitrogenic effect of soybean with
iodine deficiency [22].
Genistein (4′,5,7-trihydroxyflavone) is a phytoestrogen that belongs to the class of soy isoflavones
and is effective to treat osteoporosis, menopausal vasomotor symptoms, cardiovascular diseases,
as well as a variety of cancers. Little is known about the action of isoflavones on thyroid integrity
in humans, even if it seems that genistein does not act negatively on thyroid safety in euthyroid
humans [23]. Recently, it has been demonstrated that genistein has antineoplastic effects, but it does
not induce genotoxic effects whereas it decreases oxidative-induced DNA damage in human primary
thyroid cells from papillary thyroid cancer, supporting its potential use in therapeutic intervention [24].
A study evaluated the biological effects of genistein in rats receiving genistein aglycone in soy-free
feed fortified at 0, 5, 100, and 500 ppm, beginning in utero through 20 weeks [24]. In rat serum, the
genistein content was of 8 μM, and it increases in thyroid tissues up to 1 pmol/mg both in male and
female rats. The activity of TPO was reduced by up to 80% dose-dependently in rats of both gender.
Male and female rats receiving a standard soy-based rodent diet had TPO activity ~50% lower than
rats consuming a soy-free diet. Comparing treated and untreated groups, there were no differences in
T3, T4, and TSH serum levels, thyroid weights, and histopathology. The reported data suggested that,
even if normal rats lose partial activity of TPO when they receive soy isoflavone, thyroid homeostasis
is guaranteed by remaining enzymatic activity [25].
Quercetin is the most abundant dietary flavonoid in fruit and vegetables, and it has different
therapeutic actions, i.e., the induction of apoptosis in cancer cells, and antioxidant, antiviral,
anti-proliferative, and anti-inflammatory effects [26]. Regarding the thyroid, many studies have shown
anti-thyroid and goitrogenic effects of flavonoids, different according to each specific flavonoid [16].
As a pretreatment for Wistar rats, quercetin was administered orally at the dose of 10 mg/kg
for 7 days, and it protected them from myocardial infarction induced by subcutaneous injection of
isoproterenol. The ST-segment elevation was lowered and levels of lipid peroxidation products were
decreased in plasma and heart [27]. Moreover, the pretreatment with quercetin reduced significantly
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the levels of total cholesterol, triglycerides and free fatty acids in serum, heart, and heart mitochondria
and serum phospholipids, and it lowered levels of serum LDL and very LDL cholesterol, while raised
significantly serum HDL [27].
When quercetin was given (0.1%; w/w in diet) to human CRP transgenic mice, a humanized
inflammation model, and ApoE*3Leiden transgenic mice, a humanized atherosclerosis model, it halted
IL-1b-induced CRP expression in the first and lowered the burden of atherosclerosis (40%) in the
second through a reduction of circulating inflammatory markers, “serum amyloid A proteins” and
fibrinogen. The quercetin plasma levels (13–19 mM) were similar among both groups and to those
measured in rodents treated with the same doses (0.1%, w/w) [28].
In 2008, quercetin was shown to halt the spread in FRTL-5 thyroid cells dose- and time-dependently,
by inhibiting insulin-regulated Akt kinase action [29]. Quercetin interferes with TSH-dependent NIS
gene expression and I- transport in FRTL-5 cells. These observations may help us to understand
the molecular mechanism of the antithyroid effect of quercetin on cell growth and function. Even if
collected from an in vitro, hormonally controlled, functioning thyroid cell line, that does not have the
characteristics of a transformed cell, these results led to evaluate quercetin as an antithyroid drug in
hyperfunctioning states [29].
In recent studies, quercetin seems to reduce the expression of the thyrotropin receptor, TPO
and thyroglobulin (Tg) genes [30]. The antithyroid impact of quercetin was further evaluated
in vivo: Quercetin was administered (50 mg/kg) to a Sprague–Dawley rat and after 14 days of
treatment, radioiodine uptake decreased significantly demonstrating that quercetin may act as a
thyroid disruptor [30].
Apigenin, a plant-derived flavonoid, has been also considered able to increase the iodide influx
through Akt inhibition in thyroid cells under acute TSH stimulation [31]. Radioiodide accumulation
thanks to apigenin-mediated Akt inhibition was also described in PCCl3 rat thyroid cells overexpressing
BRAF(V600E) and in primary thyroid tumor cells from TRβ(PV/PV) mice. These results suggest that
the outcome of radioiodine therapy for thyroid cancer can be improved by apigenin and other Akt
inhibitors given as food supplements [31].
Soy extracts suppressed iodine uptake and increased the protein content of a known
autoimmunogenic Tg fragment in Fischer rat thyroid cells (FRTL). These effects might be responsible
for the association between higher incidence of Soy consumption with thyroid disorders such as
hypothyroidism, goiter, and autoimmune thyroid disease [32].
Among flavonoids, epigallocatechin-3 gallate (EGCG), a catechin abundant in green tea, when
administrated to male rats at doses of 25, 50, and 100 mg/kg body weight showed antithyroidal effects
as emerged by decreased activity of thyroid peroxidase and 5′-deiodinase I and increased thyroidal
Na+/K+ ATPase activity. In addition, serum T3 and T4 levels were reduced, while serum TSH was
elevated in rats, showing in vivo goitrogenic potential [33].
Moreover, the effect of EGCG (10, 40, 60 μM) was also tested on the proliferation and motility
of human thyroid papillary (FB-2) and follicular (WRO) carcinoma cell lines. EGCG treatment
inhibited thyroid cancer cell growth, reduced cell motility and migration with concomitant loss of
epithelial-to-mesenchymal cell transition markers [34].
5. Melatonin
Melatonin is an indoleamine with different activities in animals and plants, such as anti-aging,
antioxidant, circadian rhythm controlling, antiproliferative, or immunomodulatory [35].
In a paper published in 1991, both in the Results (“As shown in Table 2, in surviving mice at 19
and 23 months, melatonin treatment resulted in a significant decrease in night levels of T3 and T4 after
7 . . . ”) and in the Discussion (“chronic night treatment with melatonin in the drinking water in aging
mice significantly lowers night levels of T3 and T4 in peripheral blood (Table 2) and thus affects aging
related thyroid dysfunction by a mechanism yet to be elucidated”), the authors stated that both T3
and T4 decreased after 7 months of melatonin treatment [36]. However, inspection of their Table 2
146
Nutrients 2020, 12, 1337
(see the following Table 2 that was redrawn by S. Benvenga), shows that only the reduction of T3 was
statistically significant. Incidentally, another inaccuracy is that such reductions are lower (−20% for T3
and −23% for T4) than those shown in their Table 2 (−25% and −30%).
Table 2. Table redrawn from reference #36. In that paper [36], this table was Table 2, and its heading
was “Chronic (night) treatment with melatonin modifies night levels of thyroid hormones in serum











(n = 10) 19 ———— 0.854 ± 0.165 5.48 ± 1.09
Treated
(n = 10) 19 3
0.873 ± 0.160
(+ 2.2%)
P > 0.05 (NS)
5.46 ± 1.51
(− 0.36%)
P > 0.05 (NS)
Untreated
(n = 4) 23 ———— 0.850 ± 0.028 4.94 ± 1.10
Treated






P > 0.05 (NS)
* In the original Table, the Authors wrote “(−25%)”. Having noted this error, S. Benvenga wished to repeat
statistical analysis with the same test used by the Authors (two-tailed Student’s t test). He obtained, t = 6.199,
which is significant at a P < 0.001, confirming the tabulated P value. § In the original table, the authors wrote
“(−30%)”. Having noted this error, S. Benvenga wished to repeat statistical analysis with the same test used by the
Authors (two-tailed Student’s t test). He obtained, t = 1.450, which is insignificant (P > 0.10), thus confirming the
tabulated value.
One note of caution comes from preliminary experiments by the same group in C3H/He female
mice that started to be treated with melatonin (10 μg/mL in the drinking water) at 1 year of age.
“Melatonin not only failed to prolong the life span of the mice, but, on the contrary, induced a high
number of tumors primarily affecting the reproductive tract (lympho- or reticulosarcoma, carcinoma
of ovarian origin; histology not shown here) and thus adversely affected the health and survival
of melatonin-treated mice” [36]. Indeed, as stated in the Discussion “It was not surprising, in this
study, that ovarian tumors developed following chronic melatonin administration, as Kikuchi et al.
found that melatonin stimulated in vitro proliferation of a human ovarian KF cell line” [36]. Instead,
“a remarkable prolongation of life was seen when NZB mice were chronically given melatonin in the
drinking water at night, while no effect was seen when melatonin was given during the day. In spite of
the effect of melatonin, the common causes of death in all melatonin-treated or control NZB mice were
autoimmune hemolytic anemia, nephrosclerosis and development of systemic or localized type A or B
reticulum cell neoplasia” [36]. “A repetition of our experiments by night administration of melatonin
in older, aging C57BL/6 male mice resulted again in a significant prolongation of their survival” [36].
At the end of a 4-week duration study in adult male rats, pinealectomy was associated with
increased levels of serum FT3 and FT4 levels compared to control rats and, to a greater extent, compared
to zinc-deficient rats [37]. The same Turkish team [38] showed that, at the end of a 4-week treatment
period with 3 mg/kg/day of zinc and/or melatonin, melatonin has a thyroid function suppressing
action, just the opposite to the effect of zinc. However, when zinc is administered along with
melatonin, the thyroid function suppression exerted by melatonin is lowered. Just recently, in rats with
experimentally-induced thyroid dysfunction, Baltaci et al. [39] found that both melatonin and zinc
levels are increased in hyperthyroidism and decreased in hypothyroidism.
In cultured rat thyroid follicular cells, melatonin increases directly Tg expression, thus regulating
TH biosynthetic activity. On the other hand, it has also been reported that thyroid C-cells synthesize
melatonin suggesting in the meantime a paracrine role for this molecule in the regulation of thyroid
activity [35].
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Interestingly, melatonin was found to suppress cell viability, migration and to induce apoptosis in
thyroid cancer cell lines in vitro and reduce tumor growth in the subcutaneous mouse model in vivo.
In addition, melatonin could enhance sensitivity of thyroid cancer cells to irradiation in vitro and
in vivo, suggesting that this molecule may have clinical benefits in thyroid cancer [40].
6. Omega-3 Polyunsaturated Fatty Acids (Or Fish Oil)
Omega-3 (ω-3) polyunsaturated fatty acids (PUFAs) are docosapentaenoic acid (DPA), α-linolenic
acid (ALA), stearidonic acid (SDA), docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA).
Several clinical trials and animal models have suggested that ω-3 possess multiple effects, such as
reduction of lipid levels, direct interactions with cytosolic or membrane bound proteins, metabolic
effects, alteration of membrane fluidity (after being incorporated into the phospholipid bilayer) or
cardiac tissue remodeling and cell-to-cell communications, even if the data demonstrating improvement
remain contradictory [41].
Some Authors demonstrated the anti-apoptotic action of ω-3-fatty acids (ω-3 FAs) on cerebellar
organogenesis in a murine model of hypothyroidism-induced neuronal apoptosis [42]. Pregnant and
lactating rats were first made hypothyroid by methimazole (MMI) administration and then received
ω-3 FAs as a mixture of DHA and EPA. Serum levels of T3, T4, TSH, and the cerebellum of postnatal
pups at 16 days of age were evaluated. Compared with the euthyroid pups, serum T4 and T3 levels
were significantly lower in the untreated hypothyroid and ω-3 FA-treated hypothyroid pups. Thus,
ω-3 FA-supplementation caused no significant change in serum T4 and T3 levels in the hypothyroid
d16 pups. Compared with the euthyroid and untreated hypothyroid pups, the percentages of EPA and
DHA in total cerebellar FAs rose significantly in the ω-3 FA-treated hypothyroid pups. The weight
of the cerebellum decreased significantly in untreated hypothyroid pups compared to euthyroids,
which was totally recovered upon ω-3 FA treatment of hypothyroids. The cerebellar weight in
untreated hypothyroids was about 16% lower than euthyroids and ω-3 FA-treated hypothyroids.
The percentage of apoptotic cells in the cerebellum was significantly higher in hypothyroid than
in euthyroid pups. However, the apoptotic index of the ω-3 FA-treated hypothyroid pups was
not significantly different from that of the euthyroids, but was significantly lower than untreated
hypothyroid pups. There was a significantly impaired DNA fragmentation and caspase-3 activation
in the developing cerebellum of hypothyroid pups. Upon ω-3 FA treatment the cleaved caspase-3
levels attenuated significantly compared to untreated hypothyroids, nearly reaching the levels of
euthyroids. The levels of pro-apoptotic basal cell lymphoma protein-2 (Bcl-2)-associated X protein
(Bax) were significantly higher and Bcl-2 and Bcl-extra large (Bcl-xL) were significantly lower in the
cerebellum of hypothyroids than in euthyroids. In the cerebellum of ω-3 FA-treated hypothyroids,
there was significantly lower expression of Bax and significantly higher expression of Bcl-2 and Bcl-xL
compared to untreated hypothyroids. Finally, ω-3 FA-supplementation restored levels of cerebellar
phospho (p)-AKT, phospho-extracellular regulated kinase (p-ERK) and phospho-c-Jun N-terminal
kinase (p-JNK), all of these molecules being downregulated in hypothyroidism, with no impact on the
expression of myelin basic protein, a TH responsive gene. These findings suggest a protective role of
ω-3 FAs against cerebellum and brain injury due to fetal hypothyroidism [42].
Another study investigated in adult male rats the effect of hypothyroidism on spatial learning and
memory, the underlying mechanisms and the potential therapeutic role of ω-3 supplementation [43].
A subdivision into 3 groups was done starting from 30 male rats: Control, hypothyroid and ω-3 treated.
ω-3 FAs supplementation improved memory deficits, increased serum total antioxidant capacity,
and also a diminished expression of Cav1.2 protein (the voltage dependent LTCC alpha 1c subunit),
together with reduced structural changes, were observed. The data showed that ω-3 FAs could be a
useful neuroprotective agent against the cognitive damage that hypothyroidism can induce [43].
TH also have impact on lipid metabolism. For this reason, it has been explored the effect of ω-3
FAs (at dose of 200 mg/kg of body weight/day for 6 weeks) on lipid metabolism among euthyroid,
hyperthyroid or hypothyroid Lewis male rats [44]. Hyperthyroid rats had higher fasting blood
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glucose and plasma postprandial triglycerides levels compared to euthyroid and hypothyroid animals.
In contrast, hypothyroid rats had higher levels of total cholesterol, LDL, and HDL cholesterol [44].
A large body of evidence reveals that ω-3 PUFAs have general anti-inflammatory activities and
antineoplastic properties. For instance, they act through different mechanisms including alteration
of membrane fluidity and cell surface receptor function, modulation of COX activity and increased
cellular oxidative stress. The anti-cancer activities exerted by ω-3 PUFAs are also due to their ability to
bind the tumor suppressor Peroxisome Proliferator-Activated Receptor gamma (PPARγ) [45,46].
Ligand activation of PPARγ induces growth inhibition and apoptosis in different thyroid cell
lines, including anaplastic thyroid cancer cells [47–49]. Activation of PPARγ could represent a novel
treatment option for anaplastic thyroid cancer in order to extend life duration thus warranting a good
quality of life [50,51].
7. Resveratrol
Resveratrol (3,5,4′-trihydroxy-trans-stilbene) is a stilbenoid polyphenol that can be found in
various vegetables and fruit, including peanuts, peanut sprouts and grapes. As it seems to have a
significant role as either a chemo-preventive and therapeutic agent to treat different diseases [52,53],
resveratrol has recently obtained more attention among health professionals and other nutrition experts.
Resveratrol has antioxidant, anti-inflammatory, and antidiabetic effects, in particular its
cardiovascular protective actions are associated with various molecular targets, including apoptosis,
inflammation, oxidative stress, angiogenesis, mitochondrial dysfunction, and platelet aggregation [53].
In a rat model of subclinical hypothyroidism (SCH), in which SCH is caused by hemi-thyroid
electrocauterization, the effect and potential mechanism of resveratrol on memory and spatial learning
were studied [54]. The treatment with resveratrol (15 mg/kg) and L-T4 in SCH rats demonstrated
an inversion of learning and memory impairment in behavioral test. Resveratrol treatment of
SCH rats caused reduced expression of the hypothalamic thyrotropin releasing hormone (TRH)
mRNA and decreased plasma TSH. This could indicate that resveratrol treatment would reverse the
hypothalamic–pituitary–thyroid (HPT) axis imbalance in SCH rats. Furthermore, resveratrol treatment
of SCH rats up-regulated the hippocampal levels of syt-1 and BDNF. In brief, resveratrol treatment
improves spatial learning and memory of SHC rats [54].
In another study, by the same team, the possible antidepressant effect of resveratrol was evaluated,
after having previously shown that this rat model develops a depression-like behavior [55]. In SCH
rats, the over-expression of the hypothalamic TRH mRNA and the high concentration of TSH were
decreased to control levels by resveratrol treatment. Compared to SCH rats, resveratrol-treated SCH
rats showed a higher preference for sucrose in the sucrose preference test, an increase in breeding
frequency and distance in the open field test and a reduced immobility in the forced swimming
test. Resveratrol-treated SCH rats had lower plasma corticosterone levels, adrenal gland weight in
relation to bodyweight, and expression of the hypothalamic corticotrophin release hormone (CRH)
mRNA. In addition to this, resveratrol, on the one hand, adjusted negatively the relative ratio of
phosphorylated-β-catenin (p-β-catenin)/β-catenin and expression of GSK3β, and on the other, adjusted
positively the relative ratio of phosphorylated-GSK3β (p-GSK3β)/GSK3β and protein levels of p-GSK3β,
cyclin D1, and c-myc, in the hippocampus [55]. Altogether, these results indicate that the canonical
Wnt pathway was activated in the hippocampus of the untreated model rats and that activation was
ameliorated by the resveratrol treatment [36]. The authors concluded that resveratrol exerts anxiolytic-
and antidepressant-like effect in SCH rats by downregulating hyperactivity of the HPA axis and
regulating both the HPT axis and the Wnt/β-catenin pathway [55].
Fluoride is the most abundant anion in groundwater, creating problems in drinking water and
causing metabolic, functional, and structural damage in several organ systems, including structural
abnormalities of the thyroid follicles. It was shown that resveratrol supplementation in fluoride-exposed
animals prevented metabolic toxicity caused by fluoride, and restored the functional status and the
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ultra-structural organization of the thyroid [56]. Hence, this study shows therapeutic efficacy of
resveratrol as a natural antioxidant in thyroprotection against toxic insult caused by fluoride [37].
The antiproliferative effect of resveratrol depends on the induction of ERK1/2- and p53-dependent
antiproliferation in tumoral cells, binding to a specific receptor on plasma membrane integrin αvβ3,
and the accumulation of resveratrol-induced nuclear COX-2; in turn, COX-2 combined with ERK1/2,
and ultimately with p53, generates a transcriptionally active complex [57]. To date there are conflicting
opinions on the preventive and therapeutic abilities of resveratrol. Physiological concentrations of TH
(especially T4) interfere with the antiproliferative/anticancer action of resveratrol. This suggests that
the in vivo block of the surface receptor for TH on cancer cells, as well as the reduction of circulating
levels of T4 and the substitution of T3 (to maintain a condition of euthyroidism), could be used as
strategies to recover or potentiate the clinical effectiveness of resveratrol in tumor treatment [57,58].
Resveratrol has been reported to inhibit sodium/iodide symporter (NIS) gene expression and
function in FRTL-5 cells, decreasing cellular iodide uptake after 48-h treatment and this effect was also
confirmed in in vivo Sprague–Dawley rats [59].
Recently, resveratrol has been investigated for its antithyroid effects in vitro and in vivo models.
Specifically, in FRTL-5 cells resveratrol has been found to reduce the expression of thyroid-specific
genes, such as Tg, TPO, TSHR, NKX2-1, Foxe1, and PAX8 while in rats treated with resveratrol 25 mg/kg
body weight intraperitoneally for 60 days a significant increase in thyroid size along with higher serum
TSH levels compared with control rats were found [60].
Regarding the role of resveratrol as antineoplastic agent, it has been recently reported that this
compound inhibits cell proliferation through STAT3 signaling involvement [61] and reverses retinoic
acid resistance of anaplastic thyroid cancer cells [62].
More importantly, resveratrol sensitizes selectively thyroid cancer cells to 131-iodine toxicity,
while it exhibited radioprotective effects on normal cells, thus for these beneficial actions, resveratrol
might improve the treatment of patients with thyroid cancer during radioiodine therapy [63].
In the thyroid setting, the proliferation of thyroid tumoral cells can be stopped by resveratrol,
due to the resveratrol-induced increases the quantity and phosphorylation of p53 [1]. Resveratrol also
has an action on iodine trapping, for which it appears to be a promising anti-thyroid drug. Overall,
the in vitro and in vivo data indicate that resveratrol may act as a thyroid disruptor and a goitrogen,
which should be taken into account for potential therapeutic use of resveratrol or as a supplement.
8. Selenium
The chemical non-metal element selenium is an essential micronutrient necessary for cellular
function. Selenium exerts its nutritional functions in the form of the amino acid selenoCysteine (SeCys)
inserted into a group of proteins known as selenoproteins, some of which are the antioxidant enzymes,
glutathione peroxidase (GSH-Px) and thioredoxin reductase, and the three deiodinases of thyroid
hormones [64]. The major sources of selenium intake are meat and meat products (31%), fish and
shellfish (20%), pasta and rice (12%), and bread and breakfast cereals (11%), while the largest selenium
concentrations (1 mg/kg) are found in Brazil nuts and offal [64].
One study investigated the improving effects of selenium on cerebrum and cerebellum impairments
caused by the MMI-induced hypothyroidism in suckling rats [65]. Pregnant rats were randomized
into 4 groups to receive control diet, MMI alone, MMI plus selenium, or selenium alone. Treatments
were given from the 14th day of pregnancy until day 14 after delivery. Following the treatment with
MMI, a reduction in plasma levels of FT3 and FT4, protein, DNA and RNA contents in cerebrum and
cerebellum was observed, in comparison to controls. These parameters improved after cotreatment
with selenium. Furthermore, antioxidant enzyme activities (SOD, CAT, GSH-Px) decreased significantly
in the group treated with MMI, while malonaldialdehyde (MDA) levels in cerebrum and cerebellum
raised. Co-administration of selenium restored these parameters to near normal values. The authors
concluded that selenium improved the cerebral and cerebellar damages induced by MMI in suckling
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rats, and because of such neuroprotection selenium could be used as a dietary supplement against
brain impairments [65].
Laureano-Melo and colleagues [66] evaluated potential behavioral alterations in offspring of female
rats supplemented with sodium selenite during pregnancy and lactation. Selenium supplementation
raised T3 and T4 serum levels, decreased tryptophan hydroxylase 2 expression and cholinesterase
activity, and increased tyrosine hydroxylase expression in the hippocampus. In childhood, the
selenium-supplemented offspring had a decrease in anxiety-like behavior; in adulthood, the locomotor
activity and rearing episodes increased in selenium-treated pups. These findings demonstrated that
maternal supplementation by sodium selenite induced psychobiological alterations during childhood
and adulthood, probably caused by neurochemical changes generated by TH during the critical period
of the central nervous system ontogeny [66].
One study evaluated the effect of selenium on CD4(+)CD25(+)Foxp3(+) regulatory T cells (Treg) by
using an iodine-induced AIT model [67]. This study aimed to explain clinical observations concerning
decreased serum levels of thyroid autoantibodies in patients with autoimmune thyroiditis (AIT).
NOD.H-2(h4) mice received 0.005% sodium iodine (NaI) water for 8 weeks, and AIT was induced.
The group of selenium-treated mice were fed 0.3 mg/L sodium selenite in drinking water. AIT mice
showed fewer Treg cells and lower Foxp3 mRNA expression in splenocytes compared to controls
(P < 0.01). However, both Treg cells and Foxp3 mRNA expression increased after the treatment
with selenium, in comparison to untreated AIT mice (P < 0.05). Moreover, selenium-treated AIT
mice had lower serum Tg antibody (TgAb) titers and reduced lymphocytic infiltration in the thyroid
than untreated AIT mice. These findings suggested that selenium supplementation, through the
up-regulation of the Foxp3 mRNA expression, can restore normal levels of CD4(+)CD25(+) T cells in
mice with AIT [67].
In the thyroid oncology setting, data are available for human cell lines of thyroid malignancy ARO
(anaplastic), NPA (BRAF positive papillary), WRO (BRAF negative papillary), and FRO (follicular)
cells treated with 150 microM seleno-l-methionine (SM) were assessed for viability at 24, 48, and
72 h. Seleno-methionine treatment was found to inhibit thyroid cancer cell proliferation through the
overexpression of GADD (growth arrest and DNA damage inducible) family genes and cell cycle arrest
in S and G2/M phases [68].
Although these data are intriguing, the available evidence on the relationship between selenium
and thyroid cancer is yet inconclusive [69].
9. Vitamins
9.1. Vitamin A
Vitamin A deficiency (VAD) and iodine deficiency (ID) are major global public health problems,
affecting more than 30% of the population worldwide. VAD can adversely affect thyroid metabolism [70].
A study investigated the effect of concurrent vitamin A and ID on the thyroid-pituitary axis in rats [70].
Weaning rats received for 30 days a diet deficient in vitamin A (VAD group), iodine (ID group), vitamin
A and iodine (VAD+ID group), or sufficient in both vitamin A and iodine (control). Serum retinol levels
were ~35% lower in the VAD and VAD+ID groups (P < 0.001), in comparison to controls and ID groups.
No significant differences in TSH, TSH-beta mRNA, thyroid weight, or TH levels, were observed in the
VAD and control groups, while they were higher in the VAD+ID and ID groups, and FT4 and TT4
were lower compared to controls. The authors concluded that moderate VAD alone has no measurable
effect on the pituitary-thyroid axis, and that concurrent ID and VAD produce more severe primary
hypothyroidism than ID alone [70]. Repletion studies in VAD and ID animals suggested: a) In animals
with concurrent moderate VAD and ID, primary hypothyroidism does not reduce the effectiveness
of high doses of oral Vitamin A; b) VAD does not lower the effectiveness of dietary iodine to correct
pituitary-thyroid axis dysfunction due to ID; c) without iodine repletion, high-dose Vitamin A alone in
combined VAD and ID could decrease both thyroid hyperstimulation and the risk for goiter [71].
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One Chinese study [72] moved from the fact that the interconnections among neural tube defects
(NTDs) and TH or vitamin A have been investigated previously but the interaction between the TH
and vitamin A pathways were not elucidated. The authors measured the expression levels of TH
signaling genes in human fetuses with spinal NTDs associated with maternal hyperthyroidism, and the
levels of retinoic acid (RA) signaling genes in mouse fetuses exposed to an overdose of RA on spinal
cord tissues [72]. The promoters of cellular retinoic acid-binding protein 1 (CRABP1) and retinoic acid
receptor beta (RARB) (both being RA signaling genes) were ectopically occupied by elevated retinoid
X receptor gamma (RXRG) and retinoid X receptor beta (RXRB), but had lowered levels of inhibitory
histone modifications, indicating that elevated TH signaling improperly induces RA signaling genes.
On the contrary, the observed decrease in deiodinase type 3 (Dio3) expression in the mouse model
could be explained by raised levels of inhibitory histone modifications in the Dio3 promoter region,
indicating that overactive RA signaling could ectopically derepress TH signaling. These data led to
hypothesize a potential improper cross-promotion in vivo between two different hormonal signals
through their common RXRs, and then histone modifications recruitment [72].
In FRTL-5 cells, all-trans retinoic acid (ATRA) exerts protective role attenuating endoplasmic
reticulum (ER) stress-induced alteration of NIS by modulating the phosphorylation of p38 MAPK [73].
ATRA has been also known to induce in vitro radioiodine uptake and to inhibit cell proliferation
and invasion of human thyroid carcinoma cells [74,75], thus making this molecule a promising drug
able to improve the isotope sensitivity of the most aggressive thyroid carcinoma.
9.2. Vitamin D
Cholecalciferol (or vitamin D3) is synthetized in the skin upon the exposure to ultraviolet B
radiation, and it is also introduced from few dietary sources (such as fatty fish). Ergocalciferol (vitamin
D2) is synthesized by plants and fungi. Both forms are hydroxylated to 25-hydroxyvitamin D in the
liver [76].
Mice, previously sensitized with porcine Tg, and injected intraperitoneally with/without calcitriol
(0.1–0.2 μg/kg body weight/die), showed a minor severity of thyroid inflammation vs mice treated with
placebo [77]. This effect was even higher in the case of injection with calcitriol and cyclosporine [78].
In another study, mice were pre-treated with intra-peritoneal injection of calcitriol (5 μg/kg every
48 h) before sensitization with porcine Tg. The thyroid did not show the standard inflammation signs
compared to controls, indicating a protective role of vitamin D in preventing thyroiditis [79].
The effect of vitamin D was also investigated in animal models of Graves’ disease (GD) [80].
By immunization with adenovirus encoding the A-subunit of thyrotropin receptor, BALB/c mice
became model of GD. Hyperthyroid BALB/mice fed with a vitamin D deficient diet showed fewer
splenic B cells, decreased interferon-gamma responses to mitogen and lack of memory T-cell responses
to A-subunit protein, with respect to mice fed with a regular diet. No differences in TSHR antibody
levels were observed. Furthermore, vitamin D deficient BALB/c mice had lower pre-immunization
T4 levels and developed persistent hyperthyroidism, indicating that vitamin D is able to modulate
thyroid function in this animal model [80].
A study investigated the potential pathophysiological mechanisms for hypocalcaemia in
hyperthyroid cats [81]. Hyperthyroid cats had lower ionized calcium levels than healthy geriatric cats,
and ionized calcium concentrations were higher in hyperthyroid cats with concomitant or masked
chronic kidney disease than non-uremic hyperthyroid cats. Moreover, hyperthyroid cats had higher
plasma calcitriol concentrations than control cats. In hyperthyroid cats, hypocalcaemia was not
associated with concomitant or masked chronic kidney disease or reduced plasma calcitriol levels.
Elevated TH concentrations might influence ionized calcium levels independently from the control by
parathyroid hormone and calcitriol [81].
Evidence suggests that vitamin D can negatively regulate the entire process of tumorigenesis,
from initiation to metastasis by multiple mechanisms including the regulation of growth factors, cell
cycle and signaling pathways [82]. Indeed, it has been largely reported the antineoplastic activities
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of vitamin D alone and/or in combination with other agents on thyroid cancer cells [83–85]. These
findings suggest that the activation of vitamin D signaling could be a promising strategy for prevention,
as well as treatment of thyroid cancer.
9.3. Vitamin E
Due to its ability to scavenge free radicals, vitamin E is considered an antioxidant. Vitamin E is
also very active in the antioxidative protection of thyroid cells membranes, and it is concentrated in the
thyroid in control rats, and increased two fold in goiters. Acute and excessive iodine supplementation
can cause iodine-induced thyroid cyto-toxicity, that is probably due to an excessive oxidative stress.
A study aimed to investigate whether vitamin E could improve iodine-induced thyroid cytotoxicity [86].
Rats received a low-iodine (LI) diet for 12 weeks and developed goiter. A 50-fold vitamin E dose
could attenuate two fold iodine-induced thyroid cytotoxicity, even if weight or relative weight of the
iodine-induced involuting gland was not diminished by its supplementation, showing that excess
iodine can cause thyroid damage and vitamin E can improve in part the iodine-induced thyroid
cytotoxicity [86].
In Sprague–Dawley rats, the oxidative stress status of the serum and hippocampus in
hypothyroidism, and the effect on cognitive deficit, of L-T4 replacement therapy with vitamin E
supplementation, were evaluated. It was shown that L-T4 replacement therapy with vitamin E
can improve cognitive deficit in propylthiouracil (PTU)-induced hypothyroidism by decreasing the
oxidative stress status [87]. Another study confirmed that L-T4 replacement therapy in combination
with vitamin E reduces hippocampus cellular apoptosis index by ameliorating oxidative stress,
suggesting that in a hypothyroid rat model the mechanisms of hippocampus tissue damage are
associated with hippocampus apoptosis caused by a marked oxidative stress [88].
The role of vitamin E and curcumin has been investigated on hyperthyroidism-induced
mitochondrial oxygen consumption and oxidative damage to lipids and proteins of rat liver [89]. Adult
male rats received 0.0012% L-T4 in their drinking water and became hyperthyroid, and vitamin E
(200 mg/kg body weight) and curcumin (30 mg/kg body weight) for 30 days. Both vitamin E and
curcumin have differential regulation on complexes I and II mediated-mitochondrial respiration and
were protective against hepatic dysfunction and oxidative stress induced by L-T4 [89].
Another study, conducted in Labeo rohita juveniles fed normal or increased levels of vitamin
E and tryptophan for 60 days and then exposed to sub-lethal nitrite for another 45 days without
changing their diet, reported that the negative impact on steroidogenesis exercised by environmental
nitrites could be bypassed by supplementation of high levels of vitamin E and to a lesser extent of
tryptophan [90].
Recently, vitamin E has been found in combination with curcumine and piperine to exert inhibitory
effect on cell proliferation through influencing cell cycle regulators such as β-catenin, cyclin D1 and
p53 in human thyroid papillary carcinoma cells; however, further studies are necessary to candidate
vitamin D as alternative cancer therapy [91].
10. Zinc
The negative effect of zinc deficiency and positive effect of zinc supplementation on thyroid
function of adult male rats (as measured by serum FT3 and FT4 levels) have been mentioned
above [36,37]. In these rats, circulating zinc levels are increased in hyperthyroidism and decreased in
hypothyroidism [38].
In adult male rats, thyroid function has been slightly damaged by the oral administration of 3 mL
30% ethanol [92]. The moderate decrease in serum T3 and T4 and increase in serum TSH was reversed
by the 8-week administration of zinc (Zinc sulfate, 227 mL in the drinking water). Of note, serum Zn
levels were low upon ethanol feeding, but they were restored to normal levels after Zn supplementation.
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In contrast with the above data on adult male rats [36,37], there are findings from obese mice [93] and
from small ruminants [94]. Obese mice and lean controls received a basal diet or a zinc-supplemented
diet (200 mg/kg diet) for 8 weeks. After the basal diet, obese mice had lower serum and hepatic T4 and
T3 levels than lean mice (P < 0.05). Zinc supplementation diminished significantly circulating T4 levels
in both groups [93]. A total of 24 healthy male ruminants (12 lambs and 12 goats) were subdivided in
2 groups: Control or Zn group [94]. Control lambs and goats received basal rations alone (40 mg/kg
and 35 mg/kg in dry matter, respectively). Both species of animals in the Zn group received a basal
ration added with zinc sulphate up to a dose of 250 mg Zn/kg. The treatment lasted for 12 weeks
in lambs and 8 weeks in goats. Animals receiving Zn showed more elevated plasma Zn levels than
controls during all the experimental period, excluding the 4th week in goats. Compared to controls,
the levels of serum total T4 and total T3 were lower in lambs and goats receiving Zn, except in the 4th
week. Furthermore, circulating total TH levels of the goats were higher at the 4th week than at the
8th week. Even if a decrease (vs. controls) in the levels of free T4 and free T3 of both small ruminant
species in the Zn groups was present, it was not statistically significant [94].
In another study, adult male rats were supplemented for 45 days with either zinc (227 mg/L) or
magnesium (100 mg/Kg body weight) and then treated with daily intraperitoneal injection of 100 mg/kg
body weight of alloxan for 15 days (days 46 to 60) to induce diabetes mellitus. Circulating total
cholesterol, triglyceride, and glucose levels were higher while serum T3 and T4 were lower in diabetic
rats than controls. Zinc supplementation did not change any parameter in diabetic rats, whereas
magnesium decreased the elevated total cholesterol and triglyceride levels of the diabetic rats to the
control level [95].
FRTL-5 cell model, derived from a Fischer rat thyroid and displaying follicular cell phenotype,
was used to study the effect of zinc depletion, upon the zinc-specific chelator N,N,N0,N0-tetrakis
(2-pyridylmethyl) ethylene-diamine, on thyroid function. In this experimental setting which would
mimic the in vivo condition, Tg secretion was decreased. Proteomic analyses performed comparing
data from zinc depleted/repleted thyroid cells have identified 108 proteins modulated by intracellular
zinc status with important physiopathological implications for this endocrine tissue [96].
11. Inositol
Inositol is a water-soluble compound strictly related to the vitamin B group (also called vitamin
B8). Its most abundant form is myo-inositol [97].
That myo-inositol plays an important role in the thyroid gland can be inferred by the evidence, in
male rats, that radioactive myo-inositol is accumulated rapidly (within 1 h) by the thyroid [98].
A previous study in primary cultures of sheep and human thyrocytes demonstrated the TSH
regulates myo-inositol transport through an increased phospholipase A2-mediated turnover of
phosphatidylinositol and a simultaneous increase in arachidonic acid turnover [99]. Biosynthesis
of myo-inositol has been investigated in hypophysectomized and thyroidectomized male rats [100].
It was shown that inositol-1-phosphate synthase is controlled by the pituitary in the reproductive
organs and by the thyroid in the liver [100].
Myo-inositol is the precursor for the synthesis of phosphoinositides, implicated in the
phosphatidylinositol (PtdIns) signal transduction pathway, and it is involved in different cellular
processes. In the thyroid cells, PtdIns takes part in the intracellular TSH signaling, via Phosphatidylinositol
(3,4,5)-trisphosphate (PtdIns(3,4,5)P3) (PIP-3) [101].
In a recent systematic review on metabolite profile alterations of thyroid cells myo-inositol has
been suggested as a thyroid cancer oncometabolite [13].
The effects of inositol supplementation on serum levels of thyroid hormones were evaluated in
dairy cows [102]. The supplementation decreased circulating T3 and FT3 concentrations, but not T4
and FT4 concentrations [102].
In humans, it has been shown that the increased levels of TSH declined in patients with AIT and
subclinical hypothyroidism, treated with myo-inositol and seleno-methionine. The concentration of
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both TPOAb and TgAb decreased in both groups. The supplementation with seleno-methionine alone
was not able to promote the same reduction [103].
Another paper first showed an immune-modulatory effect of myo-inositol in association with
seleno-methionine in patients with euthyroid AIT [104].
A paper reported the beneficial effects of myo-inositol, seleno-methionine or their combination on
peripheral blood mononuclear cells (PBMC) exposed in vitro to hydrogen peroxide (H2O2)-induced
oxidative stress in both control and women with Hashimoto’s thyroiditis (HT) [105]. PBMC, from 8 HT
women and 3 controls, were cultured in the presence of H2O2 alone, or with subsequent addition of
myo-inositol, seleno-methionine, or their combination. H2O2 alone decreased PBMC proliferation, and
it decreased furtherly and dose-dependently in either group. Moreover, H2O2 alone reduced vitality
both in controls and HT women, but vitality was rescued by the three additions, contrasting also
genotoxicity. Chemokines levels were increased by H2O2 alone (more in HT women than in controls),
and each addition dose-dependently decreased these concentrations in either group, particularly with
Myo+SelMet [105].
Another study investigated whether myo-inositol alone, or its combination with seleno-methionine,
is effective in protecting thyrocytes from the effects given by cytokines, or H2O2 [106]. H2O2 had a toxic
effect in primary thyrocytes increasing the apoptosis, and decreasing the proliferation, slightly reducing
cytokines-induced CXCL10 secretion. The interferon(IFN)-γ+ tumor necrosis factor alpha(TNF)-α
induced secretion of CXCL10 was reduced by myo-inositol+seleno-methionine, in both the presence or
absence of H2O2. Seleno-methionine alone had no effect. These findings suggested a protective effect
of myo-inositol on thyroid cells [106].
Finally, the beneficial effects of myo-inositol, either alone (2.5 g/kg/day in the drinking water) or
administered in association with T3 (30 micrograms.kg-1.day-1 s.c.), were investigated on the cardiac
lipid content and function of streptozocin-induced diabetic (STZ-D) rats [107]. The elevations in both
plasma and myocardial lipids associated with diabetes were prevented by myo-inositol treatment.
Moreover, a partial improvement in cardiac performance of STZ-D rats was observed in the group
treated with myo-inositol alone and the group treated with myo-inositol plus T3 [107].
12. Conclusions
Nutraceuticals have a place in complementary medicines, defined as a “food, or parts of a food,
that provide medical or health benefits, including the prevention and treatment of disease” [2], for
the prevention of different pathological conditions, including thyroid diseases. Thyroid supplements
have gained lots of attention in the last years. Iodine is the major nutrient for thyroid function, but
also other dietary components can have a key role in clinical thyroidology. In this review, we have
summarized the cell cultures and animal studies present in literature, focusing on the commonest
nutraceuticals generally encountered in the clinical practice (such as carnitine, flavonoids, melatonin,
omega-3, resveratrol, selenium, vitamins, zinc, inositol), highlighting conflicting results (Table 3 and
Figure 1). These experimental studies are expected to improve the clinicians’ knowledge about the
main supplements being used, in order to clarify the potential risks or side effects and support patients
in their use.
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Table 3. Summary of the main findings.
Compounds Main Findings References
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antidepressant effect





















vitamin D immunoregulationantineoplastic effects
[77–80]
[82]
vitamin E antioxidative protectionantineoplastic effects
[86–89]
[91]
zinc modulation thyroid function [36–38,92–96]
inositol
involvement in the intracellular TSH signaling, via PIP-3
inositol supplementation decreased circulating T3 and FT3
concentrations
thyroid diagnostic oncometabolite
the treatment, in combination with seleno-methionine,
declined the elevated levels of TSH in patients with AIT
and subclinical hypothyroidism
immune-modulatory effect of myo-inositol in association
with seleno-methionine in patients with euthyroid AIT
beneficial effects of myo-inositol, seleno-methionine or
their combination on PBMC exposed in vitro to
H2O2-induced oxidative stress in both control and women
with HT
protective effect of myo-inositol on thyroid cells
myo-inositol, either alone or in association with T3










AIT, autoimmune thyroiditis; H2O2, hydrogen peroxide; HT, Hashimoto’s thyroiditis; PIP-3, Phosphatidylinositol
(3,4,5)-trisphosphate (PtdIns(3,4,5)P3); PBMC, peripheral blood mononuclear cells.
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Figure 1. Summary of the main findings. NIS, sodium/iodide symporter; TPO, thyroid peroxidase;
AIT, autoimmune thyroiditis.
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Abstract: In recent years, there has been a growing interest in nutraceuticals, which may be considered
as an efficient, preventive, and therapeutic tool in facing different pathological conditions, including
thyroid diseases. Although iodine remains the major nutrient required for the functioning of the
thyroid gland, other dietary components play important roles in clinical thyroidology—these include
selenium, l-carnitine, myo-inositol, melatonin, and resveratrol—some of which have antioxidant
properties. The main concern regarding the appropriate and effective use of nutraceuticals in
prevention and treatment is due to the lack of clinical data supporting their efficacy. Another limitation
is the discrepancy between the concentration claimed by the label and the real concentration. This
paper provides a detailed critical review on the health benefits, beyond basic nutrition, of some popular
nutraceutical supplements, with a special focus on their effects on thyroid pathophysiology and aims
to distinguish between the truths and myths surrounding the clinical use of such nutraceuticals.
Keywords: nutraceuticals; thyroid function; dietary supplements
1. Introduction
1.1. Definition of Nutraceutical
The definition of nutraceuticals is still in the grey area between food, food supplements, and
pharmaceuticals. Some definitions [1–5] of nutraceuticals are provided in Table 1. The term
“nutraceutical” was coined in 1989 by Stephen De Felice, founder and chairman of the Foundation for
Innovation in Medicine, an American organization which encourages medical health research. He
defined a nutraceutical as a “food, or parts of a food, that provide medical or health benefits, including
the prevention and treatment of disease” [4]. Japan was among the first countries to face the issue
of regulating food supplements and foodstuffs. This legislation, originally set in 1991, evolved into
the 2003 Health Promotion Law [5]. The current European regulation (Regulation No. 1924/2006 of
the European Parliament and of the Council, recently updated by EU Regulation 2015/2283) defines
food categories and includes a definition of food supplements, although there is no official mention or
recognition the term “nutraceutical” [6]. Accordingly, the European Food Safety Authority (EFSA)
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does not make any distinction between “food supplements” and “nutraceuticals” for beneficial health
claim applications for new products. In a similar way, the Dietary Supplement Health and Education
Act (DSHEA, 1994) [7] defined dietary supplements as a category of food, as did the US Food and
Drug Administration (FDA) [8]. Indeed, in America “medical foods” and “dietary supplements” are
regulatory terms, however “nutraceuticals”, “functional foods”, and other such terms are determined by
consultants and marketers, based on consumer trends. Further information on the dietary supplements
given by the Food and Drug Administration (FDA) on its website [9] is summarized in Appendix
Table A1.
Table 1. Some definitions of “nutraceutical”.
Reference Definition
[1] “A foodstuff (such as a fortified food or dietary supplement) that provides health benefits inaddition to its basic nutritional value. (First known use: 1990)”.
[2] “A food to which vitamins, minerals, or drugs have been added to make it healthier.”
[3]
“Nutraceuticals, which have also been called medical foods, designer foods, phytochemicals,
functional foods and nutritional supplements, include such everyday products as “bio”
yoghurts and fortified breakfast cereals, as well as vitamins, herbal remedies and even
genetically modified foods and supplements. Many different terms and definitions are used in
different countries, which can result in confusion.”
[4]
“I propose to redefine functional foods and nutraceuticals. When food is being cooked or
prepared using “scientific intelligence” with or without knowledge of how or why it is being
used, the food is called ‘functional food’. Thus, functional food provides the body with the
required amount of vitamins, fats, proteins, carbohydrates, etc., needed for its healthy survival.
When functional food aids in the prevention and/or treatment of disease(s) and/or disorder(s)
other than anemia, it is called a nutraceutical.”
[5]
Nutraceutical combines two words the term ‘nutrition/nutrients’ (a nourishing food
component) and ‘pharmaceutical’ (medicine or a substance used as a medication) applied to
food or food component products sometimes with active principle from plants that can
provide health and medical benefits, including the prevention and treatment of disease.
1.2. Search of the Literature
A PubMed search, run on 14 July 2017, using the word “nutraceutical” as the entry, yielded
67,344 results. Results fell to 4820 using the entry “nutraceuticals AND hormones” and to 553 using
the entry “nutraceuticals AND thyroid”. Approximately 18 months later (5 February 2019), the
corresponding numbers were 78,919 (+17%), 5538 (+15%) and 642 (+16%), indicating that the interest
in the thyroid proceeds with the same pace as that for nutraceuticals in general and hormones in
general. Confirmation of these data came from a final search that was run on 9 July 2019 (Table 2).
In the following text, different nutraceuticals possibly influencing human thyroid function and/or
immunity will be reviewed and commented upon.
A general effect of the nutraceuticals beyond the thyroid effect is not within the scope of this
review, nor is a meticulous review of animal or other experimental studies. We were guided by
our clinical practices, particularly those for which patients were most curious. As mentioned in the
following section, there is indeed a growing market for such nutraceuticals.
There was relatively scant literature on the topic, and most research focused on thyroid cancer
and was experimental in nature, concerning the nutraceuticals illustratively mentioned by the Food
and Drug Administration, as shown in Appendix Table A1.
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Table 2. Summary of number of articles on given nutraceuticals retrievable on PubMed as of 9 July 2019.
Entry
No. of Items Proportions
Total Human Human/Total Thyroid/Total Thyroid/Human
1 nutraceuticals 81,422 52,406 64.4% N/A N/A
2 nutraceuticals AND hormones 5698 3664 61.4% N/A N/A
3 nutraceuticals AND thyroid 656 487 74.2% 0.8% 0.9%
4 carnitine 16,737 7831 46.8% N/A N/A
5 carnitine AND thyroid 145 68 46.9% 0.9% 0.9%
6 inositol 44,801 16,700 37.3% N/A N/A
7 inositol AND thyroid 295 141 47.8% 0.6% 0.8%
8 melatonin 24,921 10,740 43.1% N/A N/A
9 melatonin AND thyroid 514 195 37.9% 2.1% 1.8%
10 resveratrol 11,983 5447 45.4% N/A N/A
11 resveratrol AND thyroid 78 47 60.2% 0.6% 0.9%
12 selenium 33,980 13,333 39.2% N/A N/A
13 selenium AND thyroid 938 576 61.4% 2.8% 4.3%
Note that the number of items under the keyword “nutraceuticals” underestimates the bulk of the literature. Indeed,
by adding items #4, 6, 10, 12, 14 and 16 the sum is 164,513, which is greater than 81,422 for item #1. Similar
considerations apply for the corresponding human studies (67,565 vs. 52,406), and for the thyroid studies (total
studies = 2305 vs. 656; human studies = 1269 vs. 487).
1.3. Market and Sales
Based on data from a decade ago, annual supplement sales were $23 billion, and about 40,000
supplement products were on the market in the United States [10]. In 2015, the American market for
dietary supplements was valued at $37 billion, with the economic impact in the United States for 2016
estimated at $122 billion, including employment wages and taxes [11]. One 2016 analysis estimated
the total market for dietary supplements could reach $278 billion worldwide by 2024 [11]. Table 3
summarizes the details for the nutraceuticals reviewed here [12–16].
Table 3. Economic issues for the reviewed nutraceuticals.
Nutraceutical Market and Sales ˆ
l-carnitine
l-carnitine market is expected to be worth USD 127 million by 2017, with the United States
being the largest market, and the Asia-Pacific region, particularly China, expected to
experience a 5.5% annual growth rate through 2017 [12].
No. of items on sale-Amazon: 53; Walgreens: No match; CVS Pharmacy:13.
Myo-inositol
In the consumption market, the global consumption value of inositol increases with the
2.01% average growth rate. Europe and China are the mainly consumption regions [11].
With myo-inositol being the most common form of inositols, over the next five years the
inositol market, will register a 6.8% compound annual growth rate in terms of revenue, the
global market size will reach US $140 million by 2024, from US $94 million in 2019 [13].
No. of items on sale-Amazon: 3; Walgreens: No match; CVS Pharmacy: No match.
Melatonin
The North America region is the largest supplier of melatonin, with a production market
share nearly 54% in 2016, Europe coming next with 27% [14]. The global market size will
reach US $2080 million by 2024, from US $700 million in 2019 [14].
No. of items on sale-Amazon: 122; Walgreens: 11; CVS Pharmacy: 91.
Resveratrol Resveratrol supplements, with annual sales of $30 million in the United States [15]No. of items on sale-Amazon: 45; Walgreens: No match; CVS Pharmacy: 19.
Selenium Selenium market reached $87 million U.S. in 2017 [16].No. of items on sale-Amazon: 91; Walgreens: No match; CVS Pharmacy: 84.
ˆ Numbers in brackets are references. Internet sales by Amazon, Walgreens and CVS Pharmacy are reported. Search
was performed for the pure nutraceutical, such as entering “pure melatonin”. Search performed on the Amazon
website by omitting the word “pure”, yielded a greater number of results (973 for l-carnitine, 48 for myo-inositol,
178 for resveratrol, over 1000 for selenium, and over 1000 for biotin). Search on the Walgreens website by omitting
the word “pure”, yielded a greater number of results (12 for l-carnitine, 1 for myo-inositol, 107 for melatonin, 10 for
resveratrol, 21 for selenium, and 71 for biotin).
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1.4. The Issue of Purity
“The biggest problem with supplements is that many of them do not actually contain what the
label claims. As many as 70% of the supplements on the market either don’t have ingredients that match
their labels or contain contaminants of some kind” [17]. In his review, Lockwood aimed to investigate
the extent of substandard formulated and raw material nutraceuticals [17]. The key findings were that
“published evaluations of over 70 formulations of 25 different nutraceuticals revealed variable quality;
no nutraceutical showed consistent high quality, but a number revealed consistent low quality, thereby
making the case for closer regulation of manufacturers. Whole food sources have also been shown
to be widely variable in constituent levels.” [17]. Concerning the issue of purity, the illegal presence
of thyroid hormones in the majority of dietary health supplements marketed for “thyroid support”
potentially exposes patients to the risk of developing iatrogenic thyrotoxicosis [18].
In the following text, we now give some data concerning the nutraceuticals dealt upon in our
paper. Concerning carnitine, of 12 over-the-counter carnitine formulations, the actual mean content
was only 52% of that indicated on the label [19]. Furthermore, of the same 12 preparations, five had
unsatisfactory pharmaceutical dissolution characteristics.
Concerning myo-inositol, one study evaluated label accuracy of four myo-inositol products,
designed for polycystic ovary syndrome (PCOS) treatment and available on the Italian market, and
performed a cost comparison based on myo-inositol content in milligrams for products analyzed [20].
A significant difference in the myo-inositol content, compared with the labeling was found for the
products. Only one product contained more than 95% of the myo-inositol content claimed on the label,
and there was a product with less than 75% of the labeling amount. Based on a 2-g myo-inositol per
day dose, the cost of a 30-day supply ranged from Euro 20.77 and Euro 71.86, after correction by the
actual amount of myo-inositol.
One recent study aimed to determine the dose of melatonin in food supplements marketed in
Europe (pharmacies of Spain) and the United States (supermarkets of San Francisco, CA, USA) by
validating a liquid chromatography method with diode array detection (LC-DAD) [21]. The authors
tentatively identified eight tryptophan-related contaminants in melatonin supplements, with only one
supplement declaring its addition on the label. Label melatonin doses varied from 1–1.95 mg/unit and
0.3–5 mg/unit for supplements marketed in Europe (Spain) and the US, respectively. Four out of 17
supplements showed significant deviations from melatonin content declared on the label (from −60%
to −20%). Only five out of the eight supplements purchased in Spain actually met the qualifications
needed to claim to reduce the time to fall asleep. Another study analyzed the actual melatonin content
(and presence of contaminants) in 31 melatonin supplements purchased from groceries and pharmacies
in one city in Canada [22]. Melatonin content varied from −83% to +478% of labeled melatonin and
approximately three-fourths had melatonin concentration ≤10% of what was claimed. Worse yet, the
content of melatonin between lots of the same product varied by as much as 465%. An additional 26%
of the 31 melatonin supplements were found to contain serotonin.
Concerning resveratrol, 14 brands of resveratrol-containing nutraceuticals were evaluated [23].
The 14 preparations were purchased directly from online stores during 2010 and were analysed
before their expiry dates. Only five out of 14 brands had near label values, compliant with Good
Manufacturing Practices (GMP) requirements (95%–105% content of active constituent), four products
were slightly out of this range (83%–111%) and three were in the 8%–64% range. Two samples were
below the limit of detection. The greater the difference between actual and labeled resveratrol content,
the lower the antioxidant and antiproliferative activity strength.
With regard to selenium, one study analysed six different brands of yeast-based selenium food
supplements that were obtained from local stores [24]. These supplements were treated with milder
extraction and hydrolysis conditions to analyse for the expected selenomethionine content. Only two
brands had high levels of selenomethionine, one brand appeared to contain all inorganic selenium,
and one brand appeared to contain greater than half inorganic selenium despite label claims of content
being only selenomethionine.
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2. Carnitine: Compound and Physiology
Carnitine is a quaternary ammonium compound (3-Hydroxy-4-(trimethylazaniumyl) butanoate)
that is ubiquitous in tissues and biological fluids of mammals [25]. The natural enantiomer is l-carnitine,
which acts as an obligatory cofactor for β-oxidation of fatty acids by facilitating the transport of the
long-chain fatty acids across the mitochondrial inner membrane as acyl-carnitine esters. This oxidation
liberates energy via the production of ATP in the respiratory chain, thus playing a role in cell’s energy
metabolism. Particularly, l-carnitine exerted a physiological benefit with a positive impact on cardiac
function through reduced oxidative stress, inflammation and necrosis of cardiac myocytes. [26]. Only
25% of the body stores of carnitine come from biosynthesis and 75% comes from the diet. The main
source is red meat and dairy products. Muscles are the most prominent carnitine depository since
they store about 95% of the 120 mmol total amount contained in the adult human body, and the
concentration in skeletal muscle (3.5 mmol/L) is 70-fold greater than that in plasma.
The main interest in carnitine supplementation comes from athletes and other physical exercise
performers [27]. Thus, repeated-dose carnitine supplements may increase skeletal muscle content.
For instance, long-distance runners given a daily dose of 2 g carnitine for 28 days and subjected to a
four-week training period [28] increased skeletal muscle carnitine by approximately 13% as compared
to a decrease of about 10% in placebo-treated athletes. In other athletes, supplementation with 1
g/day carnitine for 120 days of training increased carnitine concentrations in skeletal muscle by an
average of 9% compared to a decrease of 5% in the placebo-treated athletes [29]. Carnitine is critical
for normal skeletal muscle bioenergetics [30–32], and skeletal muscles suffer seriously in states of
carnitine deficiency. A relative carnitine deficiency can occur in athletes as a result of increased energy
metabolism, unbalanced nutrition, decreased skeletal muscle content and increased renal excretion of
carnitine. The important energetic role of carnitine, the relative deficiency associated with sustained
physical exercise, and the fact that carnitine is a natural compound, has led healthy subjects aiming
to improve their exercise performance to conclude that “more carnitine should be better [30–32], but
basically this was proven to be without any beneficial effect.
Carnitine and Thyroid Function
A German group of authors conducted pivotal clinical studies as early as 1959 in a very limited
number of patients with Graves’ disease, using a mixture of the two isomers (l-and d-carnitine) [33].
The first patient was a 53-year-old bedridden woman with very severe Graves’ disease and nervousness,
insomnia, weight loss, sweating, tachycardia and Graves’ orbitopathy. Basal metabolic rate (BMR)
was +82%, and she was administered 1 g/d d,l-carnitine. After 10 days, BMR was unchanged but one
week later it fell to +59%. Five weeks after starting d,l-carnitine, BMR was still +50% and the authors
switched to the naturally occurring l-carnitine. After only 10 days BMR dropped more rapidly to
+8% with associate improvement in general well-being and heart rate. Atrial fibrillation disappeared
and heart rate was 80–90 beats/min. To prove that the improvement was due to l-carnitine, it was
withdrawn in the 7th week from admission. BMR rose to +39%, but after rechallenge with l-carnitine
it fell again to +18% [33].
In the English-language literature, the first three monotherapy carnitine-treated hyperthyroid
patients were reported in the mid-1960s [34]. The authors found that patients became clinically
euthyroid without any consistent changes in the thyroid function tests, thus supporting the notion
that the antithyroid effect of carnitine is one of peripheral antagonism of thyroid hormone, rather
than a direct inhibition of thyroid gland function [35]. This was consistent with human tissue culture
experiments where l-carnitine inhibited both cell entry and, to a greater extent, nuclear entry of both T3
and T4 [36]. These data are consistent with carnitine being a peripheral antagonist of thyroid hormone
action, with a site of inhibition at or before the nuclear envelope [36].
The first controlled clinical trial addressing the value of l-carnitine in antagonizing elevated
circulating levels of thyroid hormones was conducted in 50 women under Thyroid stimulating
hormone (TSH)-suppressive l-T4 therapy for cytologically benign thyroid nodules who received
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a simultaneous treatment for six months with placebo (n = 10), or for given periods of time with
l-carnitine (2g/d or 4 g/d to test dose-dependence) [37]. Evaluation by both extensive clinical and
biochemical assessment demonstrated positive effects with the exception of osteocalcin, which increased
further during l-carnitine administration and partial exception of total cholesterol (minimal or no
increase during l-carnitine administration). Serum FT3, FT4 and TSH remained unchanged throughout
the 180 day-duration of the trial. Thus, there was no antagonism from l-carnitine on the negative
feedback that thyroid hormones exert on thyrotropin releasing hormone (TRH)/TSH. In addition to the
hypothalamic TRH-producing neurons and the pituitary thyrotropin, also osteoblasts were refractory
to the thyroid-hormone antagonizing effect of l-carnitine (see above). Thus, l-carnitine synergized with
thyroid hormone on the osteoblasts to increase osteocalcin serum concentrations. The favorable effect
on the osteoblasts was supported by measuring femur and lumbar bone density by dual-energy-X-ray
absorptiometry [37].
More recent cases of severe forms of Graves’ disease-related hyperthyroidism, including thyroid
storms, were treated successfully with l-carnitine [38–40]. Recently, a pilot study indicated the beneficial
effects of a combination of l-carnitine and selenium supplementation in subclinical hyperthyroidism [41].
A rationale for a beneficial effect of l-carnitine supplementation in hyperthyroid patients seems likely
because increased levels of thyroid hormones deprive the tissue deposits of l-carnitine itself [42], which
is further substantiated by the finding of decreased concentrations of carnitine in the skeletal muscles
of hyperthyroid patients. Interestingly, trendwise decreased concentrations of carnitine were found
in skeletal muscles of hypothyroid patients [43], which were restored upon regaining euthyroidism.
Therefore, decreased concentrations of carnitine in skeletal muscles may contribute to myopathy
associated with either hypothyroidism or hyperthyroidism.
Sixty thyroid-hormone adequately replaced hypothyroid Korean patients (age 50.0 ± 9.2 years,
57 females) continued to complain of fatigue [44]. These patients were given l-carnitine (990 mg
l-carnitine twice daily; n = 30) or placebo (n = 30) for 12 weeks. After 12 weeks, although neither
the fatigue severity score nor the physical fatigue score changed significantly after 12 weeks, but the
mental fatigue score was significantly improved by treatment with l-carnitine compared with placebo
(p < 0.01). In subgroups, both the physical and mental fatigue scores improved significantly in patients
younger than 50 years and those with free T3 ≥ 4.0 pg/mL by treatment with l-carnitine compared with
placebo. Other case-based studies have indicated a benefit from l-carnitine on hypothyroid symptoms,
but all of them have been case-based [45], while other studies may support benefits in the corticosteroid
hormone setting [46].
3. Inositol: Compound and Physiology
Inositol is a water-soluble compound closely associated with the vitamin B group (also known as
vitamin B8) [47]. Inositol is a carbohydrate which has a taste half as sweet as that of sucrose. Inositol
has long been known for its metabolic effects in humans, where it plays a part in the synthesis of
secondary messengers within cells. It is an essential component of the phospholipids that makes up
cellular membranes and is found in virtually all cells. The most abundant form of the nutrient is
myo-inositol. It assists in the transmission of nerve signals, helps to transport lipids within the body,
and is also critical for the proper action of insulin and maintenance of cellular calcium balance. Foods
containing the highest concentrations of myo-inositol include fruits, beans, grains and nuts. However,
in grains, it is in a non-available form called phytate. The more bioavailable form of inositol comes from
lecithin. Inositol is a necessary component of all cellular membranes. It is a member of the B-vitamin
family that contributes to muscular and nerve function and participates in the metabolism of fats in
the liver. Myo-inositol is the most abundant form of this nutrient, with its highest concentrations being
found in the brain and central nervous system. Myo-inositol in particular is a versatile nutrient for the
promotion of emotional and mental wellness, healthy eating patterns, and restful sleep through its
critical role in neurotransmitter messaging systems. In addition, it is an important nutritional element
for the maintenance of ovarian health and normal blood sugar maintenance, especially in women.
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Inositol is a non-essential member of the B-complex family with dietary sources from both animal
and plant foods. The form of inositol used in this product is myo-inositol, the most abundant form of
this nutrient. Inositol is found in all cell membranes, with the highest concentrations in the brain and
central nervous system, where it plays an important role in neurotransmitter signaling. Inositol is also
critical for the proper action of insulin, lipid metabolism, and for the maintenance of cellular calcium
balance. Inositol is a necessary component of all cellular membranes. It is a member of the inositols
are marketed as beneficial nutraceutics for improving mood and for the treatment of polycystic ovary
syndrome [20]. A significant difference in the myo-inositol content of available products, and there are
no regulations to ensure homogenous quality and accuracy [20].
Inositol and Thyroid Function/Autoimmunity
Inositols are essential for the signaling of hormones such as insulin, gonadotropins (follicle
stimulating hormone [FSH] and luteinizing hormone [LH]), and TSH. In the thyroid, imbalances in
the inositol metabolism can impair thyroidal hormone biosynthesis, storage and secretion [47]. TSH
signaling is rather complex involving two different signal cascades. One branch of the signal cascade
involves as second messenger cyclic AMP (cAMP), while another branch is inositol-dependent [48].
In a controlled trial, 48 women with autoimmune subclinical hypothyroidism were randomized to
treatment with either selenomethionine alone or selenomethionine plus myo-inositol. The authors
demonstrated that patients with autoimmune thyroiditis and subclinical hypothyroidism, treated with
myo-inositol and selenomethionine, had a reduction of the increased TSH, which selenomethionine
supplementation alone was not able to promote. However, the concentration of both thyroperoxidase
and thyroglobulin autoantibodies (TPOAb and TgAb) declined in both groups [48]. In a subsequent
study of 86 patients with Hashimoto’s thyroiditis and subclinical hypothyroidism, the same authors
found that the administration of myo-inositol and selenomethionine for six months significantly
decreased TSH, TPOAb, and TgAb concentrations, while at the same time enhancing thyroid hormones
and personal wellbeing, thereby restoring euthyroidism in patients diagnosed with autoimmune
thyroiditis [49]. This was confirmed in a larger study of 168 patients with Hashimoto’s thyroiditis and
subclinical hypothyroidism (TSH 3–6 mU/L) [50].
The mechanism of this effect might be through immune modulation rather than through thyroid
function per se [51]. Using the afore-mentioned combined treatment in 22 patients with autoimmune
thyroiditis, the initial TSH levels in the high normal range (2.1 < TSH < 4.0) significantly declined,
suggesting that the combined treatment can reduce the risk of progression to hypothyroidism in subjects
with autoimmune thyroid diseases. Antithyroid autoantibody levels also declined and, moreover,
the suspected immune-modulatory effect was confirmed by the finding that the concentration of the
chemokine CXCL10 also declined. Studies are, however, awaited to extend the observations in a
larger population, to evaluate the effect on the quality of life, and to study the mechanism of the effect
on chemokines.
Very recently, thyroid nodular disease also seemed to improve after the combined treatment with
myo-inositol and selenomethionine [52], but this also needs confirmation. Final data in this study
was analyzed from 34 patients with subclinical hypothyroidism: in 76% of mixed thyroid nodules a
significant reduction of their size was observed and 56% of them significantly regressed nodule stiffness
following oral supplementation with the combined nutraceutics for six months. The mean number of
mixed thyroid nodules shifted from 1.4 ± 0.2 to 1.1 ± 0.2 (p ≤ 0.05) and the TSH concentrations dropped
from 4.2 ± 0.2 mIU/L at baseline to 2.1 ± 0.2 mIU/L post-treatment (p < 0.001). In the control group,
38% of the thyroid nodules reduced their diameter but TSH concentrations significantly increased
up to the threshold after six months (from 4.0 ± 0.2 mIU/L to 4.3 ± 0.2 mIU/L, p ≤ 0.05). However,
further studies are required, both in vitro and in vivo, in order to investigate the mechanism of this
effect on the one hand, and a possible clinical treatment use of myo-inositol plus selenomethionine for
the general management of thyroid nodules on the other.
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4. Melatonin: Compound and Physiology
The isolation of melatonin was first reported in 1958 [53]. Since the demonstration that pineal
melatonin synthesis reflects both daily and seasonal time, melatonin has become a key element
of chronobiology research. In mammals, pineal melatonin is essential for transducing day-length
information into seasonal physiological responses. Due to its lipophilic nature, melatonin is able to
cross the placenta and is believed to regulate multiple aspects of perinatal physiology. The endogenous
daily melatonin rhythm is also likely to play a role in the maintenance of synchrony between circadian
clocks throughout the adult body. Pharmacological doses of melatonin are effective in resetting
circadian rhythms if taken at an appropriate time of day and can acutely regulate factors such as body
temperature and alertness, especially when taken during the day. Despite the extensive literature
on melatonin physiology, several key questions remain unanswered. Particularly the amplitude of
melatonin rhythms has recently been associated with diseases such as type 2 diabetes mellitus but the
physiological significance of melatonin rhythm amplitude remains poorly understood.
As a nutraceutical, melatonin is easily available over the counter and is marketed to regulate the
sleep pattern and adaptation to time zone differences among numerous other conditions.
Melatonin and Thyroid Function
Melatonin has antioxidant properties, which is one of the reasons why it is assumed to be beneficial
for many disease conditions. However, very few human studies exist, and they are primarily of
a physiological nature. One such study considers several endocrine and immune interactions in
healthy persons at different ages [54] and found statistically significant time-qualified correlations
among lymphocyte subset percentages and hormone serum levels in the young and middle aged
and one could speculate that the phenomenon of lymphocyte subpopulation redistribution may be
more complex, and may involve other hormones such as TRH, TSH, GH (growth hormone), IGF1
(insulin-like growth factor 1), monoamines such as melatonin, cytokines such as IL2 (Interleukin 2),
and chemokines. The aging of immune system function may be related to the alteration of circadian
rhythmicity, with a loss of interaction among key lymphocyte subsets, immunomodulating hormones,
as well as cytokines/chemokines.
Thirty-six perimenopausal and 18 postmenopausal women between 42 and 62 years of age with
no pathology or medication were selected for a randomized study of melatonin or placebo at bedtime
(22:00–00:00). The melatonin concentration was measured in saliva to divide the participants into
low, medium, and high-melatonin subjects [55]. Three- and six-months later, blood was taken for the
determination of pituitary (LH and FSH), ovarian, and thyroid hormones (T3 and T4). The results
showed that women low in melatonin after treatment with melatonin significantly increased thyroid
hormones levels and improved gonadal functions [55]. These results were confirmed by the same
authors in another study where peri- and menopausal women (N = 139) took a daily dose of 3 mg
synthetic melatonin or placebo for 6 months. Melatonin concentrations were determined from five daily
saliva samples at fixed times while other hormone levels were determined from blood samples three
times over the six-month period [56]. The conclusion was that the six-months treatment with melatonin
produced a remarkable and highly significant improvement of thyroid function, positive changes of
gonadotropins towards more juvenile levels, and the abrogation of menopause-related depression.
In 40 menopausal women the combination of myo-inositol plus melatonin seemed to positively
affect glucose metabolism. Myo-inositol alone seemed to improve thyroid function, while addition
of melatonin increased the serum TSH concentration [57]. The reason for this is unknown, but all
melatonin products warn against worsening of autoimmune diseases on basis of its potential effect on
the immune system. Recently, SNPs related to melatonin receptor gene polymorphism haplotypes were
associated with susceptibility to Graves’ disease in an ethnic Chinese population and thus support the
involvement of the melatonin pathway in the pathogenesis of this autoimmune thyroid disease [58].
In conclusion, there is to date no controlled trials to substantiate a use of melatonin for general
thyroid health improvement.
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5. Resveratrol: Compound and Physiology
Resveratrol (3,4′,5-trihydroxy-trans-stilbene) belongs to the flavonoids family and is a major
natural polyphenolic compound found in several fruit and vegetables such as grapes, peanuts, and
peanut sprouts. It seems to play an important role as a therapeutic and chemopreventive agent used
in the treatment of various illnesses [59,60] and has therefore recently gained much attention among
health professionals as well as other nutrition experts. Resveratrol exhibits effects against several
cancers [61,62] through different pathways and, furthermore, it has antidiabetic, anti-inflammatory, and
antioxidant effects. The cardiovascular protective capacities of resveratrol are believed to be associated
with multiple molecular targets such as inflammation, oxidative stress, apoptosis, mitochondrial
dysfunction, angiogenesis and platelet aggregation [59].
Similarly, resveratrol is a potent scavenger for free radicals. The high efficiency of resveratrol might
be due to the three hydroxyl groups in its structure. Thus, the use of resveratrol as a health-promoting
dietary supplement is rapidly increasing in today’s market. Many reports have shown that resveratrol
offers a wide range of preventive and therapeutic alternatives against various diseases including
different types of cancer.
Resveratrol is a member of a family of enzymes, under the general name of stilbene synthase,
which makes up part of a larger family of proteins with numerous functions. Notably, its chemical
structure resembles that of l-T4, however it is not clear if this has any functional implications [63].
Resveratrol synthase is developed from chalcone synthase via gene duplication and mutations. The
absorption in humans is approximately 75% (delayed by food) by trans-epithelial diffusion, while
tissue accumulation enhances efficacy at target sites.
Resveratrol and Thyroid Function
Resveratrol may arrest the proliferation of thyroid cancer cells by increasing the abundance and
phosphorylation of p53 [64–66]. Moreover, resveratrol mediates the regulation of TSH while, due
to its effects on iodine trapping, it shows promise as a prospective anti-thyroid drug. On the other
hand, these effects also resulted in a pronounced proliferative action on thyrocytes and resveratrol
may therefore be a thyroid disrupting compound [67]. No clinical studies on the compound’s effect on
the thyroid has been performed in humans, so all available evidence is based on animal and in vitro
cellular studies.
Finally, resveratrol as an antioxidant agent is a free radical scavenger and this property can
be of interest in thyroid disease states that are accompanied by increased production of hydrogen
peroxide and radical oxygen species, such as autoimmune thyroiditis and hyperthyroidism [68]. Proper
randomized clinical trials would, however, be required before implementing any use.
Resveratrol supplements can be easily purchased over the counter but they are not regulated
by the FDA or any other health authority. Most resveratrol capsules sold in the U.S. contain extracts
from an Asian plant called Polygonum cuspidatum. Other resveratrol supplements are made from red
wine or red grape extracts. The dosages in most resveratrol supplements typically contain 250 to
500 milligrams, which is much lower than the amounts that have been shown beneficial in research
(2000 milligrams of resveratrol or more a day).
6. Selenium: Compound and Physiology
Selenium is a non-metal chemical element that is an essential micronutrient. Selenium salts are
toxic in large amounts, but trace amounts are necessary for cellular function in many organisms,
including all animals. Dietary selenium comes from nuts, cereals, and mushrooms. Brazil nuts are the
richest dietary source (though this is soil-dependent since the Brazil nut does not require high levels of
the element for its own needs). Selenium is an ingredient in many multivitamins and other dietary
supplements. It is a component of the antioxidant enzymes glutathione peroxidase and thioredoxin
reductase, which indirectly reduce certain oxidized molecules in animals and some plants. It is also
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found in three deiodinase enzymes, which convert one thyroid hormone to another. In living systems,
selenium is found in the amino acids selenomethionine, selenocysteine, and methylselenocysteine.
The U.S. recommended dietary allowance (RDA) for teenagers and adults is 55 μg/day. Selenium
as a dietary supplement is available in many forms, including multi-vitamins/mineral supplements,
which typically contain 55 or 70 μg/serving. Selenium-specific supplements typically contain either
100 or 200 μg/serving. In June 2015, the U.S. FDA published its final rule establishing the requirement
of minimum and maximum levels of selenium in infant formula. The reference values of EFSA for
selenium range from 15 μg/day for children aged one to three years to 70 μg/day for adolescents
aged 15–17 years [69]. The selenium content in the human body is believed to be in the range of
13–20 milligram [70].
Selenium food supplements are most efficient as yeast-based selenomethionine, but the contents
are not standardized or under any control. For instance, six different brands of yeast-based selenium
food supplements were analysed for the expected selenomethionine content [23]. Only two brands
had high levels of selenomethionine; one brand appeared to contain only inorganic selenium, and
one brand appeared to contain more than half inorganic selenium despite label claims of content
being only selenomethionine. Nevertheless, selenium supplementation is increasingly prescribed by
endocrinologists as recently documented for Italian endocrinologists [70]. In detail, approximately
one in four respondents use selenium often/always, with only one in either use never. Rates were
approximately one-fourth of respondents prescribing selenium often/always in Hashimoto’s thyroiditis,
and one-fifth prescribing selenium in the case presented. In patients with autoimmune thyroiditis
(AIT) who are planning pregnancy or are already pregnant, approximately 40% of respondents
suggest selenium use [71]. It is worth underlining that the American Thyroid Association (ATA)
pregnancy guideline reported that “selenium supplementation is not recommended for the treatment
of TPOAb-positive women during pregnancy” [72].
Selenium and Thyroid Function/Autoimmunity
Among all tissues, the thyroid gland has the highest concentration of selenium, of which much is
stored in the thyrocytes as the selenoproteins [73,74]: deiodinases (DI1, DI2), glutathion peroxidase
(GPx1, GPx3, GPx4), and thioredoxin reductases (TR1, TR2). Both the thyroid gland and all other cells
that are dependent of thyroid hormone for proper function use selenium as a cofactor for three of the
four known types of thyroid hormone deiodinases, which can both activate and deactivate thyroid
hormones and their metabolites—the iodothyronine deiodinases are the subfamily of deiodinase
enzymes that use selenium, as does the otherwise rare amino acid selenocysteine. Only iodotyrosine
deiodinase does not use selenium.
Adequate selenium intake is required for normal function of thyrocytes and the angiofollicular
units in thyroid hormone biosynthesis and storage. Inadequate selenium intake has been associated
with increased thyroid volume in females, but not males in one study [75], and in a larger Danish
population, this negative correlation between selenium status and thyroid volume was confirmed,
and there was, furthermore, a trend toward increased numbers of thyroid nodules with inadequate
selenium status [74,76]. Adequate selenium intake, with respect to proper thyroid function, can be
monitored by the analysis of serum or plasma selenoproteins such as selenoprotein P or plasma
GPx3 [74,77,78]. Intoxication has been reported in several places in China from dietary intake and
soil contamination [79,80]. Measurement of these variables is becoming more important in the view
of the increased interest in selenium supplementation in various patient groups particularly with
autoimmune thyroid diseases (see below) and since there is a risk of overdosing by general too high
doses on the one hand and supplementation of selenium sufficient individuals on the other. The
U-shaped curve of beneficial effects from selenium concentrations, i.e., exhibiting major advantages
in selenium-deficient individuals but specific health risks in those with selenium excess should be
seriously considered [81].
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Selenium status has been shown to affect immune functions, e.g., T cell differentiation, and
selenium deficiency has been associated with Th2 cells/markers, while higher selenium concentrations
seem to favor an increased Th1 and Treg response [82]. These observations are thus in keeping
with the suggestion of beneficial effects of selenium supplementation in autoimmune diseases of the
thyroid [73,83]. Newly diagnosed autoimmune hyperthyroidism, Graves’ disease, has been associated
with low selenium concentrations [84], an observation which has fuelled several interventional treatment
studies of selenium supplementation as adjunctive to antithyroid drugs in Graves’ disease [85–88].
A very recent systematic review and meta-analysis of 10 randomized clinical trials could not substantiate
a systematic effect of selenium supplementation as an adjunctive treatment in Graves’ disease [89].
Generally, the studies were all underpowered, of too short a duration, and with too broad clinical
characteristics of the patients, and the issue is therefore yet to be resolved—results from larger ongoing
prospective studies are awaited [90].
Concerning the subpopulations of Graves’ disease, however, a prospective case-control study
demonstrated lower serum selenium concentrations in patients with Graves’ orbitopathy compared
to Graves’ patients without orbitopathy in an Australian study population with marginal selenium
status [91]. Against this background, relative selenium deficiency may be an independent risk factor
for orbitopathy in patients with Graves’ diseases. This has been further substantiated by one major
multicentric prospective, placebo and serum-controlled study of Graves’ patients with orbitopathy,
with demonstration of improved quality of life and disease activity scores [92].
Several placebo-controlled and double-blind studies, both observational and prospective,
have been performed to demonstrate the improved quality of life, wellbeing, thyroid hormone
status, and disease symptoms of chronic autoimmune thyroiditis of the Hashimoto type with or
without hypothyroidism. Although many studies have consistently demonstrated a reduction in
thyroid autoantibody concentrations by selenium supplementation, including some compared with
control/placebo [93–96], recent meta-analyses found insufficient evidence for the clinical efficacy
of selenium supplementation in chronic autoimmune thyroiditis [97,98]. Hopefully, future trials
can ultimately provide reliable evidence to help inform clinical decision making. Results were less
optimistic than the individual study results, many of which were, however, underpowered, and
therefore, in this autoimmune patient group, results are unclear and further ongoing study results are
awaited [99].
In women at risk of postpartum thyroiditis, adequate selenium status prevents its development.
In a prospective placebo-controlled double-blind prevention study [100], there were fewer cases of
postpartum thyroiditis—these results, however, have not been confirmed in other studies [73,101].
Finally, there has been no indication of an increased risk of thyroid cancer in either selenium
deficiency or with supplementation of selenium [74].
In conclusion, selenium status has a high impact on normal thyroid development and function,
and it is still a potential candidate for improvement of clinical markers and quality of life in some
situations of autoimmune thyroid diseases by supplementation, e.g., Graves’ orbitopathy and possibly
postpartum thyroiditis. However, more solid evidence is awaited until firm conclusions can be made
concerning recommendations for global routine clinical use.
7. Perspective and Conclusions
As clinicians, we often see patients who are taking all sorts of supplements with the hope of
improving their health and medical conditions, as well as simply feeling better.
Thyroid supplements attract a disproportionately large amount of attention, just as the thyroid
gland gets “blamed” for multiple symptoms. There are truths and myths that this review had tried to
clarify. Of the numerous nutraceuticals out there for thyroid disease management, we focused on the
common or popular ones we encounter in the clinical practice.
Clinicians should acknowledge that over 30% of our patients are using supplements and thus
should inquire about them during our office encounters. Apart from improving their general health,
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patients are using these alleged thyroid supplements to help “improve their metabolism, have more
energy, and to lose weight”.
It is important that we do not just dismiss these patients, but rather have honest discussions about
the claimed benefits and potential risks. Physicians would do well to familiarize themselves with the
main supplements being used, and also to know the scientific evidence available to support or refute
these claims. More importantly, physicians should understand the potential risks or side effects in
order to properly counsel patients about their use.
Based on the literature reviewed in the preceding sections, the evidence for the clinical use
and potential benefit of the nutraceuticals addressed in this paper is summarized in Table 4. It is,
however, worth noting that very few studies have been randomized clinical trials and generally all the
studies have lacked proper power and even attempts to perform power calculations including the
few randomized clinical trials. For selenium, two randomized, properly powered, placebo controlled
clinical trials are ongoing and results are awaited [89,98]. Similar studies are required also for the most
relevant nutraceuticals with a possible influence on the thyroid, in order to provide proper guidance
both to patients and clinicians.
Table 4. Summary of evidence for clinical use of the nutraceuticals reviewed here in the thyroid setting *.
Question: Is There
Evidence for
Clinical Use of . . . ?
Answer
Carnitine
Currently available evidence supports the usefulness of l-carnitine in hyperthyroid
patients. Carnitine ameliorates a number of symptoms and signs, including cardiac
arrhythmia. Case reports have shown benefits even in the setting of thyroid storm.
However, no changes in thyroid function tests were reported.
One practical setting for the use of l-carnitine (two grams per day) is the control of
hyperthyroidism symptomatology when the patients need to take low doses of
antithyroid drugs. Only one Korean study is currently available for hypothyroidism,
thus precluding conclusions.
Inositols
Only in one study, MI alone (2 g twice a day) or MI plus melatonin (2 g/d MI plus 3 g/d
melatonin) were given in two groups of euthyroid postmenopausal women, and serum
FT4 and TSH evaluated. MI alone caused an almost 3.5% increase in serum FT4 and a
10% decrease in serum TSH. This contrasted with the opposite changes (3.5% decrease
in serum FT4 and almost 10% increase in serum TSH) observed in the group under MI
plus melatonin.
Few studies have been conducted only in one Western country (Italy), and with the
combination of MI plus selenium or MI plus carnitine. Supplementation with the first
combination has been used in the setting of patients with Hashimoto’s thyroiditis
related SCHypo, and it decreased both serum thyroid autoantibodies and TSH. The
combination of MI plus carnitine was only investigated in one study of patients with
SCHyper, thus precluding conclusions.
Melatonin
There has been interest in melatonin and autoimmunity and the thyroid gland has been
implicated in the discussion. It is thought that melatonin may have a paracrine role
and in thyroid disease under a condition of oxidative stress may reduce the processes
involved in thyroid antoimmunity. However, there are no controlled trials or definite
data to show conclusively that melatonin can be beneficial in thyroid disease.
Resveratrol No answer can be given, simply for lack of studies.
Selenium
Benefits have been demonstrated for mild forms of Graves’ ophthalmopathy. Benefits
for the clinical course of GD itself are controversial. In the setting of HT, a benefit has
been shown more on serum thyroid autoantibodies than on thyroid function. There is
only one study on the benefit given by selenium supplementation, both in terms of
serum thyroid autoantibodies and thyroid dysfunction, in the setting of PPT. For the
combinations of selenium with MI see above.
Abbreviations, in alphabetical order: GD = Graves’ disease; HT = Hashimotos’ thyroiditis; MI = myo-inositol;
PPT = postpartum thyroiditis. SCHyper = subclinical hyperthyroidism; SCHypo = subclinical hypothyroidism.
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Appendix A
Table A1. Information on the dietary supplements provided by the Food and Drug Administration *.
Questions Answers
What is a dietary
supplement? §
Congress defined the term “dietary supplement” in the Dietary Supplement Health and
Education Act (DSHEA) of 1994. A dietary supplement is a product taken by mouth that
contains a “dietary ingredient” intended to supplement the diet. The “dietary ingredients”
in these products may include vitamins, minerals, herbs or other botanicals, amino acids,
and substances such as enzymes, organ tissues, glandulars, and metabolites. Dietary
supplements can also be extracts or concentrates and may be found in many forms such as
tablets, capsules, softgels, gelcaps, liquids, or powders. They can also be in other forms,
such as a bar, but if they are, information on their label must not represent the product as a
conventional food or a sole item of a meal or diet. Whatever their form may be, DSHEA
places dietary supplements in a special category under the general umbrella of “foods”,
not drugs, and requires that every supplement be labeled a dietary supplement.
What is a “new dietary
ingredient” in a dietary
supplement? §
The Dietary Supplement Health and Education Act (DSHEA) of 1994 defined both of the
terms “dietary ingredient” and “new dietary ingredient” as components of dietary
supplements. In order for an ingredient of a dietary supplement to be a "dietary
ingredient," it must be one or any combination of the following substances:
a vitamin,
a mineral,
an herb or other botanical,
an amino acid,
a dietary substance for use by man to supplement the diet by increasing the total dietary
intake (e.g., enzymes or tissues from organs or glands), or a concentrate, metabolite,
constituent or extract.
A “new dietary ingredient” is one that meets the above definition for a “dietary ingredient”
and was not sold in the U.S. in a dietary supplement before 15 October 1994.
What are the benefits of
dietary supplements?
Some supplements can help assure that you get enough of the vital substances the body
needs to function; others may help reduce the risk of disease. But supplements should not
replace complete meals which are necessary for a healthful diet–so, be sure you eat a
variety of foods as well.
Unlike drugs, supplements are not permitted to be marketed for the purpose of treating,
diagnosing, preventing, or curing diseases. That means supplements should not make
disease claims, such as “lowers high cholesterol” or “treats heart disease.” Claims like
these cannot be legitimately made for dietary supplements.
Are there any risks in
taking supplements?
Yes. Many supplements contain active ingredients that have strong biological effects in the
body. This could make them unsafe in some situations and hurt or complicate your health.
For example, the following actions could lead to harmful–even
life-threatening–consequences.
Combining supplements
Using supplements with medicines (whether prescription or over the counter)
Substituting supplements for prescription medicines
Taking too much of some supplements, such as vitamin A, vitamin D, or iron
Some supplements can also have unwanted effects before, during, and after surgery. So, be
sure to inform your healthcare provider, including your pharmacist about any
supplements you are taking.
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Note: These examples do not represent either an endorsement or approval by FDA.
How can I find out
more about the dietary
supplement I’m taking?
Dietary supplement labels must include name and location information for the
manufacturer or distributor.
If you want to know more about the product that you are taking, check with the
manufacturer or distributor about:
Information to support the claims of the product.
Information on the safety and effectiveness of the ingredients in the product.
Report Problems to
FDA
Notify the FDA if the use of a dietary supplement caused you or a family member to have
a serious reaction or illness (even if you are not certain that the product was the cause, or
you did not visit a doctor or clinic).
Follow these steps:
• Stop using the product.
• Contact your healthcare provider to find out how to take care of the problem.
• Report problems to FDA in either of these ways:
• Contact the Consumer Complaint Coordinator in your area.
• File a safety report online through the Safety Reporting Portal.
§ Source is [7]. * Source is [8].
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